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Abstract 
Background: Neutropenia is a dose-limiting toxicity of chemotherapy administered to patients 
with cancer.  Neutrophil counts are usually measured using venous samples on centralised 
analysers.  The aim of this work was to explore the feasibility and potential of home 
neutrophil count monitoring during chemotherapy. 
Methods: The prevalence of febrile neutropenia was defined in an unselected population 
using routine electronic health records of patients receiving chemotherapy for cancer.  Patient 
and professional attitudes to home blood count monitoring were explored through 
questionnaires.  Performance of the Hemocue WBC DIFF analyser in measuring capillary 
neutrophil counts was evaluated in the neutropenic range.  Daily neutrophil counts were 
measured for the duration of a cycle of chemotherapy.     
Results: Baseline pathways were quantified in a Markov model using data from 28,919 
patients receiving chemotherapy for cancer.  Ten percent of all cancer site and chemotherapy 
combinations had a prevalence of febrile neutropenia of >10% (highest prevalence was 
66.7%).     
The majority (86.9%) of patients surveyed would use home neutrophil count monitoring.  
Correlation of capillary Hemocue WBC DIFF measured neutrophil counts in the neutropenic 
range to venous ADVIA 2120 measured counts was r = 0.867, 𝑦 = 0.95𝑥 + 0.01.  The capillary 
neutrophil threshold <1.1 x109/L performed best in identifying both patients at risk of febrile 
neutropenia and patients whose neutrophil count had not recovered prior to subsequent 
chemotherapy.  
The 21 daily neutrophil count profiles recorded during chemotherapy were heterogeneous.  
Four out of 10 patients with a neutrophil nadir <0.5 x109/L were admitted with febrile 
neutropenia.  Four out of 21 patients had insufficient neutrophil count recovery by day 21 for 
subsequent chemotherapy. 
Conclusion: Home neutrophil count monitoring during chemotherapy is feasible.  Electronic 
health records can be utilised to quantify patient pathways.  This work generated much 
evidence in support of adoption of home neutrophil count monitoring during chemotherapy, 
and informs future work defining the true potential. 
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Chapter 1 Introduction 
Chemotherapy is commonly given on its own or as part of multi-modality anti-cancer 
treatment in the curative and palliative settings.  Administration is limited by toxicities, one of 
the most common of which is myelosuppression resulting in reduced haemoglobin, leukocytes 
and platelets.  Leukopenia, and more specifically neutropenia, can be life-threatening when 
complicated by infection, and recovery needs to occur prior to safe delivery of subsequent 
chemotherapy cycles.  This thesis explores the principle of home neutrophil count monitoring 
in patients during chemotherapy.  It concentrates on the feasibility and potential of home 
blood count monitoring in the management of severe neutropenia and its complications, 
whilst acknowledging home blood count monitoring may have further reaching roles which 
are explored in the profiling trial described in the final chapter. 
1.1 Neutrophils 
Neutrophils are one of three types of white cells in circulating blood that are classified as 
granulocytes.  Eosinophils and basophils constitute the remaining granulocytes, all of which 
are distinguished morphologically from other differential white cells by the presence of multi-
lobular nuclei and granules in the cytoplasm.  In a healthy individual, neutrophils are the most 
abundant white cell, forming 40 to 80% of the total white blood cell count (1).  All types of 
granulocyte are involved in the immune defence against invading pathogenic organisms, with 
neutrophils performing the main anti-bacterial function through phagocytosis.    
Neutrophils are present in three compartments; bone marrow, peripheral blood and intra-
cellular.  Within the bone marrow there are three stages of development;  
(i) committed multipotent haematopoietic stem cells, which differentiate into 
progenitor cells  
(ii) mitotic compartment consisting of promyelocytes, myelocytes and myeloblasts 
(iii) maturation compartment consisting of metamyelocytes, band and 
polymorphonuclear neutrophils.  
The transit time is approximately six days through the bone marrow mitotic compartment and 
an additional six to nine days through the maturation compartment except in patients with 
infection where maturation can be as short as two days (2-5). The half-life of neutrophils in 
circulating blood is six to eight hours before sequestration into tissue for either cellular action 
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or death. It can be informative to analyse the type of neutrophils in the circulating blood as 
immature neutrophils such as bands are increased (often referred to as a shift to the left) in 
association with acute infections and inflammation (6).  An increase in mean neutrophil lobe 
count (shift to the right) can be associated with vitamin B12 or folic acid deficiency, congenital 
hypersegmentation of neutrophils or renal disease (7).  Within the circulating blood, 
neutrophils are divided approximately evenly between circulating and marginated pools, the 
latter being neutrophils that are adhered to the vascular endothelium (8). They move from 
the marginated to circulating pool in scenarios such as sepsis, high dose steroid use and 
immediately after vigorous exercise (9).  In contrast, use of granulocyte colony stimulating 
factor increases the mitotic pool of granulocytes in bone marrow and decreases the 
maturation department transit time (10), but does not promote demargination.   
Circulating neutrophils are activated by soluble chemotactic factors produced by bacteria 
themselves, interaction of bacteria with other blood components e.g. antibodies and 
complement system and interaction of bacteria with the host cells (1). Chemotactic factors 
such as platelet-activating factor and leukotrienes bind receptors on neutrophils and this 
receptor-ligand interaction activates neutrophils in seconds. The first response is that the 
neutrophils adhere to the vascular endothelial cells near the site of bacterial invasion, a 
process facilitated by cytokine-mediated presentation of adhesion molecules such as inter-
cellular adhesion molecule 1 (ICAM-1).  Once adhered, neutrophils follow a further gradient of 
chemotactic factors which guide them through the vascular endothelium.  This involves 
binding of molecules such as cleavage product component (C5a), leukotriene B4 and platelet- 
activating factor to specific neutrophil membrane receptors.  Neutrophils may then move 
beneath the vascular endothelium until they can pass through the basement membrane into 
the adjacent connective tissue.  The passage through the vessel wall tends to be irreversible 
(11, 12), but moves the activated neutrophils to the proximity of the invading organism, 
facilitating destruction through phagocytosis and release of anti-bacterial granules into the 
phagocytic vesicle.  The process from neutrophil activation to reaching the site of invading 
bacteria takes approximately thirty minutes (13).   
1.2 Neutropenic complications of chemotherapy 
Within the bone marrow, chemotherapy initiates apoptosis largely of the haematopoietic 
progenitor cells in the bone marrow (14, 15).  After standard 3 or 4-weekly chemotherapy 
administration, patients are expected to become neutropenic at days 7 to 10, with the nadir 
at days 10 to 14, when the previously affected progenitor cells would otherwise have matured 
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and entered the circulation.  Neutropenic toxicities of chemotherapy include asymptomatic 
neutropenia, febrile neutropenia and neutropenic sepsis.  The grade and duration of 
neutropenia is directly proportional to the risk of infective bacterial complications (16), albeit 
that the evidence for quantitative relationship between differential white cell counts and the 
risk of infective consequences is now quite dated. 
By definition, neutropenia is an absolute neutrophil count less than the lower limit of the 
specified “normal” range on the reference analyser.  At Leeds Teaching Hospitals NHS Trust 
the neutrophil lower limit of normal is 2.0 x109/L.  Neutropenia is categorised into grades 0 to 
4 (Table 1) in the Common Terminology Criteria for Adverse Events (CTCAE) (17).    
Version 
Adverse 
Event 
Grade 
0 1 2 3 4 
4.0 
Neutrophil 
count 
decreased 
Within normal 
limits 
< LLN to 
1.5 x109/L 
<1.5 to 
1.0 x109/L 
<1.0 to 
0.5 x109/L 
<0.5 
x109/L 
Definition: A finding based on laboratory test results that indicate 
a decrease in number of neutrophils in a blood specimen 
Table 1: Common Terminology Criteria for Adverse Events (CTCAE) neutropenia grades (17).   
LLN – lower limit of normal. 
 
1.2.1 Febrile Neutropenia 
Febrile neutropenia is neutropenia in the presence of a fever.  Neutropenic sepsis is 
neutropenia with systemic signs of infection (see 1.2.2).  However, in clinical practice, the 
terms febrile neutropenia and neutropenic sepsis tend to be used interchangeably.  For the 
purposes of clarity in this thesis, they are defined separately, but referred to as “febrile 
neutropenia or worse” when incorporated together in one group. 
The National Institute for Health and Care Excellence (NICE) carried out a survey of definitions 
of febrile neutropenia in use across all acute trusts in England and Wales (Figure 1).  Eighty 
valid questionnaires were returned from 51 centres.  Some centres had separate policies for 
specific patient groups.  The majority used a neutrophil count threshold of ≤ 1.0 x109/L in 
conjunction with a fever to be diagnostic of complicated neutropenia requiring change in 
management.  However, the consensus neutrophil count threshold below which patients with 
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fever or suspected infection warrant management with antibiotics in published guidelines is 
0.5 x109/L.  This has not changed since early guidelines published in 1994 (18).   
Table 2 summarises the definitions of febrile neutropenia and evidence supporting these in 
published guidelines.  Four of these guidelines qualify the use of neutrophil count <0.5 x109/L 
as the threshold to change management  by also including “predicted or expected” to fall to 
<0.5 x109/L within a certain timeframe.  In a patient presenting acutely, clinical management 
decisions frequently need to be made without a trend in neutrophil counts, but based on a 
single reading, so this is the likely explanation for the threshold of <1.0 x109/L neutrophil 
count being used in NHS Trusts in England and Wales.      
      
Figure 1: Neutrophil count diagnostic of neutropenia in “neutropenic sepsis” guidelines in 
use in England and Wales.   
n = 80, reproduced from NICE Neutropenic Sepsis Clinical Guidelines (19). 
 
1.2.2 Neutropenic sepsis 
Neutropenic sepsis is neutropenia in the presence of systemic manifestations of infection.   
Table 3 lists some of the diagnostic criteria for sepsis endorsed by the “Surviving Sepsis 
Campaign” (20, 21).  However, some of the parameters listed in  
Table 3 could be present in patients with cancer on chemotherapy in the absence of sepsis,  
such as significant oedema, elevated C-reactive protein and thrombocytopenia.  Therefore 
this has to be interpreted with caution and each parameter considered in relation to an 
individual patient’s baseline and clinical context.  It should also be noted that much of the 
evidence around neutropenic sepsis pre-dates this sepsis guideline, and so should be 
evaluated with that in mind. 
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Table 2: Definitions and evidence supporting the definitions of febrile neutropenia in published local, national and international guidelines.   
ANC, Absolute neutrophil count; MASCC, Multinational Association for Supportive care in Cancer; NICE, National Institute for Health and Care Excellence; ESMO, 
European Society of Medical Oncology; ASCO, American Society Clinical Oncology; EORTC, European Organisation for Research and Treatment of Cancer; LTHT, 
Leeds Teaching Hospitals NHS Trust; NCCN, National Comprehensive Cancer Network; IDSA, Infectious Diseases Society of America; CTCAE, Common toxicity 
criteria of adverse events.  
Guidelines 
(Year of publication) 
ANC (x10
9
/L) Temperature Evidence informing ANC threshold 
MASCC Scoring System (2000) (22) <0.5 1 x >38
o
C 
Link not made to evidence.  Introduction cites 1 publication which refers to 
granulocyte count and risk of infection (number of patients = 52) (16). 
CTCAE version 4.03 (2009) (17) <1.0 
1 x >38.3
o
C or ≥38
o
C 
sustained over 1 hour 
Evidence not discussed. 
ESMO (2010) (23) 
≤0.5 or expected to 
fall below 0.5 
1 x >38.5
o
C or 
2 x >38
o
C for 2 hours 
Link not made to evidence or indication of level of evidence to inform decision 
values. 
EORTC (2011) (24) 
<0.5 or <1.0 and 
predicted to fall 
below 0.5 within 48 
hours 
Fever 
No specific temperature 
specified 
Referenced a definition in which the link is not made to evidence (25).  Studies 
included in analysis not limited to a specific definition of neutropenia. 
IDSA (2011) (26) 
<0.5 or expected to 
decrease to <0.5 
during the next 48 
hours 
1 x ≥38.3
o
C (101
o
F) or 
≥38
o
C sustained over 1 
hour 
Link not made to evidence, but introduction cites 2 studies showing ANC <0.1 
x10
9
/L and prolonged neutropenia increases risk of bacteraemia (number of 
patients = 52 and 403) (16, 27). 
NICE (2012) (19) ≤0.5 1 x >38
o
C 
Carried out own systematic review, reported within guideline, included 11 
eligible studies, found quality of evidence to be low. 
NCCN (2012) (28) 
<0.5 or <1.0 and a 
predicted decline  to 
≤0.5 over the next 48 
hours 
1 x ≥38.3
o
C or 
≥38.0
o
C over 1 hour 
Link not made to evidence but described as based on low-level evidence and 
uniform NCCN consensus. Introduction cites 2 studies showing decrease in 
neutrophils leads to increased infections (16, 29). 
ASCO (2013) (30) 
<1.0 (severe <0.5, 
profound <0.1) 
≥38.3
o
C 
Link not made to evidence.  Recommendations refer to 2 studies from >35 
years ago (number of patients = 52 and 494) (16, 31). 
LTHT (2014) 
Guidelines for the management of 
suspected neutropenic sepsis 
≤0.5 
1 x >38.5
o
C or 
>38
o
C for ≥1 hour or 
2 x >38
o
C in 12 hours 
Local expert consensus indicating either no guidance found or wide 
disagreement in expert consensuses. 
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Table 3: Diagnostic criteria for sepsis.   
WBC, white blood cell.  CRP, C-reactive protein. BP, blood pressure.  INR, international 
normalised ratio. APTT,  activated partial thromboplastin time.  Adapted from Levy et al., 2001 
(20). 
 
 
 
 
Infection, documented or suspected, and some of the following: 
General variables 
Fever (>38.3oC) 
Hypothermia (<360C) 
Heart rate >90 /min 
Tachypnoea 
Altered mental status 
Significant oedema or positive fluid balance (>20mL/kg over 24 hours) 
Hyperglycaemia (plasma glucose >7.7mmol/L) in the absence of diabetes 
 
Inflammatory variables 
Elevated CRP 
Elevated procalcitonin 
 
Haemodynamic variables 
Hypotension (systolic BP <90mmHg or systolic BP decrease >40mmHg) 
Organ dysfunction variables 
Arterial hypoxaemia 
Oliguria (urine output <0.5mL/kg/hour) 
Creatinine increase (>44.2µmol/L) 
Coagulation abnormalities (INR>1.5 or APTT >60 seconds) 
Ileus 
Thrombocytopenia (platelet count <100 x109/µL) 
Hyperbilirubinaemia (plasma total bilirubin >70µmol/L) 
 
Tissue perfusion variables 
Raised lactate (>1mmol/L) 
Decreased capillary refill or mottling 
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1.2.3 Incidence of febrile neutropenia 
The incidence rates of all cancers combined are projected to increase by 2% in the United 
Kingdom between 2014 and 2035, to 742 cases per 100,000 people by 2035 (32), with the 
number of patients living with and beyond cancer also increasing.  Despite the recent 
advances in the use of targeted and immunotherapies (33, 34), chemotherapy is likely to 
remain the backbone of systemic treatment for most patients with cancer, and thus the 
absolute number of patients experiencing neutropenic complications is expected to increase.  
The risk of febrile neutropenia after chemotherapy has been categorised into low (<10%), 
medium (10-20%) and high (>20%) according to primary cancer site and chemotherapy 
regimen received (24).  In addition, uncomplicated neutropenia following certain targeted 
therapies has been described as >10%, but the risk of febrile neutropenia is <10% (35).  
However, the reported incidence of febrile neutropenia after common chemotherapy 
regimens varies considerably between randomised controlled trials; trial patient cohorts 
usually do not reflect the more unselected patients of routine practice who may be at greater 
risk of febrile neutropenia and other toxicities.  Certainly uncomplicated neutropenia as a 
toxicity of chemotherapy is under-estimated, because routine blood counts during 
chemotherapy cycles are done more often in trials than in routine clinical practice (36).        
Individual patient characteristics increase the risk of febrile neutropenia including prior 
chemotherapy, age >65 years, co-morbidities, low estimated glomerular filtration rate, low 
baseline white cell count, low haemoglobin level, elevated bilirubin, elevated alkaline 
phosphatase and elevated transaminases (37-43).  For example, in a study including patients 
with solid tumours or lymphoma, where a predictive model was trained on a derivation cohort 
(n=2425 patients) and validated on a different cohort (n=1213 patients), multivariate analysis 
showed an elevated bilirubin at the start of cycle 1 chemotherapy to increase the odds ratio 
for either uncomplicated severe neutropenia (neutrophil count <0.5 x109/L) or febrile 
neutropenia to 2.152 (95% confidence interval (CI) was 1.235-3.747, p=0.007) (37).  The risk of 
febrile neutropenia is greatest within the first cycle of chemotherapy as patients generally 
receive the full dose intensity of chemotherapy (44), usually without prophylactic measures 
such as granulocyte colony stimulating factor (37, 43, 45).  There are assessment models for 
predicting risk of infective neutropenic complications (37, 46), but these were developed on 
data from the United States and are currently not embedded within routine clinical practice in 
the United Kingdom.  There is, therefore, a need to collect comprehensive, country-specific, 
clinical data on the incidence of neutropenia and neutropenic complications in routine clinical 
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practice, thus minimising the potential for bias with a view to optimising treatment and 
maintaining patient safety. 
1.2.4 Consequences of febrile neutropenia 
Infective neutropenic complications are associated with reduced quality of life, and increased 
morbidity, mortality and cost (47).  In a robust study of 41,779 patients who were admitted 
with chemotherapy-induced febrile neutropenia across 115 US medical centres between 1995 
and 2000, the mean duration of admission was 11.5 days, median duration was 6 days, with 
35% of patients admitted for ≥ 10 days (47).  However, there were outliers with prolonged 
admissions, and the 35% of hospitalisations for ≥ 10 days accounted for 74% of overall 
hospital days.  In addition, this study included patients with haematological malignancies and 
since the data were collected, there has been a trend towards using risk stratification to 
down-scale antibiotics early in low-risk patients (22), and may facilitate earlier discharge.  
Moreover, it was carried out in the US medical system where care is often paid for through 
insurance schemes, which have the potential to prolong duration of admission (48).  However, 
the duration of admission for chemotherapy-induced febrile neutropenia from an audit of 
care in the NHS at the South West London Chemotherapy Network in 2006 was comparable 
(49).  It included a considerably smaller number of patients, but 64 patients were admitted 71 
times over a 4 month period, with the median admission duration being 5 days, the mean 9 
days and the range 1-60 days.  Again, the data distribution is not normal, as with the US data. 
In the absence of preventive measures, between 48 and 60% of febrile neutropenic patients 
have an established or occult infection, and around 16 to 20% of patients with neutrophil 
counts less than 0.1 x109/L have bacteraemia (16, 29, 50).  Consequently, neutropenic sepsis 
can be life-threatening, with studies showing inpatient mortality rates of 4.2% to 12.5% (49, 
51, 52).  Individual patient risk factors should be considered with respect to risk of death for 
patients admitted with neutropenic sepsis.  For example, mortality has been reported in 
relation to the number of co-morbidities; in a trial of adult patients with a range of tumour 
types and chemotherapy regimens who were admitted to hospital in the United states with 
febrile neutropenia (n=41,779), having no co-morbidities was associated with 2.6% risk of 
death, 1 co-morbidity was associated with 10.3% risk of death and >1 co-morbidity was 
associated with 21.4% risk of death (47).   
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1.2.5 Interventions 
In addition to reducing mortality, prevention of febrile neutropenia reduces hospital 
admissions and associated costs, antibiotic usage and dose reductions or delays in subsequent 
chemotherapy cycles, which are associated with worse cancer outcomes (53-59).  Where 
phase III trials show chemotherapy as the best available treatment for a cancer, particularly in 
the curative setting, it may be desirable to consider prevention of complicated neutropenia in 
order to maintain dose intensity and/or density (59).  Historically, two approaches have been 
used to prevent febrile neutropenia; prophylactic granulocyte colony stimulating factor and 
prophylactic antibiotics.  Both are briefly discussed below.  
1.2.5.1 Prophylactic granulocyte colony stimulating factor 
Granulocyte colony stimulating factor is an endogenous cytokine produced by monocytes, 
fibroblasts and endothelial cells, which stimulates the production, maturation and activation 
of granulocytes (neutrophils, basophils, eosinophils).  Filgrastim is the generic drug name of a 
synthetic analogue of granulocyte colony stimulating factor which can be administered 
subcutaneously or intravenously.   Another preparation of filgrastim has polyethylene glycol  
(PEG) attached and is known as PEG filgrastim.  The polyethylene glycol attachment slows 
degradation and elimination of filgrastim from the body, hence enabling a single injection 
compared to the recommended single dose of 5 consecutive days for unpegylated filgrastim. 
Much work has been done evaluating the effectiveness of primary and secondary prophylactic 
granulocyte colony stimulating factor in the setting of chemotherapy-induced neutropenia.  
The majority of this supports the use of filgrastim to decrease the severity and duration of 
neutropenia (60-64).  Current guidelines recommend primary prophylactic use of GCSF when 
the risk of febrile neutropenia is approximately 20% or higher.  These recommendations are 
based largely on two phase III clinical trials (65, 66) and a systematic review of primary 
prophylaxis (67):   
1. The Vogel et al. trial reported administration of primary prophylactic PEG-filgrastim at 
6mg subcutaneously on day 2 following docetaxel chemotherapy at 100mg/m2 for breast 
cancer as superior to placebo at preventing febrile neutropenia (1% versus 17%, p<0.001), 
febrile neutropenia-related hospitalisation (1% versus 14%, p<0.001), and intravenous 
antibiotic use (2% versus 10%, p<0.001) (65).  The methodology was strong with a large 
sample size (n=920), multi-centre recruitment and it was placebo controlled.  However, 
the definition of febrile neutropenia had stricter boundaries than used in current practice 
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(it used temperature >38.2oC and neutrophil count <0.5 x109/L), meaning it may have 
underestimated the benefits, and although it recorded some patient factors, it did not 
include co-morbidity, a characteristic previously linked to poor outcome (47).   
 
2. In the Timmer-Bonte et al. trial (66), primary prophylactic granulocyte colony stimulating 
factor administered along with prophylactic antibiotics was found to be superior to 
prophylactic antibiotics alone at preventing febrile neutropenia in cycle one of 
cyclophosphamide, doxorubicin and etoposide for patients with small-cell lung cancer 
(incidence of febrile neutropenia was 10% versus 24%, p=0.01).  There were 175 patients 
randomised in this trial, where the primary outcome measure was difference between the 
2 arms in proportion of patients with febrile neutropenia in the first cycle of 
chemotherapy.  Exploratory analyses of length of febrile neutropenia, length of hospital 
admission for febrile neutropenia, or death secondary to infection (cycle 1, death 
secondary to infection was 2% (antibiotic + GCSF arm) versus 5% (antibiotic only arm), p = 
0.37) found the difference between the arms to be not statistically significant.    
 
3. In the systematic review, granulocyte colony stimulating factor was effective at reducing 
incidence of febrile neutropenia compared to the controls  receiving placebo or no 
prophylactic therapy (relative reduction = 0.54, 95% CI 0.43-0.67, p<0.001), infection-
related mortality (relative reduction = 0.55, 95% CI 0.33-0.90, p=0.018) and all-cause 
mortality (relative reduction = 0.60, 95% CI 0.43-0.83, p=0.002), independent of age, 
secondary GSCF prophylaxis and antibiotic prophylaxis.  Seventeen randomised controlled 
trials were analysed, but only 15 of these (including the two randomised controlled trials 
mentioned above), totalling 3182 patients, reported febrile neutropenia as an outcome.  
Strengths include robust methodology as the strategy recommended by Cochrane 
Collaboration was followed and studies (n=3) were permitted where both the 
experimental and control arms received prophylactic antibiotics.  The analysis did not, 
however, include patients receiving dose-dense chemotherapy regimens, and only one 
study used PEG filgrastim whereas the others used filgrastim.  
As with all treatment, the advantages should be offset against the disadvantages.  With 
filgrastim these are most commonly reported as bone pain (35% PEG-filgrastim, 36% 
filgrastim) (68), which sometimes requires opiate analgesia, and drug costs including 
administration (65, 69, 70).  In 1998, Lyman et al. reported a risk of 20-25% of febrile 
neutropenia to justify the cost of prophylactic granulocyte colony stimulating factor (69, 70).  
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However, a more recent study in 2006 found that the addition of granulocyte colony 
stimulating factor to prophylactic antibiotics, was only cost saving if the probability of febrile 
neutropenia was greater than 84%, the cost of granulocyte colony stimulating factor was less 
than €469 per patient, and the cost of an episode of febrile neutropenia was greater than 
Euro(€)11,552 (70).  Given that the mean cost of an episode of febrile neutropenia in this trial 
was €3,300, it would seem likely that most patients would not qualify to receive prophylactic 
granulocyte colony stimulating factor.  Moreover, a study conducted in the United States only 
two years earlier reported a mean cost of an episode of febrile neutropenia of US$12,302 
(71).  Both trials used robust methods of cost calculation and adjusted the cost to year-specific 
price levels.  The main difference in costs was for hospitalisation.  For example, antibiotics 
cost less in the Netherlands, there was more frequent use of intensive care in the US, and 
definitions of febrile neutropenia varied.  These differences highlight the need for country and 
population-specific economic analyses, in order to inform routine practice, in which primary 
prophylactic granulocyte colony stimulating factor is not currently embedded as standard.   
1.2.5.2 Prophylactic antibiotics 
Much work has also been done evaluating prophylactic antibiotic use.  There was a meta-
analysis in 2006 with 3440 patients (72), including a large randomised controlled trial of 1565 
patients of whom 72.3% had a diagnosis of breast, testis or lung cancer (73).  The meta-
analysis concluded that prophylactic fluoroquinolone antibiotics reduced all-cause mortality 
during the first cycle of chemotherapy in patients with solid tumours or lymphomas (patients 
receiving prophylactic antibiotics versus either placebo or not antibiotics, relative risk 0.51, 
95% CI 0.27-0,97) (72).  Given concerns regarding the use of prophylactic antibiotics in 
patients on chemotherapy such as selection of resistant strains of bacteria and the use of 
quinolones resulting in a resurgence of Gram positive bacteraemia, Cullen et al. addressed the 
issue of selective application of prophylactic quinolones to prevent fever and hospitalisation 
from infection amongst patients with a range of characteristics, including diagnoses of breast, 
testis and small cell lung cancer (74).  They found antibiotic prophylaxis to be most effective 
during the first cycle of chemotherapy, during subsequent cycles after an episode of fever, 
and they reported the efficacy to be consistent across age, gender, performance status, 
treatment context and disease type.  
 
Cochrane published a systematic review on antibiotic prophylaxis during chemotherapy in 
2012 (75).  The relative risk reductions in main endpoints were quite persuasive; antibiotic 
prophylaxis significantly reduced the risk of death from all causes (risk ratio (RR) 0.66, 95% CI 
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0.55 to 0.79), the risk of infection-related death (RR 0.61, 95% CI 0.48 to 0.77), the occurrence 
of fever (RR 0.80, 95% CI 0.74 to 0.87), clinically documented infection (RR 0.65, 95%CI 0.56 to 
0.76) and microbiologically documented infection (RR 0.51, 95% CI 0.42 to 0.62).  This 
included a large number of patients (13,579), but 70 out of the 109 studies included only 
patients with haematological malignancies and only 13 studies comprised >80% patients with 
solid tumours, making the conclusions from this more applicable to haematological practice 
than solid tumour oncology.  Other anomalies are that 22 studies were included that started 
antibiotic prophylaxis when the patient became neutropenic rather than at initiation of 
chemotherapy; the majority of studies did not report antibiotic compliance and in many the 
follow-up was too short to assess bacterial resistance.  This review has not resolved the 
subjectivity reflected in international guidelines, recommending quinolone prophylaxis for 
intermediate and high risk patients with solid tumours determined by the expected extent 
and duration of neutropenia (19, 26, 28, 30).  Despite this, use of primary prophylactic 
antibiotics is not common practice in the United Kingdom for low or intermediate risk 
chemotherapies.  This may be because of the changing landscape brought about by initiatives 
such as use of the MASCC score to identify patients at low risk of complications of febrile 
neutropenia (22).  This presented the opportunity to select patients for novel pathways, such 
as early downscaling of intravenous antibiotics to oral and subsequently earlier discharge, 
thus reducing the burden and therefore opportunity costs of febrile neutropenia.  There are 
other methods with potential to be used to select patients according to their risk of 
neutropenic complications, including use of diagnostics to monitor neutrophils at different 
stages of a chemotherapy cycle.      
 
1.3 Diagnostics 
Diagnostics are defined as instruments or techniques used in medical diagnosis.  Diagnostics 
are used routinely in medical practice, for example, blood test measurement in the 
laboratory, X-rays, blood pressure measurement, temperature measurement.  The key aspect 
when considering diagnostic tests is to establish whether the patient is likely to benefit from 
the test and whether the potential of the benefits out-weigh the associated risks.     
1.3.1 Point of care testing 
Point of care testing refers to diagnostics carried out at or near the patient.  It is sometimes 
known as “near patient testing”.  It is in contrast, for example, to a routine venous laboratory 
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blood sample, where the tube of blood is transported to the laboratory analyser, and is not 
measured at the time or place of the patient.  The benefit of point of care testing is assumed 
to be convenience of bringing the test to the patient, often with expedition of speed of the 
result in comparison to traditional methods.  The “point of care” test may be by a professional 
within a primary or secondary care environment, but to maximise benefit to the patient, it 
may be in their home, or even a self-test in their home.  The challenge is delivering the quality 
of measurement in a cost effective manner that does not result in inferior care for the patient 
in comparison to standard practice.   
A successful example of using in vitro device testing at the point of care has been the 
introduction of self-management of International Normalised Ratio (INR) in patients on 
warfarin in reducing further thrombotic events (76).  This has gone a step further than many 
point of care testing devices in use, by being proven to be effective in the hands of patients, 
thus making “point of care” the patient’s home rather than an NHS care provider. 
Desktop laboratory haematology analysers can be used in oncology departments, but these 
still require operation by a professional and therefore do not negate the need for the patient 
to travel to hospital.  A major burden and limiting factor in measuring blood counts in patients 
on chemotherapy is that usually the patient is required to visit a hospital or their local general 
practitioner’s surgery.  Patient-led home blood count monitoring may be possible using 
patient-obtained capillary samples and this has the potential to improve clinical pathways by 
reducing patient journeys to hospital.  It is currently common practice to routinely measure 
capillary blood counts in neonates, but not adults.  Another advantage of testing capillary 
samples in adult patients on chemotherapy is that it requires a smaller volume of blood than 
venous samples and is less invasive in patients who require preservation of veins for the 
delivery of chemotherapy and frequent blood tests.   
1.3.1.1 Evaluation  of point of care testing 
The evaluation of diagnostics has historically been given less attention than, for example, 
pharmaceutical interventions (77).  This may be in part because pharmaceutical interventions 
often have a more direct impact on patient outcome, whereas the link to outcome with 
medical tests depends on how the result is used to guide clinical management.  Therefore, 
evaluation of diagnostics should include; 
 Analytical performance: a measure of how reliably results correspond to the true 
value. 
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 Clinical performance: a measure of whether the diagnostic distinguishes disease from 
the non-diseased state. 
 Clinical effectiveness: a measure of whether the diagnostic guides management 
better than not relying on that test (includes costs to the patient and service 
provider). 
As such, evaluation of diagnostics is complex and may require a multi-disciplinary approach.  
In the context of using an in vitro-diagnostic device to measure neutrophil counts, this 
requires involvement from haematology laboratory professionals and clinicians.  
There are national and international guidelines and standards to ensure that point of care 
testing is conducted to high standards and minimises risk to patients (78-81).  These provide a 
framework for local arrangements for point of care haematology tests within NHS hospitals, 
and are prescriptive regarding requirements for point of care tests to be comparable to those 
of local reference laboratory analysers, including how flagged results should be managed. 
The gold standard for testing white cell differential counts is manual counting (82).  However, 
this method of differential counting is not feasible in a time frame required in acute hospitals 
such as in Leeds Teaching Hospitals NHS Trust, due to the number of tests being done and the 
fact that white cells degrade in vitro.  Moreover, manual counting is unlikely to be precise in 
the extreme neutropenic range as the number of white cells can be insufficient to reach the 
minimum required to standardise the count (83).  Therefore it has been suggested that flow 
cytometry using monoclonal antibodies may be a more suitable reference for neutropenic 
samples (84).   
Leeds Teaching Hospitals NHS Trust haematology laboratories currently use the Siemens 
ADVIA 2120 automated haematology cell counter to measure total blood counts.  There are 
four of these machines within the St James’s site haematology laboratory alone.  These are 
subject to both internal and external quality assurance processes.  The internal processes 
involve daily quality control checks using samples bought from the manufacturer with three 
levels of control covering the normal and both extremes of range.  The values are set by the 
manufacturer and +/- 10% of the value is indicated as acceptable performance.  The external 
process uses the UK National External Quality Assessment Service (NEQAS), which is an 
independent service aiming to ensure the optimal quality in testing for the benefit of patients.  
This distributes commercially-prepared whole blood samples to registered laboratories to be 
tested on analysers, and performance across the country is independently compared and 
statistical calculations applied.  The performance is reported in comparison to the mean of the 
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anonymised analysers in all other registered laboratories across the UK.  The limits of 
acceptance for neutrophil counts are +/- 2 standard deviation (SD) indices from the overall 
mean count, which is a measure of how close an individual laboratory analyser performed in 
relation to the mean value.  Leeds Teaching Hospitals NHS Trust haematology laboratories 
receive and test a full blood count sample that includes total white cell count every month, 
and they receive a sample for differential white cell count testing including neutrophils every 
other month.  The reference neutrophil value of the sample varies from neutropenic, through 
the normal range to neutrophilic.  Figure 2 shows an example NEQAS performance report for 
a laboratory measuring neutrophil counts.  
For all analyses in this thesis, the neutrophil count from the Siemens ADVIA 2120 automated 
analysers used by Leeds Teaching Hospitals NHS Trust were taken as the reference counts.  
This is because the overarching important clinical question is regarding whether a point of 
care white cell differential analyser can be safely used in place of the current standard of care 
laboratory generated results.  Published independent performance analyses of the ADVIA 
2120 in comparison to both manual counting and flow cytometry indicate high accuracy and 
precision, with the warning of imprecision in cell counts with low numbers.  In a study of 106 
patients with a neutrophil count <2.0 x109/L, the correlation of the ADVIA 2120 with flow 
cytometry reference counts reported the correlation as r2=0.968, y=0.99𝑥 + 0.02, and the 
precision was reported as co-efficient of variation (CV) 5.7% (85).  In another study where the 
neutrophil count was measured in 593 venous blood samples across the full range of 
neutrophil counts by both manual counting and on the automated ADVIA 2120, r was 0.948, 
with the line of best fit being 𝑦 = 0.90𝑥 + 0.73 (86).  Given the Leeds Teaching Hospitals NHS 
Trust ADVIA 2120 machines report within 10% of the reference value in internal quality 
control procedures, this is the limit of error around what is used as the reference value in the 
forthcoming performance analyses.  
1.3.1.1.1 Relevant statistical terms 
There are a number of statistical terms or methods that are of paramount importance in 
analysing and discussing the performance of point of care devices in measuring neutrophil 
counts in comparison to the laboratory automated ADVIA 2120 neutrophil counts.  These are:  
(i) Accuracy   
Defined as deviation of measurements from the standard or true value, and tends to be 
expressed as; 
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• Correlation – degree of association between two variables. 
 
 
Figure 2:  Example extract from a UK NEQAS performance report for a laboratory using 
automated differential leucocyte analysers.   
This is reproduced from a paper copy of a monthly report of the performance of one of the 
Leeds Teaching Hospitals NHS Trust, Siemens ADVIA 2120 analysers, with permission from 
Leeds Teaching Hospital NHS Trust pathology department.  This shows the performance of the 
neutrophil counts only, on 2 different test samples; a) target neutrophil count within “normal” 
range, and b) target neutrophil count within neutropenic range.  DI, deviation index.  CV, co-
efficient of variation (%).  The performance score is also plotted on a distribution graph, 
comparing to all other participating laboratories. 
 
 
a) 
b) 
Your instrument is Siemens 
ADVIA 2120 
Your result: 4.59 
Target value: 4.56 
DI: 0.06 
CV: 5.75 
N: 191 
Your instrument is Siemens 
ADVIA 2120 
Your result: 1.35 
Target value: 1.32 
DI: 0.07 
CV: 7.19 
N: 191 
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• Correlation co-efficient (r) – a measure of how close observations are to the straight 
line which best describes the linear relationship within the range of measurements plotted.  If 
r = +/- 1.0 then there is perfect correlation. 
• Co-efficient of determination (r2) – a measure of how well the line of best fit 
approximates the data. 
• Bland-Altman plots - demonstrate the agreement between the two assays, including 
identifying bias and outlying measurements (87).  In these plots, each of the samples is 
represented by assigning the mean of both measurements as the x-axis value, and the 
difference between the two values as the y-axis value.  The mean difference is the estimated 
bias, and the SD of the differences measures the random fluctuations around this mean.  
Good concordance tends to be represented by 95% of the differences falling within 1.96 SDs 
from the mean difference, and the mean difference being close to zero.  The first example of a 
Bland-Altman plot in this thesis is in Figure 17, chapter 3.  
• Receiver operator characteristic (ROC)curves – assess the ability of a test to correctly 
classify patients into diseased or non-diseased groups.  In these curves, false positive rate (1-
specificity) is plotted on the x axis, versus true positive rate (sensitivity) on the y axis, for 
different cut-off values of a parameter (neutrophil count in the context of this thesis).  These 
performance terms are explained in Table 4.  Each observation plotted represents a 
sensitivity/specificity pair corresponding to a particular decision threshold.  The area under 
the curve (AUC) is calculated and is a measure of how well the parameter (neutrophil 
threshold) can distinguish between two groups (neutropenic and not neutropenic).  The closer 
to 1.0 the AUC is, the more accurate the test.  The first example of a ROC curve in this thesis is 
in Figure 26, chapter 4. 
(ii) Precision 
Defined as how close a group of measurements are to one another, and tends to be expressed 
as co-efficient of variation (CV =
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑚𝑒𝑎𝑛
 ).  The closer the data is clustered, the 
smaller the coefficient of variation. 
The larger the number of paired and repeated measurements, the tighter the CIs are around 
the accuracy and precision. 
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There is a diagrammatic representation of accuracy and precision in Figure 3. 
 
Figure 3: Bulls eye visual demonstration of accuracy and precision.   
The circular grids represent the target measurement, where the central circle indicates the 
true or comparator value.  The larger circles indicate values successively further from the 
comparator value.  The black dots represent theoretical values indicated by the test device. a) 
The black dots close to the comparator value, but spread in different directions represent 
accurate, but not precise measurements. b) The black dots clustered together far away from 
the comparator value represent precise, but not accurate measurements. c) The black dots 
spread far from the comparator value and each other in all directions represent neither 
accurate or precise measurements. d) The black dots clustered close together and to the 
comparator value represent both accurate and precise measurements.  Use of the “bull’s eye” 
diagram to explain accuracy and precision is common practice.  This diagram has been 
adapted from multiple freely available sources. 
 
It is also useful to understand the measures of performance of tests in identifying disease, 
which is neutropenia in the context of this thesis.  Table 4 is used to explain the terms.  For 
example, in a situation where a point of care device is being used to identify patients who are 
neutropenic in those with suspected febrile neutropenia, sensitivity is the statistical term 
which corresponds to the proportion of patients out of all those who are neutropenic on the 
reference analyser who are  correctly identified using the point of care device.  Again in the 
situation where a point of care device is being used to identify patients who are neutropenic 
in those with suspected febrile neutropenia, the important clinical question is “what 
proportion of patients who are identified as not neutropenic by the point of care device, are 
19 
 
in fact incorrectly identified as they are truly neutropenic?”.  The statistical term which 
correlates with this patient group is 1 – negative predictive value. 
1.3.2 The devices 
There are three devices discussed in this section; 
1. Philips XBC 
2. Philips Minicare H-2000 
3. Hemocue WBC DIFF 
 
These devices measure either finger-prick granulocyte or neutrophil counts and there are 
photographs of each in Figure 4.  This project progresses from investigating the XBC, to the 
Minicare H-2000 through to the Hemocue WBC DIFF, as support for the former two devices 
was withdrawn during the time-period of this work.  This is why chapter 4 addresses the role 
of granulocytes being used as a surrogate for neutrophil counts, but subsequently, the 
performance analysis in chapter 5 uses the Hemocue WBC DIFF and specifically neutrophil 
counts.    
1.3.2.1 XBC  
Horizon scanning of the international market identified three devices and one technology in 
development capable of being used to measure either granulocyte or neutrophil counts at 
point of care (87).  One of these was Chempaq XBC which was “Conformité Européene” (CE) 
marked for professional use and was capable of measuring haemoglobin and 3-part 
differential white cell counts via a finger-prick capillary blood sample.  Philips Healthcare 
bought this device, and re-packaged it as the XBC.  It used the Beckman-Coulter counter 
principle to measure the granulocyte count in which cell counting and sizing is based on the 
detection and measurement of changes in electrical impedance (resistance) produced by a 
particle as it passes through a small aperture.  Generation of the granulocyte count required 
finger-prick blood sampling by a health-care professional using a lancet, such that a blood 
droplet was formed.  This droplet was then placed in a cartridge, which was introduced to the 
device which then took three minutes to display and print the result. 
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a) Laboratory venous ADVIA 2120 neutrophil count 
POC neutrophil count Neutropenic Not neutropenic Total 
Neutropenic a b a+b 
Not neutropenic c d c+d 
Total a+c b+d n=a+b+c+d 
b) 
Measure of 
performance 
Equation Description 
Sensitivity 𝒂
(𝒂 + 𝒄)
 
Proportion of individuals who are neutropenic and are 
correctly identified by the point of care device. 
Specificity 𝒅
(𝒃 + 𝒅)
 
Proportion of individuals who are not neutropenic and are 
correctly identified by the point of care device. 
True positive 𝒂 
Individuals who are neutropenic and are correctly identified 
by the point of care device. 
True negative 𝒅 
Individuals who are not neutropenic and are correctly 
identified by the point of care device. 
False positive 𝒃 
Individuals who are not neutropenic and are incorrectly 
identified as neutropenic by the point of care device. 
False negative 𝒄 
Individuals who are neutropenic and are incorrectly 
identified as not neutropenic by the point of care device. 
Positive 
predictive value 
𝒂
(𝒂 + 𝒃)
 
Proportion of individuals who are truly neutropenic of all 
those identified as neutropenic by the point of care device. 
Negative 
predictive value 
𝒅
(𝒄 + 𝒅)
 
Proportion of individuals who are truly not neutropenic of all 
those identified as not neutropenic by the point of care 
device.   
False negative 
rate 
𝒄
(𝒂 + 𝒄)
 
Proportion of individuals identified as not neutropenic by the 
point of care device of all those who are truly neutropenic.   
False positive 
rate 
𝒃
(𝒃 + 𝒅)
 
Proportion of individuals who are identified as neutropenic 
by the point of care device of all those who are truly not 
neutropenic.   
Table 4: Tables explaining parameters used to describe the performance of a test. 
a) 2 x 2 table demonstrating identification of neutropenia by the reference and point of care 
methods, and b) Table explaining measures of performance.  POC – point of care. 
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Figure 4: Images of the three point of care devices with capabilities of measuring finger-
prick white cell counts.   
a) Philips XBC – for professional use to generate haemoglobin, total white cell count and 3-
part white cell differential count.  b) Philips Minicare H-2000 – intended for patient self-test 
use to generate haemoglobin, total white cell count, 3-part white cell differential count using 
the finger-prick blood sample, and to measure tympanic membrane temperature using the 
Bluetooth-linked thermometer, and to transmit these results electronically to the health-care 
provider through the 3G, 4G or GPRS network. c) Hemocue WBC DIFF – for professional self-
test use to generate haemoglobin, total white cell count, 5-part white cell differential count.    
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1.3.2.2 Minicare H-2000 
The Minicare H-2000 was developed to facilitate patient self-test home monitoring of 
haemoglobin, total white cell count and granulocyte count, temperature recordings and 
symptoms.  The blood count measuring technology was as described for the XBC.  As it was 
intended for patient self-test use, the method of ascertaining sufficient blood sample within 
the cartridge and the way in which the cartridge was received into the reader were more 
patient-appropriate.  The four integral components facilitating home self-test use were;  
i) blood count measuring technology for use with a capillary sample  
ii) a Bluetooth connected thermometer  
iii) a tele-hub with touchscreen allowing pre-defined two-way communication 
between patient and health-care provider 
iv) secure communication technology allowing linkage to a server within the 
secondary care provider via the 3G, 4G or general packet radio services (GPRS) 
networks or internet. 
 
Manufacture of the Minicare H-2000 on a larger scale than the early prototypes was fraught 
with complications which were not overcome by the manufacturing quality control team in a 
time scale or resource use that was acceptable to Philips.  Most of the complications were 
directly related to materials being used, but in some cases they affected the performance of 
the device, and as such were critical hurdles.  Philips Healthcare withdrew support for this 
device in October 2016. 
1.3.2.3 Hemocue WBC DIFF 
The Hemocue WBC DIFF System is “Conformité Européene” (CE) marked for professional use 
and measures total white cell count, neutrophils, lymphocytes, monocytes, basophils and 
eosinophils.  It therefore has the advantage over the other devices of generating a neutrophil 
count, thus negating the need to incorporate a margin to account for using the granulocyte 
count in oncology practice that now tends to use the neutrophil count for safe delivery and 
management of toxicities of chemotherapy.   
The device uses image analysis techniques to count the white blood cells and perform a 5-part 
differentiation.  Ten microlitres of blood from a droplet obtained via a finger-prick skin 
puncture is drawn by capillary action into the microcuvette, which is preloaded with reagent 
and serves as a pipette, sample container and reaction chamber.  The erythrocytes are 
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haemolysed and the leukocytes are stained with methylene blue within the microcuvette. A 
camera repeatedly moves through the cavity of the microcuvette to capture images of the 
stained white cells.  It takes more than 30 images of each cell, merging these into one final 
image. More than 30 different features, such as size, shape, texture, granules etc, have been 
identified for each cell type and translated into a mathematical algorithm which is 
implemented in the device.  It is capable of using this state-of-the-art imaging technology to 
count total white cells in the range 0.4 – 30 x109/L. It has an inbuilt Quality Control system 
which checks for problems such as incorrect filling of the microcuvette, improper light, blurred 
cells, reagent stability and it displays an error code without the result if the QC check fails.   
1.4 The innovation 
The National Chemotherapy Advisory Board Good Practice guideline promotes patient 
empowerment and pro-active monitoring of patients on chemotherapy to improve quality of 
care of patients on chemotherapy (88).  A device suitable for patient self-test home blood 
count monitoring has the potential to facilitate both of these approaches and to personalise 
patient care.  This could initially be in collaboration with health-care professionals co-
ordinating the care, but subsequently could be through clinician pre-defined parameters 
stored on the device.  We hypothesized that there are four time points during a cycle of 
chemotherapy where there is scope to explore the potential role of home neutrophil count 
monitoring in individualising patient care: 
1. After chemotherapy delivery to identify if early changes in neutrophil counts are 
predictive of neutropenic complications. 
2. Any time during the cycle to exclude neutropenia in those with suspected febrile 
neutropenia. 
3. At intervals during the cycle to quantify neutrophil nadir.  
4. Prior to delivery of the subsequent chemotherapy cycle to confirm sufficient 
neutrophil recovery.  
 
In an NHS under ever-increasing financial constraints, this personalised medicine approach 
has the potential to be used to risk stratify patients on chemotherapy and hence streamline 
the service and clinical pathways according to the greatest need.  Clinical pathways could be 
defined according to risk of febrile neutropenia, thus focusing resource on those that are most 
likely to benefit.  Interestingly, there is convincing evidence of prognostic value in attaining 
neutropenia during chemotherapy (89-93), and of progression-free survival benefit using the 
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neutrophil nadir to tailor chemotherapy dosing (94).  For example, a retrospective review of 
routine practice in the adjuvant breast cancer setting reported a 10% absolute survival 
advantage for those with a grade 2 or 3 neutropenia (89).  However, most data supporting 
prognostic value is in the adjuvant breast cancer setting only and is retrospective.  Moreover, 
the prospective trial only collected the neutrophil count at day 10 during the chemotherapy 
cycle, and therefore may also underestimate the true nadir and its prognostic value.  Thus 
there is a potential to use home blood count monitoring to guide chemotherapy dose 
intensity and density to improve outcomes.  This is discussed further in the introduction to 
chapter 6.  
 
This thesis explores the potential of home blood count monitoring to individualise 
chemotherapy delivery and supportive management through prediction of neutropenia, it’s 
duration and complications, early detection of neutropenia and monitoring of recovery.  The 
ambition in the long-term would be to evaluate a self-test device in high risk patient groups at 
all points in the pathway stated above.   The potential gains envisaged with a successful test 
and treat risk stratified strategy using home neutrophil count testing in patients during 
chemotherapy could include: 
 
(i) Reduction in frequency and severity of chemotherapy-induced neutropenic 
adverse events, achieved by; 
a. more intense testing schedule in high risk patients to provide an early alert of 
severe neutropenia.  
b. intervention such as prophylactic use of antibiotics or granulocyte colony 
stimulating factor in high-risk groups. 
 
(ii) Reduction in patient hospital attendances through; 
a. advising the patient to stay at home if mildly unwell mid chemotherapy cycle, 
and they are not neutropenic. 
b. developing novel pathways of care such as delivery of antibiotics in the 
community for well patients with febrile neutropenia.  
c. advising the patient to stay at home if the neutrophil count on the day 
subsequent chemotherapy is due has not recovered sufficiently for safe 
delivery. 
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(iii) Improve patient outcomes through; 
a. reduction in frequency and severity of neutropenic complications. 
b. potential to improve cancer outcomes through personalising dose intensity 
and density of chemotherapy based on neutrophil nadir, and early re-
treatment once the neutrophil threshold for treatment is crossed. 
 
(iv) Improved patient experience through; 
a. any of 1, 2 and 3 above. 
b. reducing anxiety and inconvenience through retrieving  prompt neutrophil 
results. 
 
(v) Financial savings through; 
a. reduction in number and length of inpatient admissions and outpatient 
attendances. 
b. reduction in laboratory investigations. 
c. reduction in transport costs. 
d. reduction in wasted chemotherapy. 
 
1.5 Objectives 
This thesis aims to explore the feasibility of home neutrophil count monitoring in patients 
with cancer on chemotherapy.  It forms the necessary early work in a longer-term vision that 
is to use home blood count monitoring to change treatment pathways of patients with cancer 
by individualising chemotherapy delivery and supportive management, through prediction of 
neutropenic complications, early detection of these, quantifying the neutrophil nadir and 
monitoring of neutrophil recovery.  The objectives of this thesis are re-defined through 
progression of the project due to the challenges and limited functionality of the available 
devices.  The primary objectives are addressed throughout each chapter, and the secondary 
objectives align with individual chapters. 
The final objectives are; 
 Primary 
1. To explore the feasibility of self-test home neutrophil count monitoring in 
patients on chemotherapy. 
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2. To generate sufficient evidence to justify a test and treat pilot study using patient 
self-test home neutrophil count testing to improve patient experience and 
neutropenic complication outcomes.  
 
 Secondary 
1. To explore patient and professional views on the acceptability of home blood 
count monitoring. 
2. To define error and risk associated with using haematological parameters 
available on point of care devices as surrogate markers of laboratory-generated 
results. 
3. To assess performance of the Hemocue WBC DIFF device in the neutropenic range 
clinically relevant to oncological practices.     
4. To define the extent of neutropenic complications in current practice. 
5. To profile neutrophil counts during chemotherapy to identify points in the clinical 
pathways where there is potential for use of home testing to improve patient 
experience and outcomes. 
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Chapter 2 Characterising clinical pathways during chemotherapy to 
define the incidence of neutropenic complications 
2.1 Introduction 
In an NHS under ever-increasing financial and performance pressures, the need for change to 
current practice in order to find efficiency savings whilst maintaining clinical standards has 
never been greater.  This is true in oncological practice where the number of patients living 
with cancer is increasing and forecast to continue in this way, in addition to the increasing 
cost of new treatments.  Importantly, although many new treatments are either molecularly 
targeted agents or immunotherapies, these are often given in combination with cytotoxic 
chemotherapy which will remain central to the treatment of patients with cancer for the 
foreseeable future. 
Challenges within oncological practice were identified by the National Confidential Enquiry 
into Patient Outcome and Death (NCEPOD) in 2008, which reported that 42% of patients who 
died within thirty days of systemic anticancer therapy were admitted with a treatment-related 
complication to a general medical ward, rather than to a ward with oncology-specific 
expertise (95).  This identified problems at a high level with limited amount of detail.  The 
NCEPOD and the National Chemotherapy Advisory Group highlighted the incompleteness of 
patient records, many of which were paper-based at the time, along with shortcomings of 
conventional real-life data collection (96).  At LTHT, electronic health records (EHRs) have 
been used in routine practice to collect comprehensive clinical data on oncology patients 
since 2004, and this chapter realises some of the benefits of this data collection by processing 
it in such a way that it can be used to characterise clinical pathways of patients on 
chemotherapy.  
Existing clinical pathways establish the expected standard of care, which in turn guides the 
processes and procedures required to meet those standards (97). These pathways are 
increasingly more evidence-based (98, 99), but such evidence is generally derived from 
carefully structured clinical trials rather than learning directly from routine clinical practice 
which can be very different to the trial situation. For example, the reported incidence of 
febrile neutropenia after common chemotherapy regimens varies considerably between 
randomised controlled trials, and trial patient cohorts usually do not reflect the more 
unselected patients of routine practice; consequently, uncomplicated neutropenia as a 
toxicity of chemotherapy may be under-estimated (36).  Thus, it is important to question 
whether perceived patterns of existing care are accurate and meaningful.  
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In oncology, there is increasing attention on the use of large datasets (100), with much of the 
focus being on applications of next generation sequencing genomics (101). Process mining is 
one emerging “big data” approach for discovering and analysing process models based on the 
very large event logs contained within information systems (102) and there is a growing body 
of literature on process mining in healthcare (103).  A review of the process mining literature 
identified thirty-seven peer reviewed papers using electronic health record (EHR) data to map 
pathways in oncology (104). This review was hindered by there being no standard medical 
subject heading (MeSH) term for “process mining” and therefore may not be comprehensive.  
None of the thirty-seven papers specifically reported mapping neutropenic complications. 
Challenges included the difficulty of capturing outpatient events (105), the use of data 
collected for non-clinical purposes, missing data or unstructured data and clinically inaccurate 
time-stamps (106).   This issue of data quality in electronic health records, and therefore 
suitability for research, has been acknowledged (107, 108).  An example is the discrepancy in 
quality associated with structured and unstructured data fields.  A structured data field allows 
only a finite list of possible data entries chosen from a list, whereas unstructured can be free-
text, meaning similar content can be entered in a number of different ways, hence making it 
difficult to group these for audit or research purposes.  
The Leeds Teaching Hospitals NHS Trust has developed and uses Patient Pathway Manager 
(PPM) as the Trust-wide electronic health record (EHR).  It is a mature EHR that is used to 
capture comprehensive clinical data on all patients undergoing treatment for cancer at the 
Leeds Cancer Centre.  It was initially developed in 2003 to support collection and reporting of 
the National Cancer Outcomes Services Dataset (109).  It has extended further more recently 
to collate data on all patients whose care has been delivered at LTHT since the year 2000.  In 
this chapter, PPM is the data source used to map patient pathways during chemotherapy.  
These pathways are comprehensive and patient-centred, addressing issues in published 
oncology process mining by reporting most contacts the patient has with the hospital 
including in- and out-patient events and pathology results. A novel iterative approach is used 
to address data quality through clinical review to refine the model.   The results are reported 
through formulation of a Markov model (see following paragraph), quantification of pathways 
followed within two exemplar chemotherapy regimen and diagnosis combinations and 
compared across all chemotherapy regimen and cancer diagnosis site combinations.  The 
reported febrile neutropenia rates are compared to existing published rates.    
Markov models are often used to aid health care decision making. They are suited to decisions 
where the timing of events is important and when events may happen more than once, 
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appropriate when the strategies being evaluated are of sequential or repetitive nature.  The 
principles of Markov modelling are briefly described here as they are comprehensively 
discussed in the literature (110, 111).  A cluster of clinical events are simplified by defining 
them as clinically important health states or Markov states.  For example, in the model 
described in this chapter during chemotherapy, a patient in the health state of febrile 
neutropenia, has; 
(i) an entry in the hospital admissions table. 
(ii) a neutropenic blood count. 
(iii) blood cultures analysed that did not grow a pathogenic organism. 
Markov models assume that the health states are mutually exclusive as a patient cannot be in 
more than one state at any one time.  The transition of a patient from one health state to 
another is assigned a probability, known as the transition probability.  Markov models 
represent repetitive processes over time whereby the patient passes through the same health 
state on more than one occasion, represented in this model by the delivery of chemotherapy.  
Patients can therefore, only exit the repetitive model via defined exit states, which in this 
model exist as one of only three states; complete chemotherapy, stop chemotherapy 
prematurely, death.  There is also an assumption that transition to future states depend only 
on the current state, and not on any events that occurred before the current state.  This is 
known as the Markov assumption.     
The work described in this chapter defines the baseline patient pathways during 
chemotherapy and quantifies the real-life extent of neutropenic complications, with the 
potential to identify where in the pathway there is scope to use home blood count 
monitoring.  Understanding the real-life starting point early is well characterised as an 
essential step in the process of change management; “dissatisfaction with the status quo is 
not enough to create change on its own – there needs to be a vision of the future and the first 
few steps mapped on the path to get there” (112).  This has been expressed mathematically 
as; 
Change = current pain x vision x easy first steps 
This chapter deals with understanding the “current pain”, in other words, the real-life 
prevalence of neutropenic complications in an unselected population of patients served by 
Leeds Cancer Centre.  It determines the value of establishing the local baseline pathways over 
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and above the information which is available from published trials, in order to inform patient 
selection for the trial described in chapter 6. 
2.2 Objectives 
2.2.1 Primary objectives: 
1. To understand the prevalence of febrile neutropenia or neutropenic sepsis in the 
unselected patient population on chemotherapy served by LTHT. 
2. To map clinical pathways of unselected patients on chemotherapy, thus defining and 
quantifying the baseline patient pathways. 
3. To compare the prevalence of neutropenic complications to published data in order to 
identify the value in establishing institution specific prevalence. 
2.2.2 Secondary objectives: 
1. To inform patient selection criteria for the subsequent trial aiming to profile 
neutrophil counts during chemotherapy. 
2. To inform clinical and health economic modelling processes of where in clinical 
pathways the use of home blood count testing has the potential to be of benefit. 
 
2.3 Methods 
2.3.1 Resources 
2.3.1.1 Patient Pathway Manager 
PPM integrates electronic data held within multiple disparate systems within the Trust into a 
single EHR database including data on patient admissions and out-patient events from the 
Patient Administration System (PAS), chemotherapy data from Chemocare (113), radiotherapy 
data from Mosaiq (114), blood, pathology and microbiology results from laboratory systems 
and data entered directly into PPM including surgery, cancer waiting times and multi-
disciplinary team meetings. Figure 5 illustrates how components of PPM are entered.  In PPM, 
each event is recorded with a patient identification and date time stamp, enabling a historical 
pathway to be extracted for every patient. 
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2.3.1.2 Computing facilities and expertise 
An information technology data analyst, Karl Baker, developed the datamining software with 
capabilities to develop the pathway model of patients on chemotherapy.  The data mining 
software created a warehouse database by extracting and transforming data from PPM. The 
warehouse database is used to generate Comma Separated Value (CSV) exports of aggregate 
figures. This software was written in C# and was run on a machine with an Intel Core I7 
processor with 16GB of memory.     
 
 
Figure 5: Overview of data entered into PPM.  
MDT, multi-disciplinary team. Chemocare, chemotherapy electronic prescribing system. PAS, 
patient administration system. Results server, LTHT software importing all patient 
investigation results from multiple disciplines. CWT, cancer waiting times. MOSAIC, radiation 
oncology software. ePRO, clinical information management system working with Winscribe’s 
digital dictation system. Telephone contact, hospital staff telephone patient.  Patient 
telephone enquiries, patient rings hospital with a clinical enquiry.  Some of the data in PPM 
was not used in this analysis as it either was not a result of direct patient contact with the 
hospital (i.e. it was generated by previous contact, such as MDT review), it was unstructured 
(for example, clinical letters), or it did not form part of the pathway during a cycle of 
chemotherapy.  
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2.3.2 Processes 
2.3.2.1 Defining the Markov Model 
The steps followed to construct a Markov model are described below and were; define the 
patient inclusion criteria, defined the relevant health/Markov states, defined acceptable 
transitions between health states, identified transition probabilities, identified health 
outcomes, then ran the model over repeated Markov cycles.  The transition probabilities were 
calculated by patient data from PPM, in contrast to estimations where such a comprehensive 
dataset is not available to inform the process.   
All clinical parameters underlying the model were defined, with a data analyst (KB) translating 
these into C# language and developing the software to support the model.  With KB a model 
was developed and refined through the iterative process described below.   
2.3.2.1.1 Clinical Definitions 
Patient characteristics  
Patient data were included in the dataset if they had a diagnosis of cancer and received either 
cytotoxic chemotherapy or targeted therapy for this diagnosis at Leeds Cancer Centre on or 
between 1st April 2004 to 1st January 2016. Table 5 shows the rules used to define the clinical 
characteristics. 
Patients receiving single agent hormones or bisphosphonates were excluded.  The recorded 
treatment intent was not used as a selection criterion, as this was considered to be unreliable 
after manually reviewing a random selection of approximately 100 records.  Patients receiving 
prophylactic granulocyte colony stimulating factor during the cycle of chemotherapy were 
included.  The period before (7 days) and after chemotherapy administration (5 days) 
accounts for the fact that the date held electronically for granulocyte colony stimulating factor 
was the date of dispensing from pharmacy, and not the date of administration to the patient.  
Prophylactic granulocyte colony stimulating factor is most commonly dispensed at either the 
chemotherapy pre-assessment visit or chemotherapy delivery.  Granulocyte colony 
stimulating factor used therapeutically in an acutely unwell patient is not recorded 
electronically as it is dispensed form ward stock and is therefore not included in this analysis. 
Health states 
Clinical rules were defined and applied to the data to create the model health states.  All 
events had to occur between the start and end date of chemotherapy.  Day 1 was considered  
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to be the day chemotherapy was delivered.  Table 6 shows the rules used to define the model 
health states. 
 
  
 
 
Table 5: Description of rules and methods used to define patient clinical characteristics.  
ICD, International Classification of Diseases.  PPM, Patient Pathway Manager. CDS, 
Commissioning Data Sets site diagnosis code.  CWT, Cancer Waiting Time.  SACT, Systemic 
Anti-cancer Therapy.  GCSF, granulocyte colony stimulating factor.  *Patients managed in 
other hospitals can be discussed at Leeds MDTs as it is a tertiary referral centre.  These 
patients’ records are in PPM, but as they receive chemotherapy at their referring institution, 
PPM does not hold the records of their care during chemotherapy. 
 
 
 Clinical 
characteristic 
Defining rules and methods 
Diagnosis of 
cancer 
Used ICD-10 codes for cancer (begin with C or D), which is automatically 
generated in PPM when malignancy, primary site and morphology is 
manually entered into PPM. In the 13.9% which did not have an ICD-10 code, 
the manually entered primary site diagnosis code(CDS) was used.  Overall 
1.1% of records had neither an ICD-10 or CDS code.  
Received 
chemotherapy 
Used an entry marked as “delivered” in the PPM chemotherapy drugs table, 
if it was between the specified dates, and the primary treating institution 
was Leeds.*  Data in this table is imported from Chemocare, and “delivered” 
indicates generation of the prescription. 
Linking 
diagnosis with 
chemotherapy 
The CWT table in PPM linked the diagnosis to chemotherapy in 75% of 
records.  In the remaining 25%, if there was only 1 cancer diagnosis it was 
linked to the chemotherapy.  If ≥ 1 cancer diagnosis, a link was made if the 
same chemotherapy was given for one of the diagnoses in ≥95% of cases.  
Otherwise, the diagnosis date closest to and before the delivery of 
chemotherapy was used. 
Regimen 
nomenclature 
Chemotherapy regimens were obtained from the “regimens” table in PPM 
and labelled according to the national SACT dataset mapping.  Non-cytotoxic 
anti-cancer drugs were identified by labels in the SACT mapping.  Identifiable 
regimens delivered as part of a trial were included, but records where the 
drug could not be identified such as receiving treatment in a trial with a 
placebo arm were excluded. 
Regimen cycle 
length 
Cycle length was defined by the modal cycle length of that regimen in the 
dataset. 
Regimen cycle 
number 
Cycles were numbered continuously whilst the regimen and diagnosis 
remained the same.  The numbering restarted at “1” if the diagnosis or 
regimen changed or the same regimen was delivered ≥95 days after the start 
of the previous cycle.  
Prophylactic 
GCSF 
Used pharmacy dispensing record of GCSF. Considered prophylactic GCSF 
was used if dispensed up to 7 days before and 5 days after delivery of 
chemotherapy. It was indicated by adding GCSF to regimen name. 
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Health state Defining rules and methods 
≥1 day admission Entry in admissions table that was recorded as starting before and 
ending after midnight of the day it started. 
0 day admission Entry in admissions table, with an “non-elective” label that was 
recorded as starting before and ending before midnight of the day it 
started. 
Neutropenic A full blood count result on results server during  a cycle length, where 
the neutrophil count is <1.0 x109/L. (Neutropenia at time 
chemotherapy is due is considered to be <1.5 x109/L for 3-weekly 
regimens) 
Blood cultures 
taken 
Presence of a microbiology report of blood culture on results server. 
Bacteraemia Used microbiology free-text reports.  Searched approximately 500 
manually to identify commonly used phrases that indicate or exclude 
culture of pathogenic organisms.  Then automated the searching of 
the full dataset of blood culture results on results server taken within 
the cycle of chemotherapy using the phrases.   
Other positive 
microbiology 
As above, except samples from sites other than blood. 
Urgent outpatient 
appointment 
Entry in the outpatient appointment table, labelled as “emergency”. 
Elective ward 
review 
Entry in the admissions table, with a “non-urgent” label and duration 
of admission <1 day. 
GP contact with 
neutropenia 
Blood count result on results server with no simultaneous record of 
activity in PPM. 
Hospital 
attendance but 
no chemotherapy 
due to 
neutropenia 
Entry in admissions table labelled as elective, between 3 days before 
or 3 days after the date subsequent chemotherapy is due, but blood 
count in results server in same period showing neutropenia, and 
chemotherapy is not delivered. 
Hospital 
attendance but 
no chemotherapy 
due to other 
reasons 
As above, but blood counts do not show neutropenia. 
Reschedule 
chemotherapy 
(prior to hospital 
attendance) due 
to neutropenia. 
No entry in admissions table (elective), between 3 days before or 3 
days after the date subsequent chemotherapy is due, and the blood 
count in results server in same period shows neutropenia, and 
chemotherapy is not delivered. 
Reschedule 
chemotherapy 
(prior to hospital 
attendance) due 
to other reasons. 
As above, but blood counts do not show neutropenia. 
Table 6: Description of rules and methods used to define health states within the pathway. 
GP, general practitioner. 
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Neutropenic sepsis is defined as neutropenic and bacteraemic.  Febrile neutropenia is defined 
as one of two health states, which are necessarily mutually exclusive from neutropenic sepsis 
on the model; 
 Neutropenic, blood cultures taken and no bacteraemia. 
 Neutropenic, no blood cultures taken, but other positive microbiology. 
The presence of blood culture reports on results server were used as a surrogate for fever, as 
recording of temperature was not held electronically at the time of this analysis. 
The Markov state definitions used to define the clinically relevant situations are described 
below (the bracket contents refer to how the states are labelled in  
Figure 7); 
a) Acute Events 
1. Neutropenic Sepsis  
Neutropenic and bacteraemic, either admitted (A3,S5, M1,S6) or not 
(A2,S5,M1,S6) 
OR 
Neutropenic, no bacteraemia (A3,S5,M1,S8 or A2,S5,M1,S8)), but go to 
intensive care or high dependency unit (ICU/HDU) or die. 
OR 
Progress to either of the above scenarios (A3,S9,M1,S6 or A3,S9,M1,S6 and go 
to ICU/HDU or die). 
2. Febrile Neutropenia 
Excluded from this definition if included in Neutropenic Sepsis. 
Neutropenic, blood cultures taken, no bacteraemia, either admitted 
(A3,S5,M1,S8) or not (A2,S5,M1,S8). 
OR 
Neutropenic, no blood cultures taken, other microbiology positive, either 
admitted (A3,S5,M2,M3) or not (A2,S5,M2,M3). 
OR 
Progress to either of the above scenarios (A3,S9,M1,S8 or A3,S9,M2,M3). 
36 
 
 
3. At Risk Group (attend acute assessment and blood cultures taken) 
Excluded from this definition if included in Neutropenic Sepsis or Febrile 
Neutropenia. 
Blood cultures taken, not neutropenic, either admitted (A3,S4,M1) or not 
(A2,S4,M1).  Those who are neutropenic are already captured in Neutropenic 
Sepsis or Febrile Neutropenia groups.   
 
b) Elective Events 
1. Late Chemotherapy Delay 
Chemotherapy delayed on day of delivery secondary to neutropenia (S2) 
 
2.3.2.1.2 Allocation of patients to model states 
A brief description of the computer processes followed to define the model are described 
below, and in more detail elsewhere (115).     
Allocation of patients to model states required applying a data mining process to the data in 
two main stages; 
1. Extracting events for each patient from the many tables in PPM and transforming the 
events into a single table, ordered by date and time, thus creating an event log for 
each patient.  
2. Matching this pathway of events to a pathway of clinically pre-defined states in the 
model, using the repetitive event as chemotherapy delivery.   
 
Data modelling followed an iterative process (116). The initial data mining software was 
sufficient to extract only the parts of the patient pathway defined by the initial model, which 
was schematic of the patient pathway based on expert opinion and work with a small focus 
group of doctors and nurses involved in chemotherapy delivery.  Subsequent model iterations 
involved redefinition, accounting for complexity revealed by the data that was not previously 
foreseen.  For example, a number of patients had blood test results present outside episodes 
of hospital care due to them attending their General Practitioner.  In addition, there were 
validation checks, ensuring that transitions between health states found in the data were 
represented by pre-defined paths between the states.    
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As the model cannot accommodate transition between all health states, when patients 
experienced more than one state within a cycle of chemotherapy they were prioritised by the 
most severe event, but counts were kept of the frequency of all health states. For example, if 
a patient received chemotherapy, then had an urgent outpatient review and was admitted 2 
days later, they were represented in the model in the most severe pathway(admission), but 
are also counted in the other health state (urgent outpatient appointment).  So where there 
were 2 numbers in brackets after the proportion figure attached to each pathway, the first 
represents the number of patients where this health state was the most severe experience 
during that cycle of chemotherapy, the second number represents the total number of 
patients who experienced that health state.  The  severity was ranked from most to least 
severe using expert consensus agreement, which was (contents of brackets refer to labels in  
Figure 7); 
 Death without hospital contact (D5). 
 Emergency admission to hospital with neutropenia (A3, S5). 
 Emergency admission without neutropenia, progressing to neutropenia whilst in 
hospital (A3,S9). 
 Emergency admission to hospital without neutropenia (A3, S4). 
 Day case review (D4). 
 Urgent outpatient review (D3). 
 Contacted GP and tested positive for neutropenia (D7). 
 No contact (D1) (planned pathway). 
 
2.3.3 Quantification of clinical pathways 
The Markov model underpins this work.  The patients were grouped by combinations of 
chemotherapy regimens and cancer diagnosis site.  A high level cancer diagnosis site was 
used, such as thoracic, gynaecological, gastrointestinal, in an attempt to reduce the number of 
permutations, thus making the results more widely applicable and interpretable.  Patients 
were allocated to health states as described in 2.3.2.1.2 by regimen and site combinations.  
Health states were recorded per patient across all cycles of chemotherapy delivered, as is 
common reporting practice in clinical trials.  For example, if the rate of febrile neutropenia is 
reported as 20%, this means 20% of patients will experience febrile neutropenia at least once 
during all six planned cycles, and not that 20% of patients will experience it per cycle.  
38 
 
Aggregated numbers for each health state, representing a specific pathway, were extracted 
into a file of comma separated value (csv) format for analysis. 
Epirubicin and cyclophosphamide (EC) for breast cancer and oxaliplatin and modified de 
Gramont (OxMdG) for colorectal cancer were used to compare and contrast patient pathways 
because these combinations have the  greatest number of patients in the dataset (Table 10) 
and are most often used for different intents; EC as adjuvant therapy and OxMdG as palliative 
therapy.  This analysis of EC and OxMdG, included only cycle 1 of the first exposure a patient 
had to the same regimen where no concurrent targeted systemic anti-cancer therapy was 
delivered. 
Where chemotherapy was delivered with either granulocyte colony stimulating factor or other 
systemic anti-cancer therapy with potential to impact the proportion of patients experiencing 
neutropenia, subset analyses were performed 
2.3.4 Neutropenic complications and comparisons with previously published 
data 
The prevalence of febrile neutropenia or neutropenic sepsis was compared to febrile 
neutropenic rates reported in published phase III clinical trials.  Most published phase III trials 
report the definition of febrile neutropenia as a neutrophil and temperature threshold being 
surpassed.  Such a definition  incorporates patients with neutropenic sepsis. 
Regimen and diagnosis site combinations were selected to compare to published data if they 
were in the top 10 counts of febrile neutropenia or neutropenic sepsis in the Leeds data, or 
had >20% risk of febrile neutropenia or neutropenic sepsis in the Leeds data.  In addition, 
carboplatin AUC 2-5 and sunitinib were included as these combinations had the highest count 
of patients with the outcome of febrile neutropenia or neutropenic sepsis in the Leeds data, 
which were not already included.  The combined febrile neutropenia and neutropenic sepsis 
rates calculated from the Leeds population data did not include those of chemotherapy 
regimens given concurrently with other systemic anticancer therapies, in order to improve 
comparability of data.  For example, data for docetaxel given concurrently with trastuzumab 
were not included.   
Published trials were searched for which met the following criteria; phase III chemotherapy 
intervention in cancer patients, >50 patients received the intervention, reported worst 
neutrophil count nadir, reported the definition and prevalence of febrile neutropenia.  The 
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aim was to include two comparable published trials in each chemotherapy and site diagnosis 
combinations, with contrasting treatment intents where possible, such as adjuvant/palliative 
or good/poor prognosis disease.  Pubmed database was searched using terms for the 
chemotherapy regimen and site diagnosis in Title and Abstract.   Where two publications 
meeting the criteria could not be found, reference lists were scoured in the European 
Organisation for Research and Treatment of Cancer (EORTC) GCSF guidelines (lists regimens 
with >20% risk of febrile neutropenia) and in the Textbook of Cancer by de Vita, Hellman and 
Rosenberg (117).  Where more than 2 trials for each category were identified, those included 
either had the most equivalent patient population or the largest number of patients. 
2.3.5 Approvals 
This work was carried out with approvals from the LTHT Director of Research and Innovations 
and Director of the Clinical Commissioning Support Unit (CSU), with strict information 
governance procedures, where data were extracted, anonymised and analysed by aggregated 
pathways, not at an individual patient level.  This work pre-dates the publication of the 
Caldicott report on “Review of data security, consent, and opt-outs” (118), which 
recommends a process for patients to opt-out of their data being included in population-wide 
analyses.  It is acknowledged that there was no opt out process for patients for whom data 
were included.  
2.4 Results 
The total number of patients with a diagnosis of cancer who received either cytotoxic 
chemotherapy or targeted therapy for these diagnoses at Leeds Cancer Centre on or between 
1st April 2004 to 1st January 2016 was 33,371.  Data were excluded from the analysis if ≤25 
patients were in a diagnosis and chemotherapy regimen combination, meaning 4452 patients 
with 1222 diagnosis and chemotherapy regimen combinations were excluded.  Data were 
extracted for 28,919 patients receiving cytotoxic chemotherapy or targeted therapy for a solid 
tumour.  Within this there were 162 different diagnosis and chemotherapy regimen 
combinations and 84,668 cycles of chemotherapy delivered.  The total number of raw events 
analysed was 1,333,187, giving a mean number of 46 raw events per patient.  Raw events 
were clustered as described in the methods to form a health state in the model, such as an 
admission with neutropenia.  In total 255,156 health state events occurred in the 28,919 
patients, giving a mean number of 9 health states per patient.  
 
40 
 
2.4.1 Defining clinical pathways as a Markov model 
The data extracted from the LTHT electronic health records, PPM, were structured into a 
Markov model, representing the pathway of clinical contacts followed during cycles of 
chemotherapy.  Figure 6 represents the first model considered to be an accurate 
representation of patient-centred clinical pathways. The model includes a number of health 
states, each with a code. S1 is the point at which the patient receives chemotherapy; states 
clustered near the bottom right corner represent admissions, whereas those clustered in the 
bottom left represent events when the patient is not admitted, and states clustered in the 
upper half of Figure 6 represent events that occur when the patient is due the next cycle of 
chemotherapy.  An uncomplicated case would be represented by a patient traversing through 
chemotherapy delivery (S1), followed by no contact (D1), then by patient review (R1) and back 
to chemotherapy delivery (S1). By contrast, an emergency admission to hospital and a blood 
test result within 24 hours indicating neutropenia would represent state S5 in the model.  
Attendance for chemotherapy that was not delivered on the expected date and a blood test 
result within 24 hours indicating neutropenia would represent state S2 in the model.  For 3 
weekly chemotherapy regimens, neutropenia delaying subsequent chemotherapy cycle 
delivery was defined as neutrophil count <1.5 x109/L.  For weekly regimens, neutropenia 
delaying subsequent chemotherapy cycle delivery was defined as neutrophil count <1.0 
x109/L. 
The Markov model in Figure 6 was improved to capture differentiation between 0 day and ≥1 
day admissions, which clinically translate into patients who attend for an acute assessment 
and then go home the same day compared to those who are admitted and have an overnight 
stay in a bed.  The improved Markov model also excluded telephone contacts as these were 
identified as representing telephone calls from clinical nurse specialists to patients only.  They 
underrepresent the workload of the acute team fielding symptom-driven telephone calls as 
they did not include unplanned telephone calls from patients to the hospital.  An example of 
this improved Markov model is shown in Figure 7, in which an uncomplicated cycle of 
chemotherapy is highlighted by the red dotted line.  Both models can be accessed 
electronically for easier viewing via the links at the end of the legends.  Table 7 gives clinical 
explanations of every coded health state in the model in Figure 7. 
. 
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Figure 6: The Markov state model at the end of iteration eight.   
S1, patient presents and the chemotherapy goes ahead as normal. D0, home discharge 
following chemotherapy. D1, patient makes no contact with the hospital. D2, telephone 
contact between hospital and patient. D3, patient has an urgent outpatient review. D4, 
patient has an urgent outpatient appointment. D5, death without hospital admission. D7, GP 
attendance with neutropenia. S2, patient attends hospital for chemotherapy but it is re-
scheduled/delayed due to neutropenia. S4, patient is admitted acutely to hospital with no 
evidence of neutropenia. S5, patient is admitted acutely to hospital with evidence of 
neutropenia. S6, patient develops bacteraemia. S8, patient does not develop bacteraemia. S9, 
patient is admitted without neutropenia but develops it during admission. D6, patient dies in 
hospital. S7, patient fully recovers from acute event. F1, patient undergoes further hospital 
admissions. R1, review before the day of planned chemotherapy for patients without hospital 
admission (in that cycle). R2, review before the day of planned chemotherapy for patients 
with hospital admission (in that cycle). C1, complete all planned chemotherapy. C2, stop 
planned chemotherapy prematurely. C3, re-schedule before hospital attendance to undergo 
chemotherapy due to neutropenia. C4, re-schedule before hospital attendance to undergo 
chemotherapy due to reasons other than neutropenia. C5, patient attends hospital for 
chemotherapy but it is re-scheduled  due to reasons other than neutropenia. Bacteraemia is 
defined as a positive blood culture.  S, septic defined by positive blood cultures.  NS, not septic 
defined by no positive blood cultures. Rec., recovered. An electronic version of this Figure that 
can be enlarged is accessible via the following link into a web-browser: 
https://tinyurl.com/EDThesisFigure6 
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Figure 7: An example of the improved pathway Markov model of patient pathways during 
chemotherapy which captures 0 day and ≥ 1 day admissions.   
This shows additional clusters of health states not displayed on Figure 6.  Blue box, Markov 
health state. Red box, exit box of pathway represented by death, completion of planned 
chemotherapy or premature stopping of chemotherapy.  Green box, for data processing 
purposes only, labelled acute assessment. Grey lines with green arrow, direction of transition 
from one health state to another.  Where there are 2 numbers in brackets after the 
proportion figure attached to each pathway, the first represents the number of patients 
where this health state was the most severe during the chemotherapy cycle, the second 
number represents the total number of patients who experienced that health state.  Red star, 
chemotherapy delivered which is the entry point for all patients to the pathway.  Broken red 
line, represents patient pathway between chemotherapy cycles where there is no unplanned 
contact with the hospital between chemotherapy cycles.  Boxes clustered in the centre 
beyond the green box and the bottom right corner represent pathways of patients who are 
admitted to hospital.  Boxes clustered in the bottom left corner represent pathways of 
patients who attend hospital for an acute assessment and are discharged the same day (0 day 
admissions).  The three blue boxes in the left centre area bounded by the red broken arrow 
above and the red box below represent an urgent outpatient appointment, elective ward 
review and GP contact with neutropenia.  The four blue boxes at the top bounded by the 2 
red boxes above and the red starred box below represent scenarios where the patient does 
not receive their subsequent cycle of chemotherapy at the planned time.  An electronic 
version of this Figure can be accessed and enlarged via a web-browser: 
https://tinyurl.com/EDThesisFigure7.  A paper version printed on A3 paper is slotted inside 
the back cover. 
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Health 
states 
Description 
S1 Chemotherapy delivered. 
D0 Home discharge following chemotherapy. 
D1 No clinical contact with hospital, as defined by other health states. 
D3 Urgent outpatient review. 
D4 Elective ward review. 
D5 Death without hospital admission. 
D7 GP contact with neutropenia. * 
S2 
Patient attends hospital for chemotherapy but it is re-scheduled/delayed due to 
neutropenia.**  
A1 Acute assessment. 
A2 0 day admission, meaning acute assessment and discharge the same day. 
A2, S4§ 0 day admission, not neutropenic, discharge the same day. 
A2, S5§ 0 day admission, neutropenic, discharge the same day. 
A3 ≥ 1 day admission, meaning acute admission to a bed at least overnight. 
A3, S4§ ≥ 1 day admission, not neutropenic. 
A3, S5§ ≥ 1 day admission, neutropenic. 
A3, S9§ 
≥ 1 day admission, initially not neutropenic, but then develops neutropenia during 
admission. 
M1 Blood cultures taken. 
M2 No blood cultures taken. 
S6 Bacteraemia, defined as blood cultures positive for a pathogenic organism. 
S8 No bacteraemia, defined as blood cultures negative for pathogenic organisms. 
M3 Cultures, from any site other than blood, positive for a pathogenic organism. 
M4 Cultures, from any site other than blood, negative for pathogenic organisms. 
D6 Death in hospital. 
S7 Recovery from acute event. 
R1 
Review before subsequent chemotherapy cycle for patients without admissions in 
the cycle. 
R2 
Review before subsequent chemotherapy cycle for patients with admission in the 
cycle. 
C1 Completed planned chemotherapy. 
C2 Stop chemotherapy before completing the planned regimen. *** 
C3 Re-schedule chemotherapy before hospital attendance due to neutropenia. † 
C4 
Re-schedule before hospital attendance to undergo chemotherapy due to reasons 
other than neutropenia. ††  
C5 
Patient attends hospital for chemotherapy but it is re-scheduled/delayed due to 
reasons other than neutropenia. †† 
Table 7: Table of clinical descriptions of all the health states within the improved Markov 
model.   
* Indicated by neutropenic blood count result on Leeds Teaching Hospitals NHS Trust Results 
server, but no other hospital contact recorded within 3 days.  ** Neutropenia is defined as a 
neutrophil count of <1.5 x109/L for 3 weekly regimens and <1.0 x109/L for weekly regimens.  
*** Planned regimen defined by modal cycle length in dataset.  † Had chemotherapy more 
than 3 days late and was neutropenic up to 7 days before the scheduled cycle date and 3 days 
after.  †† Had chemotherapy more than 3 days late but was not neutropenic. §These model 
states are all first branches of pathways in the model which continue to be further defined 
into M1/M2, S6/s8, M3/M4, D6/S7. 
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2.4.2 Quantification of clinical pathways 
2.4.2.1 Within chemotherapy regimen and diagnosis combinations 
During the first cycle of the first exposure to the chemotherapy regimen, 78.6% and 76.6% of 
patients receiving EC and OxMdG chemotherapy, respectively, traversed the “planned 
pathway” (Table 8) i.e. without encountering deviation caused either by treatment toxicity, 
other health complications or personal events unrelated to health such as holidays.  Patients 
receiving the first cycle of EC chemotherapy experienced a higher percentage of urgent 
outpatient review and GP contact with positive test for neutropenia; none of these patients 
died without hospital contact.  Conversely, of the patients receiving first cycle of OxMdG 
chemotherapy, 1.1% (n=10)  died without hospital contact, and they experienced a higher 
percentage of elective ward reviews.  During cycle 1 of chemotherapy, 5.0% (n=70) of those 
patients receiving EC chemotherapy experienced febrile neutropenia or neutropenic sepsis, 
and 0.2% (n=2) of those receiving OxMdG experienced the same. 
Table 9 compares and contrasts the prevalence of health states by cycle of chemotherapy for 
EC and OxMdG.  In patients receiving EC chemotherapy, the biggest drop-out rate is between 
cycles 3 to 4 when 24.2% stop chemotherapy.  In those receiving OxMdG, the biggest drop-out 
rate is between cycles 6 to 7 (37.7%).  With both regimens, the proportion of patients per 
cycle with no unplanned contact fluctuates, but remains high for each cycle.  Despite this, 
over all the cycles less than one quarter (23.6% EC and 22.0% OxMdG) of patients received the 
scheduled six or nine cycles of chemotherapy on the planned pathway.  Of those receiving EC, 
the highest proportion of patients were admitted to hospital during cycle 1; although this is 
also the case for OxMdG, the admission rate for OxMdG during cycle 2 and 3 remained high.  
Over all cycles, the patients receiving EC had a lower rate of admission (13.3% EC and 28.0% 
OxMdG), meaning that the risk per patient of being admitted at least once during a course of 
chemotherapy is smaller whilst receiving EC than OxMdG.  The proportion of patients who 
experience either febrile neutropenia or neutropenic sepsis during EC chemotherapy is largest 
in cycle 1, being at least double the rate of any of cycles 2 to 6.  This is not the pattern during 
OxMdG chemotherapy, where the rate of febrile neutropenia or neutropenic sepsis remains 
relatively low and stable through successive cycles, with the exception of cycle 3.  The rate of 
febrile neutropenia or neutropenic sepsis across all cycles during EC and OxMdG is notably 
larger than single cycles at 11.0% and 4.8%.   
Across all cycles of EC chemotherapy a higher proportion of patients experienced febrile 
neutropenia or neutropenic sepsis than had it excluded at assessment (11.0% vs 6.4%).  In 
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contrast, across all cycles of OxMdG chemotherapy a lower proportion of patients 
experienced febrile neutropenia or neutropenic sepsis than had it excluded at assessment 
(4.8% vs 16.4%).  The number of patients who experienced neutropenic sepsis and died was 1 
of 154 patients during EC and 2 of 45 patients during OxMdG.       
 
 EC OxMdG 
Event Count Percent 
Cumulative 
(%) 
Count Percent 
Cumulative 
(%) 
Death without hospital 
contact (D5) 
0 0 0 10 1.1 1.1 
Emergency admission ≥1 
day duration (A3) 
149 10.6 10.6 77 8.2 9.3 
Emergency acute 
assessment (0 day 
admission) (A2) 
28 2.0 12.6 24 2.5 11.8 
Elective ward review (D4) 54 3.9 16.5 105 11.1 22.9 
Urgent outpatient review 
(D3) 
40 2.9 19.4 5 0.5 23.4 
GP contact with 
neutropenia (D7) 
29 2.0 21.4 0 0 23.4 
No contact (minimum 
pathway) (D1) 
1102 78.6 100.0 723 76.6 100.0 
Total 1402   944   
Table 8: Counts of the main pathways traversed for the first cycle of chemotherapy for 
epirubicin and cyclophosphamide (EC) and oxaliplatin and modified de Gramont (OxMdG).  
Ordered from most severe event type (D5) to least severe (D1). 
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2.4.2.2 Between chemotherapy regimen and diagnosis combinations 
The chemotherapy regimen and diagnosis site combination given to the highest number of 
patients was epirubicin and cyclophosphamide given for breast cancer, closely followed by 
oxaliplatin and modified de Gramont for gastrointestinal cancers.  However, more cycles of 
the latter were delivered than the former.  Table 10 and Table 11 display the chemotherapy 
regimen and diagnosis site combinations ordered by number of patients and number of cycles 
delivered.  Of note, the regimen and diagnosis site differ in several cases according to whether 
listed by patient numbers or number of cycles.  In the whole dataset, chemotherapy was given 
to the most number of patients for gastrointestinal cancers (n=8491), followed by breast 
(n=3823), gynaecological (n=3646), thoracic (n=3268), urological (n=2738), head and neck 
(n=1760), central nervous system (n=933), skin (n=444) and soft tissue cancers (n=255). 
 
Chemotherapy Regimen Diagnosis Site 
Number 
Patients 
Number 
Cycles 
Epirubicin and Cyclophosphamide (EC) Breast 1586 6907 
Oxaliplatin & modified de Gramont (OxMdG) Gastrointestinal 1226 7007 
Carboplatin + paclitaxel (3 weekly) Gynaecological 1116 4679 
Carboplatin AUC 2 - 5 Gynaecological 907 3486 
Capecitabine 35days + RT Gastrointestinal 907 910 
Cisplatin Head & neck 847 1507 
Carboplatin + etoposide IV 3 day Thoracic 740 2099 
Sunitinib Urological 677 2555 
Carboplatin & Gemcitabine days 1+8 Thoracic 612 1660 
Capecitabine Gastrointestinal 583 2530 
Cisplatin Gynaecological 557 2548 
Gemcitabine weekly Gastrointestinal 549 1588 
Epirubicin, oxaliplatin & Capecitabine (EOX) Gastrointestinal 495 1793 
Epirubicin, cisplatin & Capecitabine (ECX) Gastrointestinal 480 1747 
Capecitabine + oxaliplatin 21day Gastrointestinal 457 1841 
Erlotinib Thoracic 441 1037 
Bleomycin, etoposide & cisplatin (BEP) 3 & 5 day Urological 406 989 
Docetaxel 100mg/m
2
 (21 day) Breast 399 1309 
Temozolomide CNS 369 1886 
Fluorouracil + folinic acid weekly Gastrointestinal 368 1007 
Table 10:  The top 20 chemotherapy regimen and diagnosis site combinations ordered by 
patient number (largest to smallest).  
The names used for chemotherapy regimens map onto the national systemic anticancer 
therapy audit nomenclature.  Carboplatin AUC 2-5 incorporates weekly and 3-weekly 
regimens.  The regimen docetaxel 100mg/m2 (21 day) includes primary prophylactic 
granulocyte colony stimulating factor.  AUC, area under the curve. RT, radiotherapy.  IV, 
intravenous.  CNS, central nervous system. 
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Chemotherapy Regimen Diagnosis Site 
Number 
Cycles 
Number 
Patients 
Combined Febrile 
Neutropenia & 
Neutropenic Sepsis 
Rate 
% (patient count) 
Oxaliplatin & modified de Gramont 
(OxMdG) 
Gastrointestinal 7007 1226 4.8 (59) 
Epirubicin and Cyclophosphamide 
(EC) 
Breast 6907 1586 10.5 (167) 
Carboplatin + paclitaxel (3 weekly) Gynaecological 4679 1116 4.5 (50) 
Carboplatin AUC 2 - 5 Gynaecological 3486 907 1.3 (12) 
Sunitinib Urological 2555 677 0.9 (6) 
Cisplatin Gynaecological 2548 557 2.9 (16) 
Capecitabine Gastrointestinal 2530 583 0.2 (1) 
Carboplatin + etoposide iv 3 day Thoracic 2099 740 8.8 (65) 
Temozolomide CNS 1886 369 0.5 (2) 
Capecitabine + oxaliplatin 21day Gastrointestinal 1841 457 0.7 (3) 
Irinotecan + modified de gramont 
(IrMdG) 
Gastrointestinal 1796 320 8.1 (26) 
Epirubicin, oxaliplatin & 
Capecitabine (EOX) 
Gastrointestinal 1793 495 7.1 (35) 
All capecitabine Breast 1778 316 1.3 (4) 
Epirubicin, cisplatin & Capecitabine 
(ECX) 
Gastrointestinal 1747 480 3.8 (18) 
Carboplatin & Gemcitabine days 
1+8 
Thoracic 1660 612 5.6 (34) 
Gemcitabine weekly Gastrointestinal 1588 549 2.2 (12) 
Cisplatin Head & neck 1507 847 9.1 (77) 
Docetaxel 75mg/m2 (21 day) Urological 1496 258 5.4 (14) 
Docetaxel 100mg/m
2
 (21 day) Breast 1309 399 4.8 (19) 
Docetaxel (75mg/m
2
) Breast 1295 343 16.3 (56) 
Table 11: The top 20 chemotherapy regimen and diagnosis site combinations ordered by 
number of chemotherapy cycles (largest to smallest).   
The names used for chemotherapy regimens map onto the national systemic anticancer 
therapy audit nomenclature.  Carboplatin AUC 2-5 incorporates weekly and 3-weekly 
regimens.  The regimen docetaxel 100mg/m2 (21 day) includes primary prophylactic 
granulocyte colony stimulating factor.  AUC, area under the curve. IV, intravenous.   CNS, 
central nervous system. 
Four chemotherapy regimen and diagnosis site combinations had a high combined risk of 
febrile neutropenia or neutropenic sepsis according to the definition of febrile neutropenia 
specified in international guidelines which is >20% (24).  Thirteen combinations were within 
the limits of the intermediate risk group (10 to ≤20% risk), but notably, many of these had low 
numbers experiencing the neutropenic infective complication.  Table 12 displays the high and 
intermediate risk chemotherapy regimen and diagnosis site combinations.  All remaining 
combinations were low risk, representing the greatest proportion of chemotherapy delivered.  
Overall, 87.3% (n=117) chemotherapy regimen and diagnosis site combinations had a 
combined risk of febrile neutropenia or neutropenic sepsis less than 10%, and 64.9% (n=87) 
had a combined risk less than 5%.  
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Chemotherapy Regimen Diagnosis Site 
Combined Febrile 
Neutropenia & 
Neutropenic Sepsis Rate       
% (patient count) 
Doxorubicin + ifosfamide Soft tissues 66.7 (18) 
Bleomycin, etoposide + cisplatin (BEP) 3 & 5 
day 
Urological 24.4 (99) 
Doxorubicin 75mg/m2 Soft tissues 23.9 (28) 
Doxorubicin 75mg/m2 Gynaecological 23.3 (7) 
Docetaxel (75mg/m2) Breast 16.3 (56) 
Carboplatin + paclitaxel (3 weekly) Head & neck 15.4 (4) 
Cisplatin + doxorubicin Gynaecological 15.2 (5) 
Vinorelbine IV Thoracic 14.7 (5) 
Cyclophosphamide, doxorubicin + vincristine 
(CAV) 
Thoracic 14.3 (5) 
Cisplatin + etoposide (3 day) Urological 13.8 (4) 
Cisplatin + etoposide (3 day) Thoracic 13.3 (32) 
Bevacizumab + carboplatin + gemcitabine Gynaecological 13.2 (5) 
Carboplatin + etoposide IV 3 day Gastrointestinal 12.5 (7) 
Folfirinox Gastrointestinal 11.5 (7) 
Flurouracil, epirubcin + cyclophosphamide 
(FEC) 60 or 75 
Breast 11.3 (22) 
Cisplatin + docetaxel + fluorouracil Head & neck 11.2 (14) 
Epirubicin and Cyclophosphamide (EC) Breast 10.5 (167) 
Table 12: The chemotherapy regimen and diagnosis site combinations with a high and 
intermediate risk of combined rate of febrile neutropenia and neutropenic sepsis.   
The horizontal line demarcates the combined risk of febrile neutropenia and neutropenic 
sepsis into high risk (>20%), intermediate risk (10 to ≤20%).  
 
 
2.4.2.3 Chemotherapy given concurrently with monoclonal antibodies or 
granulocyte colony stimulating factor 
Four chemotherapy regimen and diagnosis combinations were given both on their own and 
with a subset of patients given either primary or secondary prophylactic granulocyte colony 
stimulating factor concurrently with the cytotoxic drugs.  Three of the same chemotherapy 
regimens were also given in combination with trastuzumab.  In total, there were 6 
chemotherapy regimen and diagnosis combinations given concurrently with targeted agents, 
namely either trastuzumab or bevacizumab.  The breakdown of these regimens is displayed in 
Table 13  along with the neutropenic complication risks by all patients receiving the regimen 
and diagnosis combination and the subsets of patients receiving the concurrent therapies.   
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The three chemotherapy regimen and diagnosis combinations which are sometimes given 
concomitantly with granulocyte colony stimulating factor all show that the subset of patients 
who receive granulocyte colony stimulating factor are at greater risk of either febrile 
neutropenia or neutropenic sepsis, than their counterparts who do not receive granulocyte 
colony stimulating factor.  In the patients who receive bleomycin, etoposide + cisplatin (BEP) 
over 3 days for urological cancer, this is a reflection of approximately 5 times greater risk of 
neutropenic sepsis, rather than an increased risk of febrile neutropenia.  In the other two 
chemotherapy regimen and diagnosis combinations (epirubicin and cyclophosphamide for 
breast cancer and docetaxel 75mg/m2 for breast cancer), the combined increased risk of 
febrile neutropenia or neutropenic sepsis is due to increased risk of febrile neutropenia. 
Three out of the 4 chemotherapy regimen and diagnosis combinations given concurrently 
with trastuzumab had a lower rate of combined febrile neutropenia and neutropenic sepsis 
than when compared to the same populations when chemotherapy was delivered without the 
trastuzumab.  The prevalence of febrile neutropenia and neutropenic sepsis in the 
populations receiving bevacizumab was so small that conclusions regarding the influence of 
bevacizumab on the neutropenic complication rate cannot be drawn. 
2.4.3 Comparison of neutropenic complications to published data 
Table 14 displays the comparison to published data.  The febrile neutropenia or neutropenic 
sepsis rates identified in the Leeds population data were underestimated by more than 10% in 
66.7% of the published trials, overestimated by more than 10% in 13.3% of the published 
trials, and within 10% of the Leeds population data rates in 13.3% of the trials.  In contrast, 
the rates of uncomplicated neutropenia identified in the Leeds population data were 
overestimated by more than 10% in 60.0% of the published trials, underestimated by more 
than 10% in 26.7% of the published trials, and within 10% of the Leeds population data in 
14.3% of the published trials.  For example, with epirubicin and cyclophosphamide given for 
breast cancer the combined febrile neutropenia and neutropenic sepsis rate of 10.5% in the 
Leeds population data compares to 6.0% in both the reported trials; the Leeds population 
data uncomplicated neutropenic rate of 34.7% compares to 34.0% and 43.0% in the published 
trials.   
Of the 4 chemotherapy regimens where at least one of the published trials reported a 
noticeably higher uncomplicated rate of neutropenia, 3 were for thoracic cancers (carboplatin 
and etoposide (trial 1), carboplatin and gemcitabine (trial 1), cisplatin and etoposide (trial 2)).  
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Epirubicin, 
oxaliplatin & 
Capecitabine (EOX) 
(133, 134) 
GI 7.1 (495) 21.6 
1. 7.8 (232) 
2. 3.5 (112) 
27.6 
23.2 
2. Prospective observational study using modifed EOX (capecitabine 
days 1-14 instead of 1-21). 
Carboplatin & 
Gemcitabine days 
1+8 (135, 136) 
Thoracic 5.6 (612) 26.3 
1. 9.0 (217) 
2. 6.0 (219) 
51.0
‡
 
29.4 
  
Cisplatin + etoposide 
(3 day) (137, 138) 
Thoracic 13.3 (241) 46.1 
1. 6.0 (324) 
2. 12.0 (378) 
68.0 
84.0
ƒ
 
  
Doxorubicin + 
ifosfamide (139, 140) 
Soft tissues 66.7 (27) 77.8 
1. 4.6 (149) 
2. 46.0 (224) 
92.0 
42.0 
1. Uses doxorubicin 50mg/m
2
 and ifosfamide 5g/m
2
 compared to 
doxorubicin 60mg/m
2
 and ifosfamide 9g/m
2
 at Leeds. 
2. Uses doxorubicin 75mg/m
2
 and ifosfamide 10g/m
2
 with primary 
prophylactic GCSF. 
Doxorubicin 
75mg/m
2 
(140, 141) 
Soft tissues 23.9 (117) 43.6 
1. 9.1 (110) 
2. 13.0 (223) 
53.6
‡
 
37.0 
  
Doxorubicin 
75mg/m
2 
(142, 143) 
Gynae 23.3 (30) 43.3 
1. 5.0 (171) 
2. 4.9 (82) 
43.0 
30.5
ƒ
 
1 & 2. Use doxorubicin 60mg/m
2
 compared to 75mg/m
2
 at Leeds. 
1. Reports grade 4 neutropenia only. 
Carboplatin AUC 2-5 
(144, 145) 
Gynae 1.3 (907) 11.5 
1. 0.6 (174) 
2. Not reported 
(455)** 
12.0
ƒ
 
10.0
†
 
  
Sunitinib (146, 147) Urology 0.9 (677) 5 
1. 0.5 (375) 
2. ≤1.0 (548) 
12.0 
20.0 
  
Table 14: Table showing Leeds regimen and diagnosis site combination rates of febrile neutropenia and uncomplicated neutropenia in comparison to 
published figures.     
Table continues from page 52 to 53. 
FN, febrile neutropenia.  NS, neutropenic sepsis.  IV, intravenous.  AUC, area under the curve.  Numbers in red are >10% higher than the Leeds population data 
output.  Numbers in green are >10% lower than the Leeds data output.  *A study with only n=40 receiving single agent cisplatin reported a febrile neutropenia 
rate of 2.5%.  ** A study with only n=30 receiving single agent carboplatin reported a febrile neutropenia rate of 0.0%.  
ƒ Denotes trial data where the full blood count is prospectively measured more frequently than the standard length of the chemotherapy regimen cycle.  
†Denotes where leukocytes are reported and not neutrophils.  ‡Denotes where granulocytes are reported and not neutrophils. 
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The 4th regimen was docetaxel for breast cancer (trial 2), where 17.9% of the trial patients 
received granulocyte colony stimulating factor compared to 32.9% of patients in the Leeds 
population data set.  Similar differences were not seen in the febrile neutropenia or 
neutropenic sepsis rates for these regimen and diagnosis combinations.  
2.5 Discussion 
2.5.1 Main Findings 
The key methodology underpinning this work was successful construction of the Markov 
model that was representative of the most severe events and frequency of events 
experienced by patients during a cycle of chemotherapy.  This enabled both visualisation and 
quantification of the pathways, identifying many pathway variants and most importantly, 
establishing the prevalence of febrile neutropenia in all chemotherapy regimens given to the 
unselected patient population served by Leeds Cancer Centre.  This was the first time this 
methodology has been applied to pathways of patients on chemotherapy, thus documenting 
the baseline pathways for modelling of interventions and to inform further work. 
Using the Markov model to look at subsets of patients receiving EC and OxMdG 
chemotherapy, over 75% of patients had no unplanned hospital contact during the first cycle 
of chemotherapy, but this reduced to less than 25% over all the planned cycles of both 
regimens, indicating that it is common place for patients to require some form of urgent care 
during a course of chemotherapy, regardless of the intent of treatment.  It is of concern that 
there are patients who have no contact with the hospital, but are neutropenic on bloods 
taken at their GP practice.  This in itself does not prove they have febrile neutropenia, but it is 
reasonable to assume there is an indication for the blood test, which may include symptoms 
compatible with febrile neutropenia.  The all cause emergency admission rate is high at 13.3% 
and 28.0% for EC and OxMdG respectively, not surprisingly higher in the regimen given most 
commonly for palliative intent (OxMdG), reflecting complications associated with burden of 
disease.  However, without formal statistical analysis, the all cause emergency admission rate 
during cycle 1 only, appears higher in those receiving EC than it is in those receiving OxMdG 
and in subsequent cycles, perhaps reflecting the higher doses and associated side effects of an 
adjuvant chemotherapy regimen and the “unknown” of the first cycle.  
The proportion of patients at Leeds who were admitted with febrile neutropenia or worse and 
subsequently died during the same admission was low (EC 0.8% and OxMdG 4.0%), but 
confirms that neutropenic sepsis remains a life-threatening complication of both adjuvant and 
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palliative chemotherapy.  With this in mind, and the fact that patients are strongly advised to 
seek advice from the cancer centre if they have any symptoms suggestive of febrile 
neutropenia, it is somewhat surprising that the proportion of patients receiving EC 
chemotherapy in whom febrile neutropenia was excluded is lower than the proportion who 
were diagnosed with febrile neutropenia or worse in each of the 6 cycles and across all cycles.  
It might be expected that patients in whom febrile neutropenia was excluded were included in 
a different health state, but this does not appear to be the case.  However, a proportion of 
those receiving EC had contact with the GP whilst neutropenic, which was not true in the 
OxMdG group.  Perhaps there was a higher attendance at GP practices with complications 
during EC chemotherapy than was captured by this data, such as consultations where no full 
blood count was sent to the central laboratory.  
As expected, the highest rate of febrile neutropenia or neutropenic sepsis in the EC group was 
in cycle 1, where it was approximately double the rate of subsequent cycles. This supports the 
use of cycle 1 chemotherapy regimens in selection of patients for the study profiling 
neutrophil counts during chemotherapy (45).  The rate of febrile neutropenia or neutropenic 
sepsis across all cycles during EC and OxMdG was notably larger than single cycles at 11.0% 
and 4.8%, indicating that it was mostly different patients who experienced the complication in 
each cycle.     
As discussed in 2.5.2, the Leeds population data captures prophylactic granulocyte colony 
stimulating factor use.  The only regimen at Leeds Cancer Centre where granulocyte colony 
stimulating factor was given routinely as primary prophylaxis was adjuvant docetaxel for 
breast cancer.  In each of the other three regimens where granulocyte colony stimulating 
factor was captured (BEP, EC and palliative docetaxel (75mg/m2), the rate of febrile 
neutropenia or neutropenic sepsis was higher where granulocyte colony stimulating factor 
was used.  This reflects it being used as secondary prophylactic granulocyte colony stimulating 
factor, hence only those patients with high risk characteristics, such as febrile neutropenia in 
the previous cycle, received it.  Other concurrent therapy delivered during the time limits of 
the data capture included targeted therapy.  In the Leeds population data, the concurrent use 
of trastuzumab with docetaxel 100mg/m2 in the adjuvant setting led to a higher rate of febrile 
neutropenia or neutropenic sepsis than compared to the chemotherapy alone.  This concords 
with reports of this combination of systemic anticancer therapy in the literature (148, 149).  
However, in the Leeds population data the concurrent use of trastuzumab with the palliative 
dose of docetaxel (75mg/m2) resulted in a lower rate of febrile neutropenia or neutropenic 
sepsis, which contrasts with the literature which reports an increase, as in the adjuvant setting 
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(150).  The reasons for this are unclear, but may be because patients receiving the adjuvant 
dose have often been given a course of EC chemotherapy prior to the docetaxel.    
When comparing the Leeds population data outputs to comparable published trial data, the 
Leeds data tended to underestimate the uncomplicated neutropenic rates and overestimate 
the febrile neutropenic rates.  As the Leeds population data were collected retrospectively, 
full blood counts were only measured mid chemotherapy cycle as a result of symptom-led 
assessments or pre-planned procedures, whereas the trials tended to prospectively measure 
blood counts.  For example, in one of the cisplatin and etoposide trials for thoracic cancers, 
the full blood count was measured on day 8, 9, 10 and 15, and in one of the doxorubicin and 
ifosfamide trials, it was measured on day 1, 8, 11, 15, 18 and 21 (138, 139).  Therefore this 
could explain why these published data tended to report uncomplicated neutropenia to be so 
much higher than the Leeds population data, except in the example of carboplatin and 
gemcitabine for thoracic cancer, where both the trials and in the Leeds practice, a full blood 
count is measured on day 8, yet trial 1 (Table 14) still reports a noticeably higher 
uncomplicated neutropenic rate.  Moreover, if the higher rate of uncomplicated neutropenia 
was solely due to the prospective collection of neutrophil counts, one might expect the rate of 
febrile neutropenia in the published trial to be similar or higher than the Leeds population 
data, as the knowledge of neutropenia may change patient behaviour in recognition of 
symptoms and seeking clinical assessment.  However, this is not the case; the higher rate of 
febrile neutropenia in the Leeds population data could, therefore, be attributable more to the 
inclusion of an unselected patient population, hence justifying the need to map patient-
centred real-life baseline clinical pathways.       
2.5.2 Strengths & Weaknesses 
The key strengths of this work were the volume of Leeds population data and that it was 
collected for routine clinical care purposes in a mature and detailed electronic health record.  
The data were from a large and diverse unselected patient population collected over more 
than ten years, enabling representation of real-life pathways of all comers, in comparison to 
those identified during selective clinical trials.   Close collaboration between the data analyst 
and the clinician facilitated identification of deficiencies in the methods, idiosyncrasies in the 
pathways and the generation of successively more accurate model iterations.  Using PPM  
enabled quality assurance through electronic criteria adherence reporting, computation of 
quality indicators and facilitated identification and checking of anomalies.  The use of a 
Markov model enabled visual representation of the pathways described, aided 
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comprehensible dissemination of the findings and facilitated the on-going health economic 
analysis of the aggregated patient numbers traversing each pathway.   
In terms of weaknesses, this was a retrospective analysis and as such, was limited by the data 
available.  For example, temperature recordings were not held electronically during the period 
from which data were extracted, so the presence of blood culture results was used as a 
surrogate marker for fever.  Granulocyte colony stimulating factor administered to inpatients 
was not captured in the dataset, and therefore only the use of prophylactic granulocyte 
colony stimulating factor was included.  Moreover, uncomplicated neutropenia is assumed to 
be under-reported in this dataset.  It is reasonable to surmise that the prevalence of 
uncomplicated neutropenia recorded for patients on weekly chemotherapy regimens, may be 
more accurate than for chemotherapy regimens given at longer intervals, due to the 
frequency of blood tests. 
A second limitation was the long interval of data collection.  Although it enabled larger patient 
numbers to be included, it introduced the problem of inconsistency of chemotherapy 
nomenclature over time due to changing prescription and recording systems.  The regimens 
were mapped to the National Systemic Anticancer Therapy (SACT) audit in order to group 
them in a standardised way, however, in some instances, this resulted in loss of granularity of 
data.  For example, single agent carboplatin was represented in the Leeds raw data as 
carboplatin weekly and carboplatin 3-weekly.  The SACT dataset merges this to carboplatin 
AUC 2-5, so the delivery interval is not distinguished by the name.   
Finally, whilst efforts were made during the literature search to select publications with 
characteristics comparable to those of the Leeds population dataset, some variances could 
not be eliminated.  For example, both trials of bleomycin, etoposide and  cisplatin for 
urological tumours used granulocyte colony stimulating factor that was not standard practice 
at Leeds, and one of these trials recruited good prognosis patients only, meaning they 
received three cycles of chemotherapy, whereas the reported Leeds population data included 
patients who received either 3 or 4 cycles.  Six trials reported either granulocytopenia or 
leukopenia rather than neutropenia and although many broke the neutropenia down into 
grades 3 and 4, two only reported grade 4, reducing the comparative proportion of 
uncomplicated and febrile neutropenia.  It is, however, the overall patterns identified in the 
difference between reported rates of uncomplicated and complicated neutropenia which are 
of particular value. 
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2.5.3 Implications 
In October 2016, the Department of Health published the “Accelerated Access Review” which 
was intended to be the guiding principal for introducing innovation into healthcare and is 
suitable for medical technologies and diagnostics (151).  Chapter 4 in the review addresses the 
importance of digital infrastructure to capture information on the use of innovations and 
associated outcomes.  The pathway modelling work described herein is an example of how 
the digital infrastructure at LTHT is detailed and robust enough to capture clinically useful 
information and represents a means through which data can be meaningfully shared and used 
in the first steps towards informing practice change.  It also identified the current unselected 
patient pathways, in line with the review which recommends “develop evidence of 
performance in real-world settings”.  One of the focuses of this project as a whole has been to 
develop evidence in the real-world setting, as shown by this pathway mapping and comparing 
it to published trial data, and the assessment of performance of the device specifically in 
neutropenic patients (Chapter 5).  However, this mapping provides a high-level view of the 
clinical pathways for large numbers of patients, aggregating patients within specific pathways.  
This does not give the whole view of individual patient experience, which may be better 
captured on a limited number of patients, but in extensive detail through lean pathway 
mapping of patients’ journey during chemotherapy, the methodology of which has been 
described (152).  This could serve as another measure of how accurately the data collection 
and generated pathways reflect what actually happens in the patient journey.   
This pathway mapping provides data on the real-life risk of neutropenic complications, which 
cannot be obtained through published data from clinical trials in carefully selected patient 
populations.  In addition, it provides data not always present in national cancer datasets in the 
UK such as the National Cancer Waiting Times Monitoring Dataset (NCWTMD), Cancer 
Outcomes and Services Dataset, Systemic Anticancer Therapy Dataset and cancer registries. 
Some aspects of care are not well represented in the national datasets such as suspected 
cancer diagnoses not referred by a general practitioner, care prior to a 2-week wait referral 
and care post referral to community palliative care teams.  These specific care elements were 
not captured here due to time boundaries implemented either side of the delivery of 
chemotherapy.  However, patients crossing the boundaries of primary and secondary care 
were captured, facilitated by the UK model of central rather than peripheral laboratories 
analysing samples from primary care.   
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The most tangible value of this work for the purposes of this thesis was to inform selection of 
patients at high risk of neutropenic complications for the clinical trial aiming to profile 
neutrophil counts during chemotherapy (Chapter 6).  It provides information above and 
beyond that available through other sources, and it both accurately represents the local 
population and is available on a large scale.  It has done this through identification of the rates 
and counts of neutropenic complications by chemotherapy regimen and diagnosis 
combination.  This was considered alongside individual patient characteristics and recruitment 
logistics for trial approach.   
The value of this work for the wider project was to quantify the baseline patient pathways so 
as to be able to model potential practice changes and later to be able to quantify these 
changes both in terms of clinical and health economic benefits or otherwise.  The Markov 
model enables estimates of cost and outcomes by assigning estimates of resource usage 
(using Healthcare Resource groups (HRGs)) and health outcomes to health states and 
transitions between states, then running the model over a large number of the repeated 
Markov cycles.   HRGs are standard groupings of clinically similar treatments, which are used 
to charge for treatment delivered within the NHS and are used to help institutions understand 
the clinical activity they deliver.  A finished consultant episode is a number of activities 
grouped together to indicate one episode of care such as an admission.  HRGs contain an 
“average” payment for finished consultant episodes, therefore, do not account for high costs 
sometimes associated with variant pathways such as admission to intensive care (153). As 
such, the frequency and cost of variant pathways may negatively impact provider institution 
finances, making understanding the baseline pathways of paramount importance to quantify 
the true impact of new innovations within the NHS. 
The intention is for the Markov model to be developed into a dynamic visual representation of 
patients traversing the defined pathways.  Attempts to do this have started using the software 
tool “Network Tools for Intelligent Simulation” (NETIMIS) (154), and have been well received 
whilst embedded within presentations at National conferences (155-157).  This will enable 
visual recognition of unmet needs in the patient pathway such as bottle-necks, common 
variant pathways and process delays contributing to delayed targets such as those mandated 
by the National Cancer Waiting Time Monitoring Dataset.  Dynamic visualisation of the 
pathways will be invaluable in communicating benefits to changing patient pathways to the 
wide range of stakeholders which includes patients, clinical staff, laboratory staff, NHS 
managers, finance staff, commissioners.  Moreover, the formatted dataset alone is a rich 
source of information which will be shared with clinical staff within LTHT in order that it can 
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be used to better inform clinical practice and patients of the risks associated with 
chemotherapy delivery.   
2.5.4 Conclusion 
This chapter serves as an exemplar of advantageous secondary use of data collected primarily 
for routine care purposes in electronic health records.  It has demonstrated that a surprisingly 
high proportion of real-life care pathways during chemotherapy differ from those which 
represent the expected standard of care.  It also suggests the prevalence of febrile 
neutropenia in the unselected patient population served by Leeds Cancer Centre is frequently 
different to the reported rates in the carefully selected populations of phase III clinical trials.  
Hence it shows there is value to be gained through establishing real-life patient-centred 
clinical pathways prior to introducing innovation within healthcare.  One potential advantage 
is the provision of a platform through which true benefits can go on to be quantified at a local 
level in a complex health system.  In addition to using this work to inform patient selection for 
the neutrophil profiling trial reported in a subsequent chapter of this thesis, collaborative 
work with health economists and a data analyst continues using the established pathways to 
model the potential impact on clinical outcomes and cost benefits of home blood count  
monitoring.  
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Chapter 3 Patient and professional perceptions of home blood count 
monitoring 
3.1 Introduction 
The availability of advancing technology makes the use of point of care testing (POCT) 
attractive in a health-care system such as the National Health Service, which is required to 
continually improve efficiency and patient satisfaction.  Testing for glucose in urine is often 
referred to as one of the first examples of POCT.  This evolved to patient capillary blood self-
testing, which is now such a familiar concept that it is impossible to conceive modern 
management of diabetes mellitus without patient self-testing of capillary blood samples.  
Frequent finger-prick blood glucose monitoring in most patients with type-I diabetes mellitus 
along with self-management using behavioural changes and glucose-lowering medications, is 
widely accepted as standard practice (158).  A phobia of skin prick testing has a negative 
influence on compliance with blood glucose management (159), but those who tolerate 
finger-pricks do so with the advantage of achieving tighter HBA1c control (160).  This field 
continues to develop with the ability to self-test glycated protein as an indicator of better 
longer term glucose control and considerable research directed towards non-invasive 
methods of blood glucose monitoring (161-163).   
A more recent example of successful introduction of testing at the point of care has been 
patient self-management of International Normalised Ratio (INR) in reducing further 
thrombotic events in those anticoagulated with warfarin (76).  Such practices have been 
successful as point of care self-testing necessitates patient education, enables patient 
empowerment and control over their own care, as well as offering convenience, piece of mind 
and efficiency of care with early indication of poor control (in the case of diabetes and 
warfarin treatment) and in some cases, a reduction in dependency on the health-care 
profession.  In order for such benefits to be realised, it is paramount that patient self-test 
point of care monitoring is accompanied by professional support and patient education and 
training (164-166).   
In the scenario of patients with cancer receiving chemotherapy using home blood count 
monitoring, there is the potential for the capillary tests to be used in a more acute context in 
comparison to the majority of uncomplicated patients with diabetes mellitus, where it tends 
to be used for a more chronic indication.  The patients with cancer on chemotherapy would 
only be expected to use the home blood count monitoring for a finite period of time (the 
duration of chemotherapy) and there may be urgent action required dependent on multiple 
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factors, one of which is the neutrophil result.  The consequence of poor decisions in this 
patient population can be immediately life-threatening.  To counteract the risks of delayed 
reporting of serious chemotherapy side effects, the next generation of the finger-prick blood 
count monitoring device is expected to have alerts set at clinician-defined thresholds or time-
points to prompt patients to test or contact their cancer care provider.  It is also expected to 
transfer results wirelessly to the care provider, so they can initiate a change in management 
based on incoming results, if appropriate to do so.  This approach is very topical given the 
recently published National Chemotherapy Board guidelines on “Promoting Early 
Identification of Systemic Anti-Cancer Therapies Side Effects”, which focuses on empowering 
patients and proactive monitoring (88).  
Technology has been used to enable patients on chemotherapy to report new symptoms and 
receive management advice or contact from a healthcare professional (167, 168).  Some web-
based tools used for patient reported outcome measures have a high rate of adherence (169).  
However, the proposed home blood count monitoring goes a step further by asking patients 
to perform a procedure (finger-prick) on themselves.  An unpublished study carried out in 
Dundee during the early stages of development of the home blood count testing device, 
required volunteer patients to finger-prick themselves and put the blood drop in the cartridge 
required to use the XBC (Prof N. Kearney, Nine-wells Hospital, 2012).  Out of 49 patients who 
tested themselves, 42 reported the finger-prick as painless, 49 indicated they would be happy 
to test themselves at least weekly, and 39 would be prepared to test daily.  This suggests 
there is potential for patients to be willing to use such a system.   
The proposed home blood count monitoring should be classed as a complex intervention, as 
defined by Medical Research Council (MRC) “Developing and evaluating complex 
interventions” guidelines (170).  This is because implementation will require significant 
behavioural change by those delivering and receiving the intervention, and there are a 
number of interacting outcomes.   The recognition of the concept of complex interventions, 
outside of drug development, has been in a state of development (170, 171).  The updated 
MRC guidance expands to non-drug related interventions, but acknowledges on-going debate 
on the issues surrounding evaluations of such interventions and refers to their guidance as a 
reference source, not prescriptive rules.   
Challenges involved in developing a complex intervention include; identifying existing 
evidence, identifying and developing the theory, assessing feasibility, modelling process and 
outcomes, assessing effectiveness, measuring outcomes.  Within the remit of assessing 
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feasibility of home blood count monitoring, and in an attempt to predict and minimise 
problems of acceptability, compliance, recruitment and retention, this chapter addresses end-
user views on willingness to use and methods of using a home blood count monitoring 
system.  The end-users are both patients on chemotherapy and clinicians with responsibility 
for care of such patients; without the support of both, development, evaluation and 
ultimately the uptake of home blood count monitoring will be unsuccessful.   
This chapter describes the development, conduct and results of two questionnaires, one 
distributed to patients with cancer and experience of chemotherapy and the other to 
consultant oncologists.  The aim was to establish attitudes of oncology patients and 
consultants towards the use of patient self-test home neutrophil count monitoring during 
chemotherapy.     
3.2 Objectives 
1. a) To establish patient acceptability of using home blood count monitoring to guide 
management of neutropenic complications. 
b) To ascertain acceptability to oncology consultants of their patients on 
chemotherapy measuring their own blood counts at home, in each of the following 
three clinical scenarios; 
i. In patients who are at home, have a fever and require neutropenia to be 
excluded. 
ii. Prior to delivery of subsequent chemotherapy cycles to avoid hospital 
attendance in patients whose neutrophil count has not recovered sufficiently. 
iii. In the days following chemotherapy delivery to identify those patients 
potentially at high risk of neutropenic complications. 
 
2. To establish whether patients at risk of neutropenic infections who have a fever 
would prefer to be inconvenienced by trips to hospital where they are assessed and 
sent home with no management changes, or to minimise such trips at the expense of 
a small risk of delaying treatment for a neutropenic infection. 
 
3. Establish the oncology consultant consensus neutrophil threshold to use to 
recommend urgent clinical assessment in patients on chemotherapy who are at 
home, have a fever but are otherwise well. 
  
64 
 
4. Establish if a degree of clinical risk is acceptable to consultants to gain the benefits of 
reducing unnecessary hospital visits. 
3.3 Methods 
3.3.1 Oncology patient questionnaire 
A questionnaire was developed through an iterative process involving review by; 
 members of the Psychosocial Oncology Group at Leeds Institute of Cancer and 
Pathology (University of Leeds) and Leeds Cancer Centre. 
 a patient and public involvement group. 
 a focused interview with 10 patients.  
Feedback included making the link with neutropenia and infection clearer in the introduction, 
improving flow of wording, defining start point of travel to hospital i.e. work or home.  Due to 
concerns raised about patient understanding of the risk referred to in question 3, much 
consideration was given to the presentation of this question, including use of visual analogue 
scales, Likert scales, and a decision choice experiment.  The final questionnaire used a version 
of pairwise comparison to gather information on respondent choice of current standard care 
compared to using home blood count monitoring and visual infographic to represent risk.  
Appendix 1 is a copy of the final questionnaire.  The questionnaire was piloted on 15 
experienced chemotherapy patients, before distributing to the wider population described.  
The results of these 15 patients are reported together with all the responses. 
The intention was to collect 100 completed questionnaires, a pragmatically chosen sample 
size.  Patients were invited to complete a questionnaire if they were attending an oncology 
outpatient clinic, were receiving or had previously received cytotoxic chemotherapy and were 
in one of the following diagnostic categories; breast cancer, gynaecological cancer, prostate 
cancer, gastrointestinal cancer, germ cell tumours, teenage and young adult cancer.  
Statistical analyses were performed using Stata STRS.  The Sign test was applied to 
proportional data to return a p value.  The Chi2 test was applied to categorical data with more 
than one category to return a p value.  The p value was regarded as statistically significant at 
<0.05, with a corresponding confidence interval of 95%.  Risk thresholds used to categorise 
clinical risk correspond to percentage risk and negative predictive values (NPV) shown in Table 
15.  The treating clinical team identified appropriate patients and approved approach for this 
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questionnaire.  As this was a questionnaire exploring attitudes towards service development, 
formal ethical approval was not sought.   
 
Risk % risk NPV 
1 in 5 20 80 
1 in 7.5 15 85 
1 in 10 10 90 
1 in 20 5 95 
1 in 50 2 98 
1 in 100 1 99 
1 in 1000 0.1 99.9 
Table 15: Risk thresholds of becoming dangerously unwell used in the questionnaires. 
These were used in the patient questionnaire, question 3, and the consultant questionnaire, 
question 2b.  The corresponding percentage risk and negative predictive value (NPV) are 
shown. 
 
3.3.2 Oncology consultant questionnaire 
A questionnaire was developed to explore consultant attitudes towards their patients on 
chemotherapy measuring their own blood counts at home using capillary finger-prick blood 
samples (Appendix 2).  This involved first a focused interview with an independent clinical 
registrar to ensure clarity of meaning of text and questions.  Responses were identifiable by 
respondent name, but there was the option for the response to be anonymous by removal of 
the front sheet. Responses that were identifiable, were categorised by gender, year of primary 
medical qualification (either 1990 and earlier or after 1990) using information obtained from 
the General Medical Council register, and subspecialty (medical or clinical oncology). 
All medical and clinical oncology consultants at Leeds Teaching Hospitals NHS Trust, who were 
not in a period of absence from work, were invited to complete a paper questionnaire.  The 
questionnaire was distributed via the named consultant secretaries.  Formal statistical 
analyses were not planned.  A reminder email was sent 3 weeks after distribution of the 
questionnaire. 
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Neutrophil thresholds used in the questionnaire correspond either to national and local 
guidelines for management of febrile neutropenia or higher neutrophil thresholds.  The 
percentage risk used in the questionnaire correspond to specific negative predictive values 
(NPV) as shown in Table 15.  As this was a review of clinical attitudes, prior approval was not 
sought.  
3.4 Results 
3.4.1 Oncology patient questionnaire 
Question 1 
 Question 1 sought to collect demographical information on the respondents. 
107 patients completed the questionnaire.  No record was kept of numbers of patients that 
declined to complete it.            Table 16 displays demographic details of patients who 
completed the questionnaire.  The age category and length of time taken to travel to Leeds 
Cancer Centre are shown in Figure 8.  The minimum age of respondents was 20 years (n=1) 
and the maximum was 85 years (n=1).  The median age category was 60-69 years and the 
mode was ≥70 years.  
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Demographic Percentage (n) 
Gender  
Female 51 (55) 
Male 49 (52) 
Living arrangements  
Lives on own 21 (22) 
Lives with others 77 (82) 
No answer 3 (3) 
Time since most recent chemotherapy  
Within 6 weeks 54 (58) 
Greater than 6 weeks ago 46 (49) 
Previous experience of febrile neutropenia  
Attended hospital with suspected infection 
during chemotherapy and been discharged 
the same day 
 
Yes 20 (21) 
No 77 (82) 
No answer   4 (4) 
Admitted to hospital with an infection 
during chemotherapy 
Yes 34 (36) 
No 66 (71) 
Experienced both of these scenarios    8 (9) 
Experienced neither of these scenarios  55 (59) 
          Table 16: Demographics of patients who completed the questionnaires.  
          (n=107) 
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Figure 8: Bar charts displaying demographics of patient questionnaire respondents. 
a) Bar chart displaying age distribution. b) Bar chart displaying length of time taken to travel to 
Leeds Cancer Centre. 
Question 2 
 Question 2 described a situation where the patient had chemotherapy a week ago, 
felt tired, but otherwise alright.  It sought to assess whether the respondent would 
prefer the current practice of in hospital assessment including venous blood test and 
face-to-face reassurance (scenario A), or to use self-test home blood count monitoring 
and be reassured by the blood result and advice delivered on the device screen 
(scenario B).  
Thirteen (12.1%) respondents chose scenario A and 93 (86.9%) chose scenario B.  One 
respondent did not provide an answer.  There were 8 free-text comments from those who 
chose scenario A which are displayed in Appendix 3, Table 1 and 40 free-text comments from 
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those who chose scenario B which are displayed in Appendix 3, Table 2.  Six out of the 8 
comments from those who chose scenario A were related to preferring reassurance from 
interaction either on the telephone or face-to-face with a healthcare professional.  One of the 
eight comments referred to lack of confidence in doing the blood test, and 1 of the 8 was 
referring to carer anxiety likely to be caused by having responsibility for the home testing 
process. 
Of the 40 free-text comments by those who chose scenario B, 21 mentioned choosing to use 
home blood count monitoring due to time saved.  Fourteen mentioned reassurance in their 
answers, but 5 of these were suggesting they would be reassured by the device, 4 indicated 
some doubt as to whether they would be reassured by the device alone and 7 specifically 
indicated they would like to be able to telephone to interact with a healthcare professional if 
necessary.  Eleven of the 40 free-text comments specified avoiding travelling a distance as a 
reason for choosing scenario B and 8 of the 40 specified avoiding hospital attendance as a 
reason.  Two raised concerns regarding the ease of use of the device and 1 mentioned being 
afraid of finger-pricking, stating it is painful compared to venepuncture. 
Table 17 shows the scenario chosen according to the demographic information.  None of 
gender, living arrangements, duration of travel to hospital, time since most recent 
chemotherapy or experience of febrile neutropenia influenced the choice of scenario in 
question 2 (all p values >0.05).  Some of those living within 60 minutes travel duration of the 
hospital chose scenario A, compared to 100% of those living 1 hour away or longer choosing 
scenario B.  However, even when travel duration was split into this dichomatous variable, it  id 
not reach statistical significance (p = 0.397).   
Figure 9 displays the scenario chosen in question 2 according to age group.  There are small 
numbers in the lower age categories.  There is no statistical difference in the scenario chosen 
by age category (p=0.682).  There remains no statistical difference when age categories are 
split into the dichotomous variables of <40 years and ≥40 years (p=0.219) or <60 years and 
≥60 years (p=0.667).  
 
 
 
70 
 
 
Table 17: Table showing the scenario chosen in question 2 according to the respondent’s 
demographic information.   
Scenario A is the current practice of telephoning the hospital and attending for assessment.  
Scenario B is using the home blood count monitoring system. 
 
Demographic Choice of scenario in % (n) p value 
A B  
All respondents 12 (13) 88 (93) <0.001 
Gender   
 
Female 13 (7) 87 (48) 
0.580 
Male 12 (6) 87 (45) 
Living arrangements    
Lives on own 14 (3) 86 (19) 
0.942 
Lives with others 12 (10) 87 (71) 
Duration of travel to hospital    
<30 minutes 18 (9) 82 (41) 
0.556 
30-60 minutes 9 (4) 89 (41) 
1-2 hours 0 (0) 100 (9) 
2-3 hours 0 (0) 100 (2) 
Time since most recent chemotherapy    
Within 6 weeks 10 (6) 90 (52) 
0.442 
Greater than 6 weeks ago 14 (7) 84 (41) 
Experience of febrile neutropenia   
Previously attended hospital with suspected 
infection during chemotherapy and been 
discharged the same day 
Yes 19 (4) 81 (17) 
0.758 
No 11 (9) 88 (72) 
    
Previously admitted to hospital with an 
infection during chemotherapy 
Yes 14 (5) 86 (31) 
0.724 
No 11 (8) 87 (62) 
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Age group (years) 20-29 30-39 40-49 50-59 60-69 ≥ 70 
Gender F M F M F M F M F M F M 
Scenario 
A 2 0 1 1 1 0 0 1 1 1 2 3 
B 0 6 1 4 4 6 14 5 11 11 17 13 
Figure 9: Bar graph showing the scenario chosen by respondents in question 2 according to 
age group and gender.   
Sceanrio chosen by agegroup, p = 0.682 
Question 3 
 Question 3 sought to ascertain what risk of becoming dangerously unwell 
respondents would accept, to gain the benefits of preventing unnecessary trips to 
hospital. 
Of the 107 respondents, 4 did not answer this question.  Only one of these indicated why, and 
that was because they had selected hospital attendance and face-to-face reassurance in 
question 2 and therefore felt this was not relevant to them.  Where more than one option was 
marked (n=9), the highest risk indicated was used for the analyses as this reflected the 
boundary of acceptance.   
Figure 10 displays the degree of risk respondents indicated they were willing to take.  Those 
who chose scenario A (not home blood count testing) also tended to choose the lowest risk of  
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Maximum risk  
 
<0.1% 1% 2% 5% 10% 15% 20% 
No 
answer 
Scenario A 8 0 1 0 0 0 2 2 
Scenario B 10 13 5 13 25 11 14 2 
No answer 0 0 0 1 0 0 0 0 
 
Figure 10: Bar graph displaying the maximum risk of becoming seriously unwell that 
respondents would accept to reduce unnecessary trips to hospital. 
Scenario A is the current practice of telephoning the hospital and attending for assessment.  
Scenario B is using the home blood count monitoring system.  Scenario chosen by  risk group, 
p <0.001. 
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becoming unwell ( p <0.001).   Appendix 3, Table 3 contains the free-text comments 
associated with this question.  Eight out of the 25 responses explicitly stated they would not 
want to take any risk of becoming dangerously unwell.  Five responses were very positive 
statements towards using the device, three commented on difficulties answering this 
question and 1 respondent indicated they would not mind having a trip to hospital as they live 
within 10 minutes journey. 
The nurses who interacted with the patients during conduction of this questionnaire had the 
opportunity to add free-text comments regarding their involvement/discussions with the 
respondents.  There were 6 comments indicating the respondent found the concept of risk 
very difficult to understand and needed extra explanation.  In one instance the respondent 
had said “It puts the patient in more control. I like it". 
All three patient age groups incorporating those 50 years and older, spanned the full range of 
maximum risk respondents were willing to take to avoid unnecessary trips to hospital 
(minimum of <0.1% to maximum of 20%).  The youngest patient group (20-29 years) had the 
smallest range of risk, with no respondents choosing either the maximum or minimum risk.   
Figure 11a shows that the risk respondents were willing to take was not influenced by age 
when split into above and below 60 years.  Figure 11b shows that the risk respondents were 
willing to take was not influenced by whether they lived alone or not.   
Travel time to get to Leeds Cancer Centre did not influence the risk chosen of becoming 
dangerously unwell to avoid unnecessary trips to hospital, as shown in Figure 12.   
There were no trends between any of the following demographic details and risk respondents 
were willing to accept; gender (p = 0.138), time since last chemotherapy (p = 0.412), whether 
or not the respondents had previously been assessed for febrile neutropenia and sent home 
(p = 0.533), or admitted to hospital with an infective complication (p = 0.678). 
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Figure 11:  Bar graph showing maximum risk of becoming dangerously unwell that  
respondents were willing to accept to avoid unnecessary trips to hospital, by age and living 
arrangements. 
a) Bar graph by age either side of 60 years, p = 0.398 and b) Bar graph by living arrangements, 
p = 0.317.  
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Risk <30 mins 30-60 mins 1-2 hours 2-3 hours 
<10% 27 23 1 0 
≥10% 22 21 7 2 
No answer 1 2 1 0 
 
Figure 12: Bar graph showing grouped maximum risk of becoming dangerously unwell that 
respondents were willing to accept to avoid unnecessary trips to hospital, by duration of 
travel to Cancer Centre.  Analysis by all categories of travel duration, p = 0.750.  When split 
into traval duration < 60 mins or ≥60 mins, p = 0.183. 
 
3.4.2 Oncology consultant questionnaire 
Thirty-four of 49 consultants (16 Medical and 33 clinical Oncologists) returned the 
questionnaires; the response rate was 69.4%.  Of the 49, 16 went to Medical Oncologists and 
33 went to Clinical Oncologists.  Of the 34 returned, 1 was not completed as the consultant no 
longer gives chemotherapy, and 1 answered the first question only.   
Of the 33 completed questionnaires, 10 were from Medical Oncologists, 17 were from Clinical 
Oncologists and 6 were anonymous.  Of the 27 identified respondents, 11 (41%) achieved 
their primary medical qualification in 1990 or earlier, 16 (59%) achieved this after 1990, 13 
(48%) were female and 14 (52%) were male.  Amongst either non-responders (n=15) or the 
anonymous group (n=6), 6 were Medical Oncologists and 15 were Clinical Oncologists.  
Question 1 
 Question 1 described 3 scenarios in which patient self-test home blood count 
monitoring could be used.  It sought to assess the acceptability of using it.    
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Thirteen of the 32 respondents who answered all three parts of question 1, answered “Yes” to 
all 3 parts.  No respondents answered “No” to all three parts of the question. 
Q1a: In patients who feel unwell at home and require neutropenia to be excluded. 
Of the 33 respondents, 20 (60.6%) indicated “Yes”, 6 (18.2%) indicated “No” and 7 (21.2%) 
indicated “Not sure”, p = 0.004.   
Figure 13 shows these numbers with the breakdown of oncological speciality and year of 
primary medical qualification.  Gender was represented proportionally in each of the three 
categories.  The comments associated with this question are listed in Table 18.   
 
Answer to Q1A Comment 
Yes  “With a pathway for non-neutropenic illnesses” 
No 
 “Yes with telephone consultation” 
 “Need to be seen if unwell” 
Not sure 
 “Would still want them to come in for assessment” 
 “I may ask them to come to hosp. if they are unwell” 
 “Most of my lung cancer patients who are unwell would need to 
be seen” 
 “Depends on definition.  Would not want to delay attendance” 
Table 18: Comments associated with Question 1a regarding consultant attitudes towards 
patients measuring their own blood count at home when they feel unwell and neutropenia 
is required to be excluded. 
 
Q1b: Prior to delivery of subsequent chemotherapy cycles to avoid hospital attendance in 
patients whose neutrophil count has not recovered sufficiently. 
Of the 32 respondents, 28 (87.5%) indicated “Yes”, 4 (12.5%) indicated “Not sure” and none 
indicated “No”.  Of the 28 who indicated “Yes”, 5 were anonymous.  There was no difference 
in responses according to subspecialty (p = 0.286), year of primary medical qualification (p = 
0.846) or gender (p = 0.088).  There were no comments associated with this question. 
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Question response Yes No Not Sure 
Medical Oncologists 7 1 2 
Clinical Oncologists 8 4 5 
Anonymous 5 1 0 
 
 
Question response Yes No Not Sure 
Qualified 1990 or earlier 7 1 3 
Qualified after 1990 8 4 4 
Anonymous 5 1 0 
 
Figure 13: Frequency of responses to question 1a asking if clinicians would be willing for 
their patients to measure their blood count at home when they feel unwell and require 
neutropenia to be excluded.   
a) demonstrates the proportion of each response answered by oncological speciality, p = 
0.488 b) demonstrates the proportion of each response answered according to year of 
primary medical qualification, p = 0.571. 
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Q1c: In the days following chemotherapy delivery to identify patients at high risk of 
neutropenic complications, based on the changes in the neutrophil count. 
Of the 32 respondents, 24 (75.0%) indicated “Yes”, 8 (25.0%) indicated “Not sure” and none 
indicated “No”.  There was no difference in responses according to subspecialty (p = 0.286), 
year of primary medical qualification (p = 0.740) or gender (p=0.088). 
There were only 2 comments associated with this question.  One respondent answered “yes” 
and commented “For sure!”.  The other respondent answered “Not sure” and commented “I'd 
like to see the data first. How frequently will the tests be done? Daily? For X days? May be a 
burden to patients and hospital staff”.   
Question 2  
 Question 2 considers the neutrophil threshold to be used and the acceptable 
associated risk when a patient on chemotherapy has a fever and is otherwise well and 
has a neutrophil count measured at home.   
Q2a: Please tick the neutrophil threshold you suggest we use in this scenario to recommend 
urgent clinical assessment (units are x109/L). 
Of the 32 respondents, none indicated a neutrophil count threshold greater than 1.5 x109/L.  
The modal and median threshold was a neutrophil count of <1.0 x109/L, with the range being 
<0.5 to <1.5 x109/L.  
Figure 14 shows the percentage of oncological speciality and year of primary medical 
qualification choosing each threshold.  All the respondents who indicated a neutrophil 
threshold of <0.5 x109/L were male (n=3).   
Q2b: Using the threshold you’ve selected, please tick the maximum risk of incorrectly 
advising a patient to stay at home, which you consider to be acceptable. 
The median risk option chosen was 2%. The responses are distributed with 2 modes of 1% and 
2%.  29 (90.6%) respondents chose a risk between and including 0.1% to 10%, with 23 (71%) 
choosing 1%, 2% or 5%.  Figure 15 shows the frequency of risk options chosen by oncological 
speciality and year of primary medical qualification.  The minimum (<0.1%) and maximum 
(20%) risk options given were chosen by 2 respondents and 1 respondent respectively. 
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Neutrophil threshold (x109/L) <0.5 <0.75 <1.0 <1.25 <1.5 >1.5 
Frequency Medical Oncologists 
(% of specialty) 
1 (10) 2 (20) 5 (50) 0 (0) 2 (20) 0 (0) 
Frequency of Clinical Oncologists 
(% of specialty) 
2 (13) 3 (19) 10 (63) 0 (0) 1 (6) 0 (0) 
Unknown specialty 
(% of group) 
0 (0) 1 (17) 2 (33) 1 (17) 2 (33) 0 (0) 
 
 
Neutrophil threshold 
(x109/L) 
<0.5 <0.75 <1.0 <1.25 <1.5 >1.5 
Qualified 1990 or earlier (%) 2 (20) 4 (40) 2 (20) 0 (0) 2 (20) 0 (0) 
Qualified after 1990 (%) 1 (6) 1 (6) 13 (81) 0 (0) 1 (6) 0 (0) 
Anonymous (%) 0 (0) 1 (17) 2 (33) 1 (17) 2 (33) 0 (0) 
 
Figure 14: Percentage of responses to question 2a, which asked for the neutrophil threshold 
to recommend urgent clinical assessment when a patient on chemotherapy is at home, has 
a fever and is otherwise well.  
a) demonstrates the response by percentage of each oncological speciality, p = 0.750 b) 
demonstrates the response by percentage of year of primary medical qualification, p = 0.022. 
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Figure 15: Frequency of responses to question 2b, which asked the maximum risk of 
incorrectly advising a patient to stay at home, which the respondent considered acceptable. 
a) demonstrates the proportion of each response answered by oncological speciality, p = 
0.308 b) demonstrates the proportion of each response answered according to year of 
primary medical qualification, p = 0.430. 
 
The comments associated with this question are listed; 
 “Ideally no risk”. 
 “Depends on risk of chemotherapy”. 
 “As threshold is high” (indicated <1.0 neutrophil threshold and 2% risk). 
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 “Death as a complication of management of suspected febrile neutropenia should 
be a never event. The test does not replace clinical assessment. I am more confident 
in scenarios b and c”. 
Q2a and b combined 
Table 19 shows the frequency of neutrophil threshold chosen in combination with maximum 
risk of incorrectly advising the patient to stay at home.  For example, it shows that of the 
three respondents choosing a neutrophil threshold of <0.5 x109/L, the associated risk they 
would be willing to accept is diverse (1.0, 2.0 and 20.0%).  It also shows that <1.0 x109/L is the 
neutrophil threshold most commonly chosen (n=17), but there is a large range of risk that 
respondents who chose this are willing to accept (<0.1 to 10.0%), with the maximum risk of 
1.0% being the modal value. 
 
Neutrophil 
Threshold 
(x109/L) 
Maximum risk (percent) 
<0.1 0.1 1.0 2.0 5.0 10.0 20.0 Total 
<0.5 - - 1 1 - - 1 3 
<0.75 1 2 1 2 - - - 6 
<1.0 1 2 5 4 4 1 - 17 
<1.25 - 1 - - - - - 1 
<1.5 - - 1 1 3 - - 5 
Total 2 5 8 8 7 1 1 32 
Table 19: Frequency table combining neutrophil threshold chosen to recommend urgent 
clinical assessment in a patient who is at home, has a fever and is otherwise well, with the 
maximum risk of incorrectly advising a patient to stay at home. 
 
The respondent who indicated using a <0.5 x109/L neutrophil threshold with a 20% risk of 
incorrectly advising the patient to stay at home, clarified these answers by saying the patient 
would “need a clinical assessment if high risk” and low risk patients would need a “repeat 
blood count the next day and be advised to have a clinical assessment if unwell”.   
Five of the 6 respondents who indicated they would not use the self-test home blood count 
monitoring in patients who feel unwell at home and require neutropenia to be excluded in 
question 1a, completed question 2 a and b about threshold they would use and acceptable 
risk associated with this.  Of these 5, 4 indicated they would use a neutrophil threshold of <1.0 
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x109/L, each with a different maximum risk of incorrectly advising the patient to stay at home, 
namely 0.1%, 1%, 2% and 5%.  The respondents who indicated 0.1 and 1% risk clarified their 
responses with the comments “Need to be seen if unwell” and indicated they would have 
answered question 1a as “Yes with telephone consultation”.  The remaining 1 of these 5, 
indicated a neutrophil threshold of <0.75 x109/L with a 2% risk of incorrect advise.  
General Comments 
Nine respondents entered free text comments in the space to do so at the end of the 
questionnaire.  These are shown in Appendix 3, Table 4. 
 
3.5 Discussion 
3.5.1 Main findings 
The vast majority of patients and consultants would be willing to use patient self-test capillary 
blood count monitoring.  Some of the most valuable learning points from these 
questionnaires were raised via the free-text comments.  For patients, the most frequent 
incentive was to save time, but the importance of patient choice, education and training also 
recurred on multiple occasions.  For the consultants, there were repeated references to the 
need for neutropenic risk stratification to define the clinical management pathway and the 
use of successive blood counts to monitor the neutrophil count trend.  
3.5.1.1 Patient questionnaire    
The key finding from this questionnaire was that a clear majority (86.9%) of the respondents 
indicated they would prefer to use home blood count monitoring over the current system of 
attending the hospital for assessment and reassurance by a health-care professional.  This is 
from a population where almost half (48/107) had experience of being assessed for infection 
during chemotherapy, whether they were discharged the same day or admitted for 
treatment, meaning they could reasonably be expected to have some understanding of the 
scenarios being described.  There was a greater number of respondents in higher age 
categories than younger, as might be expected, and the majority of patients lived within an 
hour’s travel time of the hospital, as Leeds Cancer Centre is based in a city.  Of those who 
preferred home blood count monitoring, the most common reason was to save time; of those, 
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on the other hand, who chose the current system of in hospital assessment, the most 
common reason was for reassurance by a healthcare professional. 
The demographics which appeared to influence choice of method of assessment (scenario A 
or B) when febrile neutropenia needs to be excluded, were time taken to travel to hospital 
being greater than or equal to one hour, experience of either assessment for febrile 
neutropenia or admission for treatment of an infection during chemotherapy, and age <40 
years.  All of those living at least one hour from the hospital chose home blood count 
monitoring as the preferred method of assessment.  This fits with the most popular reason 
being to save time, as these patients have the most potential time to save.  It appears that 
previous experience of febrile neutropenia, whether that be an assessment at the hospital 
alone or admission to hospital, may have inclined respondents to prefer hospital assessment 
rather than home blood count monitoring.  Accepting the limited numbers, it is difficult to 
ignore that a higher proportion of those less than 40 years old preferred in hospital 
assessment, compared to those over 40 years or older.  However, this may be multifactorial 
such as teenage and young adult patients receiving more intensive chemotherapy and hence 
being more likely to have experienced febrile neutropenia in the past. 
The most important message from the patient questionnaire assessment about risk is that 
respondents were willing to accept some risk to gain the benefits of using home blood count 
monitoring.  Risk is a difficult concept to portray and to understand, and definite conclusions 
cannot be drawn about the “acceptable” level of risk.  Seven out of the 10 respondents who 
preferred the current system of in-hospital assessment indicated they would be willing to take 
only the lowest risk (0.1%) of becoming dangerously unwell.  This indicates these respondents 
understood the question.  Of those who accepted the highest percentage risk categories, a 
larger proportion of these respondents lived alone and a larger proportion lived an hour or 
more travel time from the hospital, when compared to the other risk categories chosen, 
suggesting there may be confounding factors influencing their decision-making process. 
3.5.1.2 Consultant questionnaire  
The important message from this questionnaire was that generally there is enthusiasm from 
consultants for patients to use home blood count monitoring during chemotherapy in all 
three scenarios described, but with some trepidation in the patient who requires febrile 
neutropenia to be excluded (60.6% answered “yes”, 18.2% answered “no” for use in this 
scenario).  Of those who indicated “no”, clinical oncologists and those who qualified after 
1990 appeared disproportionately represented.  It is difficult to comment on the 
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proportionate representation in those who indicated “yes”, as one quarter were anonymous.  
No consultant indicated “no” to use both before delivery of chemotherapy or after 
chemotherapy to predict risk of neutropenic complications. 
The modal and median neutrophil threshold chosen to be used in the scenario where a 
patient requires neutropenia to be excluded was <1.0 x109/L.  Respondents who qualified in 
1990 or earlier were disproportionately represented in those who chose the lowest neutrophil 
thresholds (0.5 and 0.75 x109/L) and also in those who would accept the highest risk of 
incorrectly advising a patient to stay at home (10% and 20%).  Oncological sub-specialty did 
not appear to influence the neutrophil threshold chosen or maximum risk they would accept.  
It was expected that the neutrophil threshold to exclude febrile neutropenia would correlate 
with the maximum risk of incorrectly advising a patient to stay at home, such that those who 
chose the lowest neutrophil threshold would also choose the lowest acceptable risk.  This was 
not the case.  This is possibly a reflection of the difficulty in measuring risk and indicates that 
the risks and benefits reasoning should be considered on an individual basis and in 
conjunction with the patient.  Themes that repeatedly arose in the free-text comments 
support this explanation; the desire to stratify patients according to their risk of febrile 
neutropenia and using the trend of the blood count result, rather than a one-off reading, to 
use home blood count monitoring as part of pre-defined pathway-led care. 
3.5.2 Strengths and weaknesses 
Strengths of this work include the relatively large number of completed patient and 
consultant questionnaires and the demographics of respondents.  There was a wide range of 
patient ages, and a high proportion of patients (45%) having had previous experience of 
assessment or admission to hospital for an infection during chemotherapy, thus with some 
knowledge of the problem being addressed.  The proportion of oncology consultants who 
returned the questionnaire (69.4%) was much better than published work examining response 
rates (172, 173).   
Free-text answers provided respondents with the opportunity to expand and reason, 
highlighting important issues such as the value patients place upon interaction with 
healthcare professionals.  Despite this, it proved very difficult to structure short 
questionnaires to accurately assess attitudes towards trading off the benefits of one practice 
for those of another.  The iterations of the patient questionnaire progressed through using a 
visual analogue scale, Likert scale and a discrete choice experiment, before settling on a 
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version of paired comparison.  Discrete choice experiment methods have been used 
successfully in medicine to establish patient preferences, and would have been the preferred 
design as they can demonstrate reasons behind a preference, but there were too few 
attributes in the scenarios to use this (174-177).   
Portrayal of implications of risk and representation of risk are complicated, but an essential 
part of assessing acceptability of using patient self-test home blood count monitoring.  
Exploration of risk should be approached by assessing the perceived risk, prior to assessing 
attitudes towards the risk(178).  Given that the consultant questionnaire was only distributed 
to oncologists, knowledge of the perceived risk was assumed.  Assessment of consultant 
attitudes towards the risk were limited by the questionnaire design not allowing for differing 
risk in an individual’s practice to be accounted for.  It was clear that despite the patient 
involvement in developing and piloting the questionnaire, some still had difficulties answering 
the question about risk, mostly due to difficulty trading off the attributes of each scenario.  
Notably, 2 respondents indicated they would not want to use the home blood count 
monitoring, then indicated they would accept a 20% risk of becoming dangerously unwell.  
Interestingly, 20% was the maximum risk option available, but still respondents of both 
questionnaires chose this.  In hindsight, perhaps the maximum risk preferred should have 
been higher.   
3.5.3 Implications 
The risk of febrile neutropenia ranges from low (<10%) to high (>20%)(24), and is dependent 
upon the chemotherapy regimen given and other parameters such as baseline haematology, 
age greater than 65 years and co-morbidities (37, 38).  This is why results of the consultant 
questionnaire indicated a desire to consider use of patient self-test capillary blood count 
monitoring as part of a formalised pathway of triage and assessment, defined by clinical 
characteristics of the individual and chemotherapy regimen proposed to be used.  For 
example, some patients, such as those at low risk of infective neutropenic complications 
whose count falls within a “grey” area either side of the chosen threshold, could be advised to 
repeat the blood test after a specified period of time, giving information on the trend of the 
neutrophil count.  In contrast, those known to be at high risk of neutropenic complications 
could be advised to have a clinical assessment in this scenario.   
Within this stratified personalised medicine model, there could be scope for methods of 
clinical assessment other than the current advice to attend the acute assessment unit.  For 
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example, in some circumstances a telephone review may suffice, with the patient self-test 
capillary blood count results built into the triage methods.  Another option may be to use the 
home blood count testing device to intensively monitor those at high risk of neutropenic 
complications, in order to identify signs of infection as early as possible.  Use of such a device 
in the above ways, would require re-structuring of current clinical pathways and resource 
allocation or re-allocation, dependent upon the true effects of such a device in clinical 
practice.  With this in mind, it is prudent to consider the final sentence of the penultimate 
comment in Appendix 3, Table 4, which was made by a clinician with experience of 
introducing change to clinical practice across a department, highlighting the merits of a step-
wise approach. 
Through the progression of this project, it is important, as highlighted in the patient free-text 
comments, that a structured education and training plan for use of home blood count 
monitoring be developed both for patients and professionals.  This will contribute to the 
empowerment of patients, which has been a recurring beneficial theme raised in patient focus 
groups during the development of the patient questionnaire and other aspects of this project. 
Secondary gains of this work are in focusing attentions on where there is patient satisfaction 
and dissatisfaction with the current service.  The positive attributes can continue to be 
incorporated in home blood count monitoring proposals, and improvements can be made in 
the acute assessment service such as introducing a point of care device in the acute oncology 
unit.   
3.5.4 Conclusion 
The questionnaires show that there is considerable support and enthusiasm from patients and 
oncology consultants to explore ways of using patient self-test home blood count monitoring 
to improve the care of patients on chemotherapy.  There is some scepticism regarding use in 
the scenario of patients who are acutely at risk of febrile neutropenia.  However, this is only 
one of three potential time points in the pathway of a patient on chemotherapy, where it 
could be used.   
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Chapter 4 Evaluation of point of care results as surrogate indicators of 
haematological parameters 
4.1 Introduction 
Point of care technology exists to test a wide range of haematological parameters, including 
haemoglobin, glycosylated haemoglobin, glucose, white cell counts and international 
normalised ratio (INR). However they do not measure platelet count. This is limited to desktop 
and larger analysers (179).  Evaluation and reporting of analyses of point of care devices has 
been fraught with inconsistencies, resulting in the publication of the Standards for Reporting 
of Diagnostic Accuracy (STARD) statement in an attempt to standardise the approach to 
evaluations (77, 180).  One criticism of work on diagnostic test performance in the 1990s was 
apparent thinking in silos, often with the analytical performance and clinical performance 
evaluations of medical tests being disconnected (181, 182).  Work in this area has greatly 
improved, and the need to continue to do so was recognised by the National Institute for 
Health Research (NIHR), which funded four Diagnostic Evaluation Co-operatives (DECs) in 
England for four years in 2013, with the aim of helping to generate information on clinical and 
cost-effectiveness of in-vitro diagnostic devices.  With this in mind, we sought to consider the 
purpose of haematological tests in patients with cancer on chemotherapy, looking at which 
parameters are currently used to change patient pathways and how the blood count results 
generated by point of care devices may guide management decisions.    
Blood counts are carried out in patients with cancer on chemotherapy for a variety of reasons 
including (i) before starting a new cycle of chemotherapy to ensure adequate recovery from 
previous treatment, (ii) during a chemotherapy cycle to identify haematological toxicities of 
chemotherapy, and (iii) to investigate possible haematological consequences of the underlying 
malignancy due, for example, to infiltration of the bone marrow.  Blood counts performed on 
patients during chemotherapy may reveal bone marrow suppression, which can include 
pancytopenia or isolated suppression of individual haematopoietic cell lines.  In the 
management of patient with solid tumours, suppression of haemoglobin production, 
neutrophil or platelet counts may require intervention either prophylactically or in response 
to symptoms or complications.  Anaemia can be a consequence of either disease or can be 
treatment-related.  Treatment-related anaemia tends not to be an acute issue.     
In contrast, patients on chemotherapy can experience acute falls in platelet counts.  This may 
present with a bleed or they can develop severe thrombocytopenia without indicative signs or 
symptoms.  It is, therefore, relevant to consider that point of care devices measuring blood 
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counts do not measure platelets.  The British Society for Haematology guidelines on the use of 
platelet transfusions, recommend giving prophylactic platelet transfusions to asymptomatic 
patients with reversible bone marrow failure to maintain a platelet count at or above 10 
x109/L (183).  There is a risk of isolated thrombocytopenia with chemotherapy for solid 
tumours, and as such, it is important to investigate the likelihood of failing to identify such a 
thrombocytopenia whilst using the point of care home blood count monitoring devices during 
chemotherapy. 
Historically, granulocytopenia was used to identify patients at risk of severe or life-threatening 
infections during chemotherapy (16).  Despite the fifty year time lapse since publication of this 
paper and the terminology in guidelines and published evidence changing  to neutrophils 
rather than granulocytes in the early 1990s, this remains the most consistently cited work in 
current international guidelines and the most relevant to date on quantitative relationship of 
leukopenia to infection (22, 26, 28, 30).  The change from granulocytes to neutrophils 
probably occurred, at least in part, as a result of laboratory analysers being able to measure 
five-part differentials becoming common place in healthcare provider laboratories.   
Although desktop and laboratory analysers usually report five-part differential white blood 
cell counts, some hand-held point of care devices, including the XBC and others, generate 
three-part differential white cell counts comprising lymphocytes, monocytes and granulocytes 
(184, 185).  The three component cells of granulocytes (neutrophils, eosinophils and 
basophils), are distinguished morphologically by multilobular nuclei, but have different 
immunological functions.  The absolute values of differential counts in reference ranges 
depend on the specific measuring laboratory and population it serves, but neutrophils usually 
form by far the greatest proportion.  Suggested ranges are neutrophils 2.0–7.0 ×109/L (40–
80% of total white cell count), eosinophils 0.02–0.5 ×109/L (1–6% total white cell count) and 
basophils 0.02–0.1 ×109/L (< 1–2% total white cell count) (1). 
Due to the potential advantages and increasing availability of point of care devices that 
measure three-part differential white cell counts, but routine oncological practice being based 
on neutrophil counts, it is important to determine the confidence with which a granulocyte 
count can be used as an indicator of absolute neutrophil count.  A previous study aiming to 
correlate granulocyte counts from 3-part analysers to laboratory measured neutrophil counts 
found no disadvantage to using the 3-part differential analyser granulocyte count in the 
absence of a neutrophil count (185).  In the 133 samples processed, the correlation between 
3-part analyser granulocyte count and 5-part analyser neutrophil count or manual neutrophil 
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count produced an R2 greater than or equal to 0.98.  This study used robust methodology such 
as ensuring all measurements occurred within four hours of the venepuncture, that the 
samples were processed by two 3-part differential analysers (ABX Micros ES 60, Horiba 
Medical and PocH-100i, Sysmex), and that the 3-part analyser results were compared to both 
the routine laboratory analyser but also to a manual differential neutrophil count. The 
method of determining the granulocyte count in the 3-part differential analyser was 
impedance, which is also used in the XBC.  However, this study used blood samples from 
patients whose diagnosis was not reported and compared the results to a 5-part haematology 
analyser (ABX Pentra 80, Horiba Medical) different to that used in routine practice in Leeds 
Teaching Hospitals NHS Trust haematology laboratories (ADVIA 2120, Siemens). The report 
describes the accuracy of the 3-part analyser granulocyte counts in indicating neutrophil 
counts, but does not address the precision.  Moreover, there was no attempt to quantify the 
absolute differences between granulocytes and neutrophils in ranges relevant to oncological 
practice, nor apply this to clinical decision thresholds.   
In a further study evaluating the accuracy and precision of point of care analysers in the 
neutropenic range, the accuracy of the Siemens ADVIA-60 3-part differential analyser 
granulocyte count in determining the neutrophil count was reported to be satisfactory with R2 
of 0.850 and coefficient of variation of 6.0% (85).  The methodology of this study was strong 
and relevant with a sample size of 106, and blood results in the neutropenic range (neutrophil 
count <2.0 x109/L); both accuracy and precision were reported conventionally for such a study 
(using correlation, logistic regression and coefficient of variation).  However, the Siemens 
ADVIA 60 used was not subject to the same quality assurance checks as the other 
haematology analysers reported in the same study, the time lapse between venepuncture and 
analysis was long at eight hours, and the diagnosis of patients from whom the blood samples 
were obtained was not reported.  The results showed the regression line to have a large 
positive intercept (y=1.26𝑥 + 0.25), indicating that the ADVIA-60 overestimated the 
neutrophil count in samples with few neutrophils.  This, and the fact that the study again does 
not report on misclassification of samples either side of clinically relevant thresholds, 
emphasizes the need for further work comparing the appropriateness of using granulocytes as 
an indicator of neutrophils in neutropenic ranges.  
This chapter addresses how the results available from point of care analysers can be used 
appropriately in oncological practice.  The point of care device used in this project changed as 
it progressed.  The first one, the XBC, gave a 3-part white cell differential count, so the 
majority of work here focused on using granulocytes as a surrogate for neutrophils.  The later 
90 
 
device, the Haemocue WBC DIFF, gave a 5-part white cell differential count, so a lesser part of 
this chapter focused on use of neutrophils to predict thrombocytopenia.   
4.2 Objectives 
1. To determine if granulocyte counts can be used as an indicator of absolute neutrophil 
counts in the neutropenic range 
2. To determine limits of granulocyte grades that are equivalent to Common 
Terminology Criteria for Adverse Event (CTCAE) grades of neutropenia.      
3. Analyse the performance of absolute neutrophil count thresholds in identifying 
clinically significant thrombocytopenia  
4.3 Methods 
4.3.1 Granulocyte count thresholds predicting clinically significant 
neutropenia 
Venous full blood count results were extracted from the Leeds Teaching Hospitals NHS Trust 
electronic results server if they were from a patient who had received chemotherapy for a 
solid tumour, and the blood test was dated between 1st January 2004 and 1st January 2016.  
These results were all obtained using the Siemens ADVIA 2120 automated 5-part differential 
analyser, which is the Leeds Teaching Hospitals NHS Trust reference analyser.  The results of 
interest were the absolute neutrophil count and total granulocyte count, which was derived 
from the sum of basophils, eosinophils and neutrophils.  The patient group was defined as 
those with a solid tumour (excluding lymphoma) International Classification of Diseases 10th 
revision code (ICD-10) (186), with an entry indicating “delivered” in the electronic 
chemotherapy drugs table.  The data were limited to one blood count result per patient per 
day. The extracted data were anonymised.   
Correlation between the neutrophil and granulocyte counts was determined using Pearson’s 
correlation co-efficient (r), the co-efficient of determination (R2) and linear regression, where 
the neutrophil counts were ≥1.5 x109/L to 7.5 x109/L (CTCAE neutropenia grade 1 and normal) 
and also where neutrophil counts were <1.5 x109/L (CTCAE neutropenia grade ≥2).  Bland-
Altman plots were performed to analyse the agreement between the two assays, including 
identifying bias and outlying measurements, as described in the introduction chapter (187).   
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To investigate the ability to classify neutropenic CTCAE grades using granulocyte counts, the 
dataset was randomly split (1:2) into derivation and validation datasets.  Granulocyte ranges 
equivalent to the CTCAE neutropenic grades were derived by multinomial logistic regression 
classification, which was trained on the derivation dataset and tested on the validation 
dataset.  Multinomial logistic regression classification is a method used to apply logistic 
regression where there are ≥2 categorical outcomes.  It is used to predict probabilities of 
different categories of a categorically distributed dependent variable, which are the grades of 
granulocytopenia in this analysis.      
The relationship of granulocytes to neutrophils was additionally explored in 2 subsets of blood 
samples; (i) where counts from patients with eosinophilia or basophilia were excluded 
(defined as counts above the upper limit of normal), and (ii) where the samples were obtained 
within 6 weeks of chemotherapy delivery.  This was to aid understanding of how such 
conditions may be influence the utility of home blood count monitoring in clinical practice.  
Descriptive analyses were performed using Microsoft Excel 2010 and statistical analyses were 
mostly performed using Stata STRS, but Figure 16 and Figure 17 were drawn using the R 
programming language package(188-190).  The reference system used to determine grade of 
neutropenia was the Common Toxicity Criteria of Adverse Events version 4.03 (CTCAE) (17).    
This work was sanctioned under the information governance procedures of Leeds Teaching 
Hospitals NHS Trust.    
4.3.2 Neutrophil count thresholds predicting clinically significant 
thrombocytopenia 
The same rules were applied as in 4.3.1 to extract venous full blood count results from PPM, 
except there was a restriction to have received chemotherapy within 42 days of the full blood 
count result.  Again, the blood results were all measured using the Siemens ADVIA 2120 
automated 5-part differential analyser.  The results of interest were the absolute neutrophil 
count and the platelet count.  The patient group was also defined using ICD-10 as in 4.3.1, 
with an entry indicating “delivered” in the electronic chemotherapy drugs table within 42 days 
prior to the date of the blood test.  There was no limit on the frequency of inclusion of blood 
tests from a single patient.  The extracted data were anonymised.  For the purposes of this 
analysis, clinically significant thrombocytopenia was defined as a platelet count <10 x109/L.  
Descriptive analyses were performed using Microsoft Excel 2010 and statistical analyses using 
Stata STRS(188, 189).   
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The data were extracted, anonymised and placed in a research database by a data analyst.  
This work was sanctioned under the information governance procedures of Leeds Teaching 
Hospitals NHS Trust. 
4.4 Results 
4.4.1 Granulocyte count thresholds predicting clinically significant 
neutropenia 
There were 508,646 full blood count results meeting the inclusion criteria.  Of these, 134,119 
(26.4%) had CTCAE v4.03 grade ≥ 1 neutropenia (neutrophils <2.0 x109/L), 296,510 (58.3%) 
had neutrophils within the normal range (2.0 – 7.5 x109/L), and 78,017 (15.3%) had 
neutrophils above the normal range (>7.5 x109/L).  Table 20 a and b show the distribution of 
cell counts for the 3-part differential counts, and for neutropenic counts (<2.0 x109/L).     
The extent of the relationship between neutrophils and granulocytes was investigated with a 
view to using granulocytes to predict the neutrophil count.  Pearson’s correlation co-efficient 
for the full range of neutrophils versus granulocytes was 0.997, R2 was 0.995.  Figure 16 shows 
the relationship of neutrophils versus granulocytes when analysed in two groups; results with 
either grade 1 neutropenia or a neutrophil count within normal range, and neutrophil results 
categorised as grade ≥2 neutropenia.  Investigation of the relationship by individual grades of 
neutropenia fluctuated, and was better for grade 4, than grades 2 and 3;  
 grade 1 neutropenia gave an R2 of 0.848 and residual standard error of 0.112 
 grade 2 gave an R2 of 0.699 and residual standard error of 0.079 
 grade 3 gave an R2 of 0.743 and residual standard error of 0.074 
 grade 4 gave an R2 of 0.891 and residual standard error of 0.048   
Taken together, when there was a grade ≥2 neutropenia, the R2 was 0.964 indicating better 
accuracy at distinguishing either side of this threshold than identifying those samples falling 
within the boundaries of a specific grade.   
Bland-Altman plots, performed to visualise the agreement between the two parameters, are 
shown; results with either a grade 1 neutropenia or a neutrophil count within normal range 
are shown in Figure 17a, and neutrophil results categorised as grade ≥2 neutropenia are 
shown in Figure 17b.  The total agreement shown indicates the percentage of results which 
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(a) 
(b) 
    
Differential 
cell count 
Minimum 
(x109/L) 
Maximum 
(x109/L) 
Median 
(x109/L) 
Mean 
(x109/L) 
SD 
Granulocytes 0.00 213.42 3.73 4.65 4.31 
Neutrophils 0.00 180.58 3.55 4.49 4.21 
Eosinophils 0.00 53.69 0.07 0.12 0.26 
Basophils 0.00 51.43 0.03 0.04 0.15 
 
CTCAE v4.03 neutrophil grade 
(count x109/L) 
Frequency (%) 
1 (<2.0 to ≥1.5) 35,467 (26.4) 
2 (<1.5 to ≥1.0) 29,770 (22.2) 
3 (<1.0 to ≥0.5) 24,118 (18.0) 
4 (<0.5) 44,764 (33.4) 
Totals 134,119 (100) 
Table 20: The distribution of cell counts for (a) granulocytes and the 3-part differential 
counts, and for (b) neutropenic counts (<2.0 x109/L).     
 
fall within 1.96 x SD.  For example, 97.6% of granulocyte results were within 0.265 x109/L of 
the neutrophil count (Figure 17b).  Therefore, if a threshold of <1.5 x109/L neutrophil count 
was applied, using an equivalent granulocyte threshold of <1.765 would correctly identify 
97.6% of patients with a neutrophil count <1.5 x109/L.    
Analysis of CTCAE neutropenic grades individually showed that 97.0% of grade 1 neutropenic 
counts had a difference of less than 0.358 x109/L and a mean difference of 0.111 x109/L, 
96.6% of grade 2 neutropenic counts were <0.278 x109/L with a mean of 0.086 x109/L, 97.2% 
of grade 3 neutropenic counts were <0.242 x109/L with a mean of 0.066 and 97.5% of grade 4 
neutropenic counts were <0.140 x109/L with a mean of 0.026 x109/L.      
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Figure 16: Scatterplots showing the relationship of neutrophil and granulocyte counts.   
(a) neutrophil counts ≥1.5 x109/L to 7.5 x109/L (CTCAE neutropenia grade 1 and normal range) 
and, (b) neutrophil counts <1.5 x109/L (CTCAE neutropenia grade 2 or worse).  In (a) 
n=331,977 and y = 0.9659 𝐱 - 0.03453, and in (b) n=98,652 and y = 0.9074 𝐱 + 0.00671.  RSE is 
residual standard error, solid grey line is x=y, dashed grey line is line of best fit.     
 
 
Figure 17: Bland-Altman plots showing the agreement between neutrophil and granulocyte 
counts.  
 (a) Neutrophil counts ≥1.5 x109/L to 7.5 x109/L (CTCAE neutropenia grade 1 and normal 
range, n=331,977) and, (b) neutrophil counts <1.5 x109/L (CTCAE neutropenia grade 2 or 
worse, n=98,652).  Outer grey dashed lines represent upper and lower limits of agreement 
(+/-1.96 x SD) and the middle dashed line is the mean difference.  In (a) from top to bottom, 
the value of the lines are 0.600, 0.174, -0.252, and in (b) 0.265, 0.058, -0.149.  As difference 
cannot be less than zero, the lower limits are irrelevant.   
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The split data comprised derivation (n=167,853) and validation (n=340,793) datasets.  The 
granulocyte ranges equivalent to the CTCAE neutropenic grades were derived by the 
multinomial logistic regression classifier and then tested on the validation dataset, achieving 
an accuracy of 96.4%.   
Table 21 displays the performance of the equivalent granulocyte count ranges in identifying 
the neutrophil grade.  The proportion of correct predictions of the granulocyte count 
equivalent range improved as the severity of CTCAE grade neutropenia increased, with 87.3% 
of grade 1 being correct, 88.5% of grade 2, 90.5% of grade 3 and 97.5% of grade 4.  The worst 
performing equivalent granulocyte range was grade 1 where there was a 5.3% chance of 
classifying the neutropenia as grade 1 where it was truly a worse grade than this, with 0.07% 
chance of truly being grade 3 or worse.  Using the granulocyte equivalent range for grade 2, 
there was a 4.2% chance of misclassifying as grade 2, when the true neutrophil count was 
grade 3 or worse.     
Three different grade thresholds and the use of different equivalent granulocyte boundaries 
for each of these thresholds were investigated.  The thresholds were neutrophil count of <1.5 
x109/L (CTCAE 2 or worse), <1.0 x109/L (CTCAE grade 3 or worse) and <0.5 x109/L (CTCAE 
grade 4).  Table 22 displays these results.  Using a threshold of 1.5 x109/L neutrophil count, 
the equivalent granulocyte count of <1.69 x109/L performed best in terms of maximising the 
product of sensitivity and specificity, but the equivalent granulocyte threshold had to be <2.39 
x109/L to reach 100% sensitivity (when rounded up); even using this threshold, 49 results out 
of the 98,652 (0.05%) results with neutrophil count <1.5 x109/L were false negatives.  Using a 
threshold of 1.0 x109/L neutrophil count, equivalent granulocyte count of <1.13 performed 
the best in terms of maximising the product of sensitivity and specificity, but again even using 
the higher boundary of <1.71 x109/L, there were still 34 false negatives out of the 68,882 
results with neutrophil count <1.0 x109/L .   
When results were excluded if eosinophils were ≥0.4 x109/L or basophils were ≥0.1 x109/L, the 
dataset reduced to 469,433 results.  Correlation of granulocytes to neutrophils improved with 
R2 of 0.996 when the neutrophil count was ≤7.5 to ≥1.5 x109/L, and also when the neutrophil 
count was <1.5 x109/L with R2 of 0.988.  Correlation of granulocytes to neutrophils also 
improved for the categories mentioned respectively, R2 0.989 and R2 0.978, when the dataset 
was restricted to include only patient who had received chemotherapy within 6 weeks (42 
days).    
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  Performance 
 Frequency Percentage (%) 
Granulocyte Threshold (x109/L) 
True 
positive 
False 
positive 
True 
negative 
False 
negative 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
G
ra
d
e
 
2
-4
 
i) <1.53 94,250 129 409,865 4,402 
95.5 
(95.4-95.7) 
100.0 
(100.0-100.0) 
99.9 
(99.8-99.0) 
98.9 
(98.9-99.0) 
ii) <1.69 97,790 6,849 403,145 862 
99.1 
(99.1-99.2) 
98.3 
(98.3-98.4) 
93.5 
(93.3-93.6) 
99.8 
(99.8-99.8) 
iii) <2.39 98,603 55,164 354,830 49 
100.0 
(99.9-100.0) 
86.6 
(86.4-86.7) 
64.1 
(63.9-64.4) 
100.0 
(100.0-100.0) 
G
ra
d
e
 
3
-4
 
i) <1.03  66,281 195 439,569 2,601 
96.2 
(96.1-96.4) 
100.0 
(100.0-100.0) 
99.7 
(99.7-99.8) 
99.4 
(99.4-99.4) 
ii) <1.13  68,155 3,436 436,328 727 
98.9 
(98.9-99.0) 
99.2 
(99.2-99.2) 
95.2 
(95.0-95.4) 
99.8 
(99.8-99.9) 
iii) <1.71  68,848 37,051 402,713 34 
100.0 
(99.9-100.0) 
91.6 
(91.5-91.7) 
65.0 
(64.7-65.3) 
100.0 
(100.0-100.0) 
G
ra
d
e 
4
 
i) <0.51  42,703 38 463,844 2,061 
95.4 
(95.2-95.6) 
100.0 
(100.0-100.0) 
99.9 
(99.9-99.9) 
99.6 
(99.5-99.6) 
ii) <0.62  44,361 3,359 460,523 403 
99.1 
(99.0-99.2) 
99.3 
(99.3-99.3) 
93.0 
(92.7-93.2) 
99.9 
(99.9-99.9) 
iii) <1.15 44,742 28,437 435,445 22 
100.0 
(99.9-100.0) 
93.9 
(93.8-93.9) 
61.1 
(60.8-61.5) 
100.0 
(100.0-100.0) 
Table 22: Classification of neutropenic results using various granulocyte count thresholds.   
Decision thresholds represented maximise i) specificity, ii) the product of sensitivity and specificity and iii) sensitivity. n=508,646.
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4.4.2 Neutrophil count thresholds predicting clinically significant 
thrombocytopenia 
There were 279,059 full blood count results from 24,935 patients which contained a 
neutrophil count meeting the criteria.  Of these, 96 results had no platelet count result, 
leaving a total of 278,963 results with both a platelet and neutrophil count result.  The mean 
neutrophil count was 5.42 x109/L (range 0.00 to 199.98 x109/L).  The mean platelet count was 
297 x109/L (range 1 to 2163 x109/L).   The highest absolute neutrophil count in a blood result 
when the platelet count was simultaneously recorded as <10 x109/L was 33.41 x109/L.   
Table 23 shows the frequency and statistical performance of absolute neutrophil count 
thresholds in identifying thrombocytopenia.  Using the neutrophil threshold of <0.5 x109/L as 
an example; 316 samples were correctly identified as having a platelet count of <10 x109/L, 
12,031 samples with a neutrophil count <0.5 x109/L had a platelet count ≥10 x109/L, 266,330 
samples with a neutrophil count ≥0.5 x109/L were correctly identified as also having a platelet 
count ≥10 x109/L and 286 samples had a neutrophil count ≥0.5 x109/L, but a platelet count of 
<10 x109/L and so the thrombocytopenia was missed by using the neutrophil count alone.   
Of the thresholds analysed, the absolute neutrophil count threshold of <1.25 x109/L 
performed best in terms of maximising the product of sensitivity and specificity, closely 
followed by the threshold of <1.5 x109/L.  Figure 18 shows the percentage of samples where 
there was an isolated thrombocytopenia by neutrophil threshold. Based on this data, if a 
neutrophil count were to be used to indicate a patient requires an urgent assessment during 
chemotherapy, approximately 0.1% or 1 in 1000 of those who tested above the neutrophil 
threshold, would have simultaneously had a clinically significant isolated thrombocytopenia 
missed (platelets <10 x109/L). 
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Table 23: Performance of absolute neutrophil count thresholds in identifying clinically significant thrombocytopenia (platelets <10 x109/L).  
(n = 278,963) 
 Performance in predicting platelets <10 x109/L 
 Frequency Percentage (%) 
Neutrophil threshold (x109/L) 
True 
positive 
False 
positive 
True 
negative 
False 
negative 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
<0.5 316 12,031 266,330 286 
52.5 
(48.4-56.6) 
95.7 
(95.6-95.8) 
2.6 
(2.3-2.9) 
99.9 
(99.9-99.9) 
<0.75 342 17,517 260,844 260 
56.8 
(52.8-60.8) 
93.7 
(93.6-93.8) 
1.9 
(1.7-2.1) 
99.9 
(99.9-99.9) 
<1.0 372 24,417 253,944 230 
61.8 
(57.8-65.7) 
91.2 
(91.1-91.3) 
1.5 
(1.4-1.7) 
99.9 
(99.9-99.9) 
<1.25 400 32,900 245,461 202 
66.5 
(62.5-70.2) 
88.2 
(88.1-88.3) 
1.2 
(1.1-1.3) 
99.9 
(99.9-99.9) 
<1.5 412 43,184 235,177 190 
68.5 
(64.6-72.1) 
84.5 
(84.4-84.6) 
1.0 
(0.9-1.0) 
99.9 
(99.9-99.9) 
<1.75 423 54,754 223,607 179 
70.3 
(66.4-73.9) 
80.3 
(80.2-80.5) 
0.8 
(0.7-0.8) 
99.9 
(99.9-99.9) 
<2.0 440 67,137 211,224 162 
73.1 
(69.4-76.6) 
75.9 
(75.7-76.0) 
0.7 
(0.6-0.7) 
99.9 
(99.9-99.9) 
<2.25 444 79,990 198,371 158 
73.8 
(70.1-77.2) 
71.3 
(71.1-71.4) 
0.6 
(0.5-0.6) 
99.9 
(99.9-99.9) 
100 
 
 
 
 
Figure 18: Line graph of frequency of isolated thrombocytopenia according to neutrophil 
thresholds. 
The percentage represents a proportion of all samples where the neutrophil count was 
above the threshold indicated , in which the platelet count was also  <109/L .  Using the 
terms in Table 23, this translates as (
𝑓𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒
(𝑓𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒+𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒)
) .   
 
4.5 Discussion 
4.5.1 Main findings 
This analysis quantified the relationship between both granulocyte and neutrophil counts, 
and neutrophil and platelet counts.  The key finding is that neutrophils and granulocytes 
can be used as surrogate indicators of platelets and neutrophils respectively in a controlled 
manner, under defined clinical circumstances.  They are not, however, a substitute for 
direct laboratory reference analyser results outside of controlled scenarios or where there 
is any clinical doubt. 
4.5.1.1 Granulocyte count thresholds predicting clinically significant 
neutropenia 
There is a very strong correlation between granulocyte and neutrophil counts, which is 
maintained even when the absolute neutrophil count reduces to less than 1.5 x109/L, and 
improves further when excluding those with eosinophilia or basophilia.  The correlation is, 
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however, less satisfactory in the direct comparison of granulocytes to neutrophils when 
broken down into individual grades of neutropenia, with the R2 dropping as low as 0.743 
for grade 3.  However, the difference analyses reassuringly showed good agreement with 
97.6% of granulocytes being within 0.265 x109/L of the neutrophil count where all 
neutrophils counts were less than 1.5 x109/L.  This gives an indicator as to the margin 
which needs to be introduced to raise a specified threshold from that appropriate for 
neutrophil counts to that appropriate for granulocyte counts.    
One of the main outputs of this work is the first definition of granulocyte counts equivalent 
to the CTCAE v4.03 neutropenia grades, which has not been identified elsewhere.  These 
are clearly defined in Table 24, and perform considerably better (96.4% accuracy) than the 
direct comparison of granulocytes and neutrophils broken down into grades.  Given these 
definitions proposed to use the granulocyte count as a surrogate for neutrophil count, 
there are always uncertainties around extremes of thresholds due to pre-analytical, 
analytical and post analytical variables, which result in misclassification of some results.  
This may become clinically significant at thresholds that are used to change patient 
management.  So for example, using the defined equivalent granulocyte grades, a patient 
could be predicted as having grade 1 neutropenia (neutrophil count <2.0 to ≥1.5 x109/L), 
but truly have an absolute neutrophil count of less than 1.0 x109/L.    If the neutrophil 
count were known to be less than 1.0 x109/L in a patient at home, management may be 
changed.  In the data analysed, this scenario would occur 1 in every 1429 patients.  
However, it should also be remembered that international guidelines advocate the use of 
<0.5 x109/L to start antibiotics in a patient with suspected febrile neutropenia during 
chemotherapy, and misclassification of a granulocyte result as grade 1 neutropenia when it 
was truly a grade 4 (neutrophil count <0.5 x109/L), only occurred 1 in 23,509 results.  
In clinical practice there would be little need to change management decisions based on 
the specific grade of neutropenia, but more likely which side of a specified threshold, the 
patient neutrophil count falls.  Therefore the boundaries of clinically relevant thresholds 
were investigated, identifying that if neutrophils <1.5 x109/L were used, the best 
performing granulocyte count would be <1.69 x109/L, and if neutrophils <1.0 x109/L were 
used, the best performing granulocyte count would be <1.13 x109/L.  Both of these 
scenarios had a NPV of 99.8%, which translates clinically into 1 in 500 results would be 
misclassified as above the threshold, when they were truly below it.  
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Source Adverse Event 
Grade 
0 1 2 3 4 
CTCAE 
4.03 
(17) 
Neutrophil count 
decreased 
Within 
normal 
limits 
<LLN to 
1.5 
x109/L 
<1.5 to 
1.0 
x109/L 
<1.0 to 
0.5 
x109/L 
<0.5 
x109/L 
Definition: A finding based on laboratory test results 
that indicate a decrease in number of neutrophils in a 
blood specimen 
Pether 
et al. 
(191) 
Granulocyte count 
ranges equivalent to 
CTCAE neutropenia 
grades 
<7.73 to 
2.12 
x109/L 
<2.12 to 
1.60 
x109/L 
<1.60 to 
1.08 
x109/L 
<1.08 to 
0.56 
x109/L 
<0.56 
x109/L 
Table 24: Common Terminology Criteria for Adverse Events (CTCAE) neutropenia grades 
and equivalent granulocyte counts.   
LLN – lower limit of normal and is 2.0 x109/L at LTHT.  Upper limit of normal at LTHT is 7.5 
x109/L. 
 
4.5.1.2 Neutrophil count thresholds predicting clinically significant 
thrombocytopenia 
As expected, the frequency of clinically significant thrombocytopenia reduced as the 
neutrophil threshold used as the surrogate marker increased.  However, there were 
incidences of isolated thrombocytopenia even when there was neutrophilia.  This means it 
is not possible to identify a neutrophil threshold in the neutropenic range, as a surrogate 
for clinically significant thrombocytopenia, which would not produce any false negative 
results.  That said, using all 4 of the neutrophil thresholds investigated (<0.5, <1.0, <1.5, 
<2.0 x109/L), the negative predictive value was 99.9.  This translates clinically into 1 in 1000 
patients whose neutrophil result indicated they do not have a platelet count less than 10 
x109/L, and  truly do have a platelet count less than 10 x109/L.  However, this is an analysis 
of blood count results only, with no consideration of symptoms.  The odds may reduce 
further in symptom-led clinical practice, thus enhancing the performance of the neutrophil 
thresholds in identifying clinically significant thrombocytopenia.   
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Given that all thresholds analysed have the same NPV, if the sole purpose of the neutrophil 
test was to identify patients with a platelet count of less than 10 x109/L, then the correct 
neutrophil threshold to use would be identified by maximising the product of sensitivity 
and specificity of a continuum of thresholds.  Albeit with an interval of 0.5 x109/L 
neutrophils between thresholds in this analysis, the best performing threshold was <1.5 
x109/L, closely followed by <1.0 x109/L.  This is conveniently the range of thresholds which 
are in consideration for use in point of care testing to identify patients during 
chemotherapy who need urgent assessment to exclude febrile neutropenia.  As there is 
discrepancy even between laboratory reference analysers for haematological values (192), 
error always has to be considered in clinical practice, and 1 in 1000 being incorrectly 
identified as having platelets greater than 10 x109/L is debatably acceptable.   
4.5.2 Strengths and weaknesses 
An important strength was that this work was conducted on a very large dataset, using an 
unselected population of patients with solid tumours.  This was reflected in the range of 
neutrophil counts represented, including 44,764 counts of grade 4 neutropenia in the 
granulocyte versus neutrophil analysis.  Both analyses were conducted either in full or on a 
subset of results from patients who had received chemotherapy within forty-two days of 
the blood result, enabling the results to be applicable to patients receiving chemotherapy, 
which is highly relevant to the ongoing work and future applications of point of care 
devices measuring three-part differential counts.  In addition, there were clear national or 
international guidelines for the neutrophil and platelet counts which advocated a 
threshold beyond which there should be clinical intervention.  These provided benchmarks 
against which performance of the surrogate counts could be measured. 
It should be noted that these analyses are based solely on full blood count results and did 
not take symptoms into account.  Therefore many of the patients who have been 
identified as having clinically significant neutropenia or thrombocytopenia, but who had a 
surrogate blood result above the specified threshold, may have been identified in clinical 
practice as being “at risk” through clinical assessment.  Exclusion of these patients would 
likely further enhance the performance of the neutrophil thresholds.  In addition, the 
analysis was done by blood results and not by patient.  So, for example, if a patient was 
admitted and had thrombocytopenia, they would usually have had blood tests done on 
104 
 
 
 
consecutive days and all of these tests have been included in this analysis.  As a 
consequence, there would have been intra-patient variability in the dataset, but as this is 
true of routine practice, it was considered of greater value to include the data from 
patients with multiple samples than to exclude it.   
The granulocyte counts were derived from the sum of measured differential counts.  
Therefore there may be an underestimation of error between readings (pre-analytical 
variation) and of the variation between different ADVIA 2120 analysers in the laboratory 
(analytical variation)(86).  However, in current clinical practice at Leeds Cancer Centre, it is 
the results from the laboratory ADVIA 2120 analysers that are used to make clinical 
management decisions.  Therefore it remained appropriate that we compared 
performance to this, accepting there would have been variation around the reliability of 
what was considered the “true” neutrophil or granulocyte counts. Moreover, in the 
context of considering the feasibility of point of care blood count monitoring, it should be 
highlighted that these analyses were performed on venous blood counts only, meaning 
future work will need to address how this applies to comparison of capillary versus venous 
counts.   
After anonymisation of the data, it was not possible to retrospectively select subsets of 
patients by characteristics not included in the original extract.  For example, by 
chemotherapy regimen; it would have been preferable to analyse the performance of 
neutrophils in identifying clinically significant thrombocytopenia in those patients who 
received carboplatin chemotherapy, as this is a group of patients most likely to have a 
disconnect between neutrophil and platelet counts.  In addition, it was not possible to 
retrospectively analyse individual patient characteristics.  For example, it would have been 
preferable to explore individual patient characteristics such as regimen, age and cancer 
diagnosis for those patients whose blood counts gave false negative results.  Although it 
would be possible to extract the necessary data and perform analyses to achieve the two 
examples discussed, this was considered not a priority at this time, and will be considered 
in the future in the ongoing work.    
4.5.3  Implications 
The intention is not to use measurement of neutrophils in place of measurement of 
platelets in practice, but to ensure using home blood count monitoring during 
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chemotherapy would not put patients at undue risk of undiagnosed clinically significant 
thrombocytopenia.  These analyses show this can be done safely for the vast majority of 
patients.  The same is true for granulocytes as a surrogate for neutrophils, but in defining 
situations where point of care testing is to be used, there should always be a risk 
assessment that would include a baseline laboratory full blood count to exclude patients at 
high risk of misclassification using the surrogate markers.  High risk patients would include 
those prone to or with a history of thrombocytopenia, those with eosinophilia or 
basophilia, and those with allergic conditions such as Churg-Strauss syndrome or who 
experience an allergic reaction during monitoring.  
It is imperative that concern over any one of blood results, clinical symptoms or clinical 
signs, should prompt more comprehensive clinical assessment. This is true of both current 
clinical practice using laboratory reference analyser blood results and any future practice 
that may involve home blood count monitoring.  There is an element of variability in all 
reference laboratory blood count measurements as a result of pre-analytic, analytic and 
post analytic variability (193). This is often poorly understood by clinicians.  When 
comparing reference automated analysers, a correlation co-efficient of greater than 0.9 is 
generally considered acceptable (86), making the correlation of granulocyte counts versus 
neutrophils at the upper end of what is technically acceptable. 
However, clinical and technical acceptability are different, with what is acceptable clinically 
being dependent upon the consequences of misclassifying a blood result.  The important 
clinical question is: “If using the surrogate blood count parameter, how sure can we be 
that it correctly classifies either the platelet or neutrophil count?”  Using granulocytes to 
indicate a neutrophil result is less than 1.0 x109/L as an example, the best performing 
granulocyte count in terms of balancing false negatives with false positives would be <1.13 
x109/L, but in order to obtain no false negative results, a significantly higher threshold 
needs to be used.  This would be offset by increasing the false positives, and possibly 
negating the benefits of using home blood count monitoring in the scenario where febrile 
neutropenia is to be excluded.    Using the threshold of <1.13 granulocytes, 1 in 500 results 
would be misclassified as above the threshold.  This may be clinically unacceptable to some 
clinicians, and may be further justification of the approach to using the trend of 
granulocyte counts, which addresses the issue of variation around single measurements 
and would reduce the chances of misclassification. 
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4.5.4 Conclusions 
Granulocyte and neutrophil counts perform well as surrogate indicators of neutrophil and 
platelet counts respectively in this population. The definition of equivalent granulocyte 
counts to CTCAE v4.03 neutropenia grades also performs well and is widely applicable for 
three-part differential analysers, both within oncological care and other specialties.   This 
work shows how sure we can be that neutrophil and granulocyte counts correctly classify 
the platelet or neutrophil counts respectively above or below a threshold, thus indicating 
there is potential to use these surrogate parameters in point of care testing in oncological 
practice.  It also justifies the use of using granulocyte counts to rapidly detect neutropenia 
when a five-part differential analyser is not available in the same time-frame.  However, 
surrogate parameters are not a substitute for direct laboratory reference analyser results, 
which should always be used to confirm the diagnosis.   
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Chapter 5 Performance of the Hemocue WBC DIFF in oncological 
practice. 
5.1 Introduction 
Neutropenia occurs after chemotherapy administration due to the cytotoxic insult to the 
committed myeloid progenitor cells, which would otherwise differentiate into neutrophils.  
Neutrophils are the body’s primary haematological defence mechanism against bacterial 
pathogens.   Thus, the grade and duration of neutropenia is directly proportional to the risk 
of infective complications.  Neutropenia complicated by infection remains a life-
threatening toxicity of chemotherapy.  Therefore, the safe delivery of chemotherapy is 
partly dependent upon neutrophil count recovery.  It is mandatory to have the facility to 
accurately determine neutrophil counts on patients receiving chemotherapy. 
In current oncological practice, there tend to be two key decision points where neutrophil 
count is important.  One is around the safe delivery of a cycle of chemotherapy, which is 
dependent upon, amongst other factors, recovery of neutrophils usually to greater than 
1.5 x109/L in a 3-weekly chemotherapy regimen, or greater than 1.0 x109/L in a weekly 
chemotherapy regimen.  The second key decision point is around the management of 
toxicity, specifically patients with suspected febrile neutropenia, where management is 
changed when a neutrophil count is less than 0.5 x109/L or expected to fall to less than 0.5 
x109/L within 48 hours.  Therefore, the performance of any point of care device capable of 
measuring neutrophil counts which is being considered for use in oncological practice, 
needs to be verified in the neutropenic range. 
The original plan with this project was to proceed with the Philips XBC finger-prick blood 
count monitor.  There are published results of the performance of this device, but only 
across the normal granulocyte range, with no analyses specifically reporting the 
performance in neutropenic ranges (184, 194, 195).  An unpublished performance analysis 
of this device compared to the Siemens ADVIA 2120 was carried out at Leeds Cancer 
Centre, and the results were analysed as part of this project, and shown in Appendix 4.   
With progression of the plans to exchange use of the XBC analyser for the Hemocue WBC 
DIFF analyser, it was necessary to assess the performance of the Hemocue WBC DIFF on 
capillary samples.  This gave the opportunity to address the shortcomings of the XBC 
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performance analysis, such as lack of data to enable precision analysis and recording 
patients who declined to participate.  Evaluation of the performance of devices measuring 
a biological parameter in comparison to the gold standard test or true value should be 
expressed in terms of accuracy and precision, which are described in the introduction, 
section 1.3.1.1.1 (187, 196).  This is demonstrated succinctly by Haneder et al. describing 
the performance of a handheld creatinine measurement device, where they used the gold 
standard Jaffe method of creatinine determination as the comparator, and evaluated both 
accuracy and precision (197).   
Many of these methods of assessing accuracy and precision have been used by the 
manufacturer of the Hemocue WBC DIFF device to assess its performance.  They report 
accuracy of the analyser in measuring neutrophil counts in both venous and capillary 
samples, as shown in Table 25, but neither the mean or range of the neutrophil counts 
were reported.  They report precision by low, medium or high white cell counts, as shown 
in Table 26.  The neutrophil range is not reported, but can be inferred from the mean and 
SD.  Performance analyses independent from the manufacturer, have most commonly 
been evaluated in venous samples due to ease of access to samples.  Table 27 displays the 
accuracy of the Hemocue WBC DIFF reported in articles published independently from the 
manufacturers.  There are no published reports of accuracy of the Hemocue WBC DIFF 
specifically in the neutropenic range.  One of the advantages of the Hemocue WBC DIFF 
performance analyses is that, in contrast to the XBC analyses, neutrophils are directly 
measured and therefore there is less risk of error which is introduced by inferring 
neutrophil counts from granulocyte counts.  However, none of the existing Hemocue WBC 
DIFF performance analyses target oncology populations, neutropenic populations or 
explore the ability of patients to self-test.  
Much of the data available on the performance of the Hemocue WBC DIFF refers to venous 
samples.  To realise the potential advantages of using such a point of care device, capillary 
samples need to be used.  It is, therefore,  important to understand the comparability of 
neutrophil counts in venous and capillary samples, and to consider whether the application 
of venous reference decision points to capillary measurements are accurate and lead to 
correct clinical management.  It has been recognised for decades, that there are 
discrepancies in haematological blood count parameters between venous and capillary 
blood samples (198, 199).  The focus of this earlier work has been on platelets, 
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Sample 
Reference 
analyser 
Number of 
samples (n) 
Correlation 
co-efficient 
(r) 
Regression line 
of best fit 
(𝒚 = 𝒎𝒙 + 𝒄) 
Capillary 
Sysmex 
XS-1000i 
96 0.931 0.88𝑥 + 0.33 
Venous 
Beckman 
Coulter 
LH750 
596 0.984 0.96𝑥 + 0.16 
Table 25:  Table displaying the accuracy of the Hemocue WBC DIFF analyser as reported 
by the manufacturer in the Operating Manual (200).  
 
 Neutrophil count 
Number of 
samples (n) 
Mean (x109/L) SD (x109/L) CV (%) 
31 1.5 0.11 7.3 
31 3.4 0.13 3.7 
31 14.4 0.61 4.3 
Table 26:  Table displaying the precision of the Hemocue WBC DIFF analyser as reported 
by the manufacturer in the Operating Manual.   
These data were calculated using results from venous blood samples where one sample 
was measured many times on a single analyser. 
 
Report Sample 
Reference 
analyser 
Number of 
samples 
(n) 
Correlation 
co-efficient 
(r) 
Regression line 
of best fit 
(𝒚 = 𝒎𝒙 + 𝒄) 
Russcher et 
al. (201) 
Capillary 
(children <12 
years only) 
Sysmex 
XE-5000 
133 0.98 0.95𝑥 + 0.2 
Lindberg et 
al. (202)  
Venous Sysmex 
XE-2100 
101 0.994 0.87𝑥 + 0.02 
Reed et al. 
(203) 
Venous Beckman 
Coulter 
LH750 
343 0.984 0.98𝑥 + 0.17 
Table 27: Table summarising accuracy of the Hemocue WBC DIFF as available in 
published articles.   
The mean and range of neutrophil counts were not reported in any of the 3 articles.  
Russcher et al. reported the total white cell count range to be 2.6 – 26.9 x109/L, and Reed 
et al. reported the total white cell count sample distribution in bands, indicating n=2 in the 
range 0.3 – 2.0 x109/L.  
110 
 
 
 
haematocrit and red cells, with some neglect of the effect of sample site on white cell 
counts.  Finger-prick blood sampling provides a leukocyte-rich sample as it accesses 
arteriolar blood (204), in which there is a central rapid stream of the large leukocytes and 
erythrocytes, while the smaller platelets move more slowly adjacent to the vessel wall 
(205).  However, for the purposes of this thesis, capillary blood refers to finger-prick 
samples.   
Finger or heel-prick samples are commonly obtained from neonates and some older 
children, so there are studies comparing these and venous sample white cell counts (206-
208).  However, the neutrophil system in neonates is underdeveloped, has different 
neutrophil kinetics and is in a state of maturation (1).  Table 28 summarises the findings of 
the limited published work on the comparison of white cell counts in venous and capillary 
blood in older children and adults (205, 209-212).  All five studies reported the total white 
cell count to be greater in finger-prick capillary blood than venous samples.  The range of 
mean percentage difference in adults was 3.3-9.3%, but this was either not tested 
statistically or not statistically significant in two of the studies (209, 210).  Only Schalk et al. 
did a separate analysis of leukopenic samples and found the difference not to be 
statistically significant (p=0.06).  The main limitation of this literature search is that none of 
the publications reported paired measurements, so comparison of individual results and 
the impact on clinical management decisions could not be performed.  Much of this work 
was also quite dated; importantly, as a result there is little specifically on neutrophil counts 
and the AVIA2120 was not one of the four reference automated analysers used (Ortho ELT 
800 WS, Coulter S Plus, Sysmex F-820, ADVIA 120).   
However, there is much to be gained from scrutinising the methods in these studies.  In 
particular, the attention paid to reporting sources of pre-analytic variability, which can be 
greater than analytic variations (213). For example, all studies discarded the first blood 
droplet.  This is because (i) the first drop is rich in interstitial fluid, and (ii) tissue damage 
caused by the puncture initiates thromboplastin release, which initiates platelet 
aggregation, changing the platelet concentration in the first drops.  Aggregated platelets 
can be mistaken for large white cells when measured by the Coulter counter technique.  
Two studies stated the patients had been resting before the samples were obtained, 
significant as body posture and exercise can effect leukocyte concentration (214, 215).  Of 
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Study 
Blood 
counts 
(patients) 
Age           
(years) 
White cell parameter 
Venous 
range 
(x10^9/L) 
Venous mean 
(x10^9/L) 
Mean percentage difference                         
(capillary - venous) 
P value 
Daae et al., 1988 
(205) 
40 (40) 22-62 
total white cell count 4.0 - 15.1 7.13 +8.17 <0.005 
granulocytes 2.4 - 13.2 4.51 +8.19 <0.005 
Daae et al., 1991 
(209) 
16 (16) <1 - 14  
total white cell count 3.2-35.3 9.60 +19.2 not reported 
granulocytes 1.1 - 9.9 5.00 +17.2 not reported 
Leppanen et al.  
(210) 
13 (13) not reported total white cell count not reported 6.88 +3.3* ≥0.05 
25 (25) 22 - 58 
immature neutrophils not reported not reported negative** ≥0.05 
mature neutrophils not reported not reported negative** <0.05 
eosinophils not reported not reported no difference** ≥0.05 
basophils not reported not reported negative** ≥0.05 
Schalk et al.  
(211) 
463 (428) 18 - 82 total white cell count 0.1 - 299.5 8.90 +3.5 0.002 
18 (18) not reported total white cell count ≤1.00 not reported not reported*** 0.06 
Yang et al.  
(212) 
24 (24) 20 - 22 
total white cell count not reported 6.89 +9.2 ≤0.05 
granulocytes not reported 4.65 +12.6 ≤0.05 
Table 28:  Summary of published comparisons of capillary and venous sample white cells counts.   
“Mean percentage difference” refers to the mean difference of all the data, not mean difference of paired samples.  Not reported = not written in paper and 
cannot be derived.  *Derived from mean values in paper, not reported.  **Paper reports mean concentration, description refers to capillary minus venous 
mean concentrations.  ***Absolute difference is +0.1 x109/L. 
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the four studies in adults, two described promoting formation of the finger-prick blood 
droplet by pre-heating the site or gentle massage, whereas the other two described 
allowing the blood droplet to form freely.  This may be important as finger massage may 
cause demargination of neutrophils, potentially falsely elevating the capillary count.  There 
are lessons to be learned here regarding the importance of standardising the technique 
used for performance analysis, and choosing one which can be easily replicated on a larger 
clinically relevant scale. 
In this chapter, the performance of the Hemocue WBC DIFF analyser is evaluated when 
measuring capillary sample neutrophil counts  in comparison to the current standard of 
care, which is venous sample neutrophil counts.  This work addresses the shortfalls 
described in published literature by using populations of oncology patients, specifically in 
the neutropenic range, and using Leeds Teaching Hospitals NHS Trust standard of care 
analyser as reference (Siemens ADVIA 2120).  It includes an analysis of paired capillary 
versus venous neutrophil results, and provided the first opportunity to assess patients 
doing the self-test procedure.   
5.2 Objectives 
5.2.1 Primary objectives 
1. Evaluate capillary neutrophil counts measured by the Hemocue WBC DIFF in 
comparison to venous neutrophil counts measured by the Siemens ADVIA 
2120, where venous neutrophil counts are <2.0 x109/L.   
2. Identify the minimum capillary Hemocue WBC DIFF neutrophil count which 
indicates with 95% confidence that the venous ADVIA 2120 neutrophil count is 
≥1.0 x109/L. 
3. Identify the maximum capillary Hemocue WBC DIFF neutrophil count which 
indicates with 95% confidence that the venous ADVIA 2120 neutrophil count is 
<1.5 x109/L. 
5.2.2 Secondary objectives 
1. Assess the ability of trained patients to collect the self-test capillary sample for 
measurement on the Hemocue WBC DIFF.   
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2. Evaluate capillary neutrophil counts measured by the Hemocue WBC DIFF from 
patient self-test samples. 
3. Evaluate capillary neutrophil counts measured by the Hemocue WBC DIFF in 
comparison to venous neutrophil counts measured by the Hemocue WBC DIFF, 
where venous neutrophil counts are <2.0 x109/L. 
4. Obtain feedback to define training needs for future patients. 
5.3 Materials and Methods 
Approval was obtained from the Leeds Teaching Hospitals NHS Trust Research and 
Development department and clinical director of non-surgical oncology to carry out this 
study of device performance.  Samples and data were collected at two locations within 
Leeds Teaching Hospitals NHS Trust, each with different selection criteria and methods.  
These are described for each under Section 5.3.2 (“Neutropenic range evaluation”) and 
Section 5.3.3 (“Patient self-test evaluation”).    Methods of neutrophil count measurement 
and statistical analysis were common to both evaluations.  This evaluation was reported 
according to the principles of the Standards for Reporting Diagnostic Accuracy (STARD) 
Statement (180).   
5.3.1 Methods of neutrophil count measurement 
At Leeds Teaching Hospitals NHS Trust, the Siemens ADVIA 2120 automated blood count 
analyser is used to measure neutrophil counts from venous samples in 
ethylenediaminetetraacetic acid (EDTA) tubes.  This was used as the reference neutrophil 
count in evaluating the performance of the Hemocue WBC DIFF neutrophil counts.   
EDTA is used as it inhibits clotting by chelating calcium, removing it from the blood.  The 
ADVIA 2120 measures six white cell differentials through cytochemical staining and 
forward focused laser light scatter and gives the result to two decimal places.  The 
manufacturer only publishes accuracy and precision figures for the differential white cell 
counts within normal ranges; independently published validation of the ADVIA 2120 also 
does not analyse performance specifically in neutropenic ranges (86).  However, the Leeds 
Teaching Hospitals ADVIA 2120 analysers are subject to standard internal and external 
quality control procedures at defined intervals throughout the day, including testing and 
reporting of measurements on UK National External Quality Assessment Service (NEQAS) 
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reference samples, which include neutropenic specimens.  The analysers are used in 
routine clinical practice to make clinical management decisions on neutropenic patients.   
The Haemocue WBC DIFF uses imaging analysis techniques referring to a validated 
photographic library to count and differentiate white cells, primarily in capillary blood; the 
result is given to one decimal place.  The Hemocue WBC DIFF is intended for use on 
capillary blood samples.  Performance data is already described in Table 25, and Table 26.  
The Hemocue WBC DIFF was used in accordance with the Leeds Teaching Hospitals NHS 
Trust point of care testing policy. A daily internal Quality Control test was performed and it 
was cleaned in accordance with the Leeds Teaching Hospitals NHS Trust decontamination 
of medical devices policy. All members of the research team using the device were trained 
and deemed competent to carry out the procedure.   
5.3.2 Neutropenic range evaluation 
5.3.2.1 Study population 
Patients were approached in the oncology in-patient wards of Leeds Cancer Centre 
between November 2016 and April 2017.  The inclusion criteria were; (i) diagnosis of a 
solid tumour, (ii) at least 18 years old, (iii) required a full blood count test for routine care 
purposes, (iv) anticipated to have a neutrophil count of <2.0 x109/L, and (v) present when 
the trial nurse was available to perform the finger-prick test.  Exclusion criteria were; (i) 
history of haematological malignancy, (ii) on warfarin and the most recent INR >3, (iii) 
known inherited or acquired bleeding disorder, (iv) known red blood cell abnormality e.g. 
sickle cell disease, (v) considered by the clinical ward team that inclusion is inappropriate 
given their acute clinical state.   Informed written consent was obtained.  The target 
recruitment of 100 sets of neutrophil results was pragmatically chosen based on expected 
prevalence of patients with neutrophil count <2.0 x109/L, and availability of the research 
nurse; recruitment ended after 85 sets of results had been collected due to limited nurse 
availability.   
5.3.2.2 Blood sampling 
All patients had a routine full blood count obtained by venepuncture, which was processed 
and analysed by a Siemens ADVIA 2120 in the standard way.  All patients also had a 
capillary finger-prick sample attempted and measured on the Hemocue WBC DIFF, as soon 
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as possible after the venepuncture, for comparison with the venous ADVIA 2120.  Blood 
droplet formation was promoted by warming the hand under warm water, and gentle 
finger massage.  The first two droplets were discarded, and the third used for 
measurement.  A  blood droplet was also taken from the standard full blood count vial 
using a Diff-safe dispenser and analysed on the Hemocue WBC DIFF device for comparison 
of venous neutrophil counts measured by both analysers, but also to compare capillary 
versus venous neutrophil counts both measured by the Hemocue WBC DIFF.  In addition, 
patients had a second EDTA tube of blood collected to measure precision of the Hemocue 
WBC DIFF in venous blood samples.  Three microcuvettes were filled from one blood 
droplet, so one droplet was used to measure neutrophil counts in 3 different devices to 
enable calculation of between-device variation.  Three different blood droplets from the 
same EDTA blood tube were also used to measure neutrophil counts by the same 
Hemocue WBC DIFF device to enable calculation of within-device variation.   
Blood samples were obtained from the same patients on consecutive days using the 
methods detailed above, if they were expected to continue to have a neutrophil count <2.0 
x109/L.  Nurses were blind to the standard of care venous ADVIA 2120 neutrophil 
measurements at the time of performing the finger-prick test and measurement on the 
Hemocue WBC DIFF. 
5.3.3 Patient self-test evaluation 
5.3.3.1 Study population 
Patients were approached in the oncology outpatient departments of Leeds Cancer Centre 
between November 2016 until April 2017.  The inclusion criteria were; (i) diagnosis of a 
solid tumour diagnosis, (ii) were at least 18 years old, (iii) required a full blood count test 
on the same visit, and (iv) were present in the outpatient departments at the times the 
trial nurses were available.  Exclusion criteria were; (i) unable to give informed consent, (ii) 
concurrent haematological malignancy, (iii) on warfarin and the most recent INR >3, (iv) 
known inherited or acquired bleeding disorder, (v) known red blood cell abnormality e.g. 
sickle cell disease or β-thalassaemia major.  Informed written consent was obtained.  A 
target recruitment of 100 sets of neutrophil results was pragmatically chosen based on 
expected research nurse availability, but recruitment ended after 50 sets of neutrophil 
results had been collected due to limited availability of research nurses.   
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5.3.3.2 Blood sampling 
All patients had a routine venous full blood count and trial finger-prick sample obtained 
and measured as described in 5.3.2.2., excluding the second EDTA tube of blood.  In 
addition, following training and observation of the finger-prick done by the nurse, patients 
attempted to obtain their own finger-prick sample using the blood-letting lancet and 
microcuvette to collect the blood droplet as described.  The nurse used this microcuvette 
to obtain the neutrophil count from the Hemocue WBC DIFF device.   
No patient in this part of the performance evaluation provided more than 1 set of 
neutrophil count results.  The venous ADVIA 2120 analyser neutrophil count result was 
obtained from the trust results server.    
5.3.4 Statistical analysis 
Descriptive analyses were performed using Microsoft Excel 2010 and statistical analyses 
using StataSE 13 (64-bit) (188, 189).  Statistical significance was assumed at p < 0.05.  The 
accuracy of using the Hemocue WBC DIFF on both capillary and venous blood samples in 
predicting the venous ADVIA 2120 neutrophil count was determined using Pearson’s 
correlation co-efficient (r), the co-efficient of determination (r2), linear regression and 
agreement analysis as described by Bland and Altman (187).  Scatter plots were used to 
represent the correlation graphically.  Bland-Altman plots were performed to visualise the 
agreement between the two methods.   
To test the accuracy of the Hemocue WBC DIFF in identifying patients with ADVIA 2120 
neutrophil counts of either <1.0 x109/L (those at risk of febrile neutropenia) or >1.5 x109/L 
(those in whom there is sufficient neutrophil recovery to safely deliver further 
chemotherapy), ROC curves were generated.  A cut-off of  <1.0 x109/L was chosen to 
identify those at risk of febrile neutropenia as international guidelines for management of 
complicated neutropenia suggest neutrophils of ≤0.5 x109/L or in those patients where it is 
expected to fall to ≤0.5 x109/L within 24 hours should invoke a change of management.  A 
cut-off of >1.5 x109/L was chosen to identify those with sufficient neutrophil recovery to 
safely deliver chemotherapy as this is considered the safe threshold for most 
chemotherapy regimens given on a 3-weekly schedule.  Sensitivity, specificity, negative 
predictive value (NPV), positive predictive value, false negative rate (FNR) and false 
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positive rate (FPR) were calculated to answer the following two questions (Introduction 
section 1.3.1.1.1 describes these statistical terms); 
1. What is the minimum capillary Hemocue WBC DIFF neutrophil count we can be 
95% confident the venous ADVIA 2120 neutrophil count is ≥1.0 x109/L? 
2. What is the maximum capillary Hemocue WBC DIFF neutrophil count we can be 
95% confident the venous ADVIA 2120 neutrophil count is <1.5 x109/L?  
 
Precision was determined using the second venous EDTA blood sample collected 
immediately after the EDTA sample for routine care purposes.  The co-efficient of variation 
was calculated using the SD and mean of a set of 3 neutrophil measurements (CV 
=
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑚𝑒𝑎𝑛
 ).  Then the mean of the squared CVs for each set of 3 measurements 
was square rooted to give the mean CV for all the sets of 3 results.  
5.4 Results 
5.4.1 Neutropenic range evaluation 
5.4.1.1 Descriptive data 
One hundred and thirteen patients were screened for this study, of whom 52 signed the 
consent form and gave at least one blood sample over and above that required for routine 
care.  Table 29 shows the reasons why the remaining 61 patients were not entered into the 
study.  In total, 86 sets of samples were collected from the 52 patients; 29 patients 
participated once only, 16 patients participated twice, 4 patients participated 3 times, 2 
patients participated 4 times and 1 patient participated 5 times.  Of the 86 sets of samples; 
 85 had a routine venous laboratory reference neutrophil count available. 
 69 have both the routine venous neutrophil count and the capillary Hemocue 
WBC DIFF measured neutrophil count available. 
 54 have both the routine venous neutrophil count and the venous Hemocue WBC 
DIFF measured neutrophil count available (both from the same EDTA tube). 
 53 have both the venous and capillary Hemocue WBC DIFF measured neutrophil 
count available.  
These numbers are explained in the Consort diagram in Figure 19. 
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Reason patient was not enrolled Number of patients 
Declined as needle phobic 1 
Declined as feels unwell 2 
Declined as not interested in research 1 
Considered not appropriate by staff 4 
Language was a barrier to consent 2 
INR raised 1 
Routine blood sample already collected the same day 16 
Routine blood test not planned for the same day 31 
Patient discharged 3 
Total  61 
Table 29: Frequency table of reason patients who were screened did then not participate 
in the study.   
INR, international normalise ratio, which was one of the exclusion criteria. 
 
Room temperature was recorded when 67 of the 69 capillary samples were measured by 
the Hemocue WBC DIFF; it ranged from 21.9 to 23.7 o Celsius.  Only time of collection and 
not time of measurement was recorded for the routine venous laboratory sample.  The 
time difference between collection of the venous sample for laboratory measurement and 
collection of the capillary sample for Hemocue WBC DIFF measurement ranged from 1 to 
59 minutes (mean 8 minutes).  The time difference between collection and measurement 
by the Hemocue WBC DIFF of the capillary sample ranged from 0 to 48  minutes (mean 4.6 
minutes).  
Table 30 describes the neutrophil measurements according to whether it was a venous or 
capillary sample and according to the device used to measure the neutrophil count.  There 
were 15 Hemocue WBC DIFF measured capillary samples where the device indicated the 
total white cell count was <1.0 x109/L and therefore did not display the differential counts.   
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Figure 19: Consort diagram of study participants and sets of blood samples with paired 
neutrophil counts available for analysis.   
Neutropenic range refers to venous ADVIA 2120 neutrophil count <2.0 x109/L.  EDTA 
stands for ethylenediaminetetraacetic acid.   
 
This concords with the laboratory measured venous neutrophil counts in 10 corresponding 
samples that were also reported to have a total white cell count <1.0 x109/L.  Five of the 
corresponding laboratory total white cell counts were >1.0 x109/L.  They were 1.38, 1.20, 
1.16, 1.10, 1.55 x109/L, with differential neutrophil counts of 0.40, 0.27, 0.26, 0.23 and 
0.06.  Only one capillary Hemocue sample was indicated to be outside of the stated lower 
limit of detection of total white cell count (0.3 x109/L).    
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Device & sample 
used to measure 
neutrophils 
Venous ADVIA 2120 
Capillary Hemocue 
WBC DIFF 
Venous Hemocue 
WBC 
 Neutrophil count (x109/L) 
Range 0.06 - 10.70 0.2 - 5.8 0.1 - 4.1 
Mean 1.26 1.3 1.2 
 Sample frequency 
Neutrophils <2.0 
(x109/L) 
69 54 48 
Neutrophils <1.5 
(x109/L) 
63 44 37 
Neutrophils <1.0 
(x109/L) 
41 28 24 
Neutrophils <0.5 
(x109/L) 
23 9 8 
Total number of 
neutrophil results 
85 69 54 
Table 30: Characteristics of venous and capillary sample neutrophil measurements from 
the Siemens ADVIA 2120, and the Hemocue WBC DIFF.   
The neutrophil counts are reported to the number of decimal places reported by the 
measuring device; ADVIA 2120 to 2 decimal places and Hemocue WBC DIFF to 1 decimal 
place. 
 
There were 85 attempted capillary sample measurements on the Hemocue WBC DIFF.  Of 
these, there were 6 error messages (2 error code 02, 1 error code 05, 3 error code 60; 
Table 31 explains the error codes and recommended actions).  Error code 60 always 
appeared before insertion of the microcuvette and was resolved by cleaning the optical 
parts, resulting in delay of sample measurement only.  Where error code 02 was shown, 
the finger-prick was repeated and the second samples gave valid results.  In the one case 
where error code 05 was shown, it was not possible to repeat the finger-prick sample 
collection due to time constraints complicated by the fact the device also needed cleaning  
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Error 
code 
Explanation Action 
01 Part of the image area cannot be 
analysed. 
Potential causes may be: 
 Air bubbles in the sample 
 Incorrect handling of the sample 
 Abnormalities in sample 
1) Take a new microcuvette, repeat 
the measurement 
2)  If the problem persists, the sample 
should be verified with a suitable 
laboratory method 
02 Uneven spatial distribution of detected 
cells 
Take a new microcuvette, repeat the 
measurement. 
04 Acceptable light level cannot be 
achieved 
Take a new microcuvette, repeat the 
measurement. 
If the problem persists, the analyser 
needs service. 
05 Cuvette holder was not inserted in 
correct menu mode 
Remove the microcuvette. Take a new 
microcuvette, repeat the measurement. 
NOTE: Make sure the “insert cuvette” 
symbol is displayed before inserting a 
new microcuvette 
60 General hardware error Try one or more of the following: 
1a) clean the optical parts 
1b) If an error code appears when 
connecting a USB device, remove the 
device and re-start the analyser 
1c) wait 30 seconds and re-start the 
analyser 
2)  If the problem persists, the analyser 
needs service. 
Table 31: Table explaining the Hemocue WBC DIFF error codes which occurred during the 
analysis, and suggested actions to resolve them.  
Reproduced from the Hemocue WBC DIFF operating manual. 
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prior to the second sample measurement.  There were 71 attempted venous Haemocue 
WBC DIFF measurements of the sample obtained from the same EDTA tube as sent to the 
laboratory.  Of these, 7 gave an error code 01 and could not be repeated as the EDTA tube 
had been sent to the laboratory.   
For the precision analysis, the full set of 9 neutrophil results were obtained 46 times out of 
75 attempts.  Within this, 152 sets of valid neutrophil results were obtained where a single 
blood droplet was measured successfully in 3 different devices.  There were also 148 sets 
of valid neutrophil results where 3 droplets of blood from the same EDTA tube were 
measured on the same device.  There was a high frequency of error messages when 
collecting these data for the precision analysis.  There were 158 code 01 and 4 code 02, 
meaning many measurements had to be repeated to obtain valid results.   
No adverse effects of obtaining the capillary sample were reported, but 2 different 
patients commented; “it didn’t hurt” and “I would prefer to have a finger-prick rather than 
blood taken out of my arm”. 
  
5.4.1.2 Venous ADVIA 2120 reference analyser versus venous Hemocue WBC 
DIFF neutrophil counts 
Accuracy of the Hemocue WBC DIFF measured venous samples was analysed in 
comparison to the ADVIA 2120 measured venous sample from the same EDTA tube. There 
were 54 paired neutrophil counts in total, of which, 43 were in the neutropenic range (i.e. 
neutrophils <2.0 on the ADVIA 2120).  The scatter plot and correlation of these is shown in 
Figure 20.  The agreement analysis is shown as a Bland-Altman plot in Figure 21. 
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Figure 20:  Scatter plot showing the relationship of venous ADVIA 2120 and venous 
Hemocue WBC DIFF neutrophil counts in the neutropenic range.  
Solid black line is x=y, dashed black line is line of best fit.  RMSE, root mean square error.  
Seven of the dots represent more than one pair of results.     
 
 
5.4.1.3 Venous Hemocue WBC DIFF versus capillary Hemocue WBC DIFF 
neutrophil counts 
Accuracy of the Hemocue WBC DIFF measured capillary samples was analysed in 
comparison to the Hemocue WBC DIFF measured venous samples. There were 53 paired 
neutrophil counts in total.  The correlation of these results gave an r value of 0.847 (p value 
<0.001), R2 was 0.717 (p value <0.001), the root mean squared error (RMSE) was 0.390, 
and the line of best fit was y = 0.85𝑥 + 0.15.  This full range data is not represented on a 
scatter graph.  
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Figure 21:  Agreement analysis between venous ADVIA 2120 and venous Hemocue WBC 
DIFF neutrophil counts in the neutropenic range.   
This is a  Bland-Altman plot of the mean neutrophil count against the difference between 
the counts from the two analysers.  SD, standard deviation and is 0.37.  The solid black line 
represents the mean difference and is 0.178.  The black dashed lines labelled “1.96 x SD” 
represent the upper and lower limits of agreement which are the 95% CIs.  The upper 
dashed line is 0.89 and the lower dashed line is -0.54.   
 
There were 42 paired neutrophil counts in the neutropenic range (neutrophils <2.0 on the 
ADVIA 2120) from venous Hemocue WBC DIFF and capillary Hemocue WBC DIFF samples.  
The scatter plot and correlation of these in shown in Figure 22.  The agreement analysis is 
shown as a Bland-Altman plot in Figure 23. 
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Figure 22: Scatter plot showing the relationship of venous Hemocue WBC DIFF and 
capillary Hemocue WBC DIFF neutrophil counts in the neutropenic range.   
Solid black line is x=y, dashed black line is line of best fit.  RMSE, root mean square error.   
There are 33 observations as 9 observations represent more than one pair of results.      
 
5.4.1.4 Venous ADVIA 2120 reference analyser versus capillary Hemocue WBC 
DIFF neutrophil counts 
5.4.1.4.1 Accuracy 
There were 69 paired neutrophil counts in total from venous ADVIA 2120 and capillary 
Hemocue WBC DIFF samples.  Of these, 53 paired neutrophil counts were in the 
neutropenic range (neutrophils <2.0 on the ADVIA 2120) from venous ADVIA 2120 and 
capillary Hemocue WBC DIFF samples.  The scatter plot and correlation of the neutropenic 
paired samples are shown in Figure 24.  The agreement analysis is shown as a Bland-
Altman plot in Figure 25. 
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 b) 
Neutrophil counts x109/L 
Venous Hemocue WBC DIFF Capillary Hemocue WBC DIFF 
1.7 2.5 
1.7 0.9 
Figure 23: Agreement analysis between venous Hemocue and capillary Hemocue WBC 
DIFF neutrophil counts in the neutropenic range.   
a) Bland-Altman plot of the mean neutrophil count against the difference between the 
counts from the two analysers.  SD, standard deviation and is 0.29.  The solid black line 
represents the mean difference and is -0.03.  The black dashed lines labelled “1.96 x SD” 
represent the upper and lower limits of agreement which are the 95% CIs.  The upper 
dashed line is 0.53 and the lower dashed line is -0.59.  b) Table displaying the neutrophil 
counts of the two results lying out with the limits of agreement. 
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Figure 24: Scatter plot showing the relationship of venous ADVIA 2120 and capillary 
Hemocue WBC DIFF neutrophil counts in the neutropenic range.   
Solid black line is x=y, dashed black line is line of best fit.  RMSE, root mean square error.  
Fourteen dots represent more than one pair of results.   
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b) 
Neutrophil counts x109/L 
Venous ADVIA 2120 Capillary Hemocue WBC DIFF 
1.2 0.6 
1.3 0.7 
1.7 2.5 
1.8 2.5 
Figure 25: Agreement analysis between venous ADVIA and capillary Hemocue WBC DIFF 
neutrophil counts in the neutropenic range.   
a) Bland-Altman plot of the mean neutrophil count against the difference between the 
counts from the two analysers.  SD, standard deviation and is 0.26.  The solid black line 
represents the mean difference and is 0.03. The black dashed lines labelled “1.96 x SD” 
represent the upper and lower limits of agreement which are the 95% CIs.   The upper 
dashed line is 0.54 and the lower dashed line is -0.48.     b) Table displaying the neutrophil 
counts of the four results lying out with the limits of agreement. 
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5.4.1.4.2 Performance around thresholds in oncological practice 
What is the minimum capillary Hemocue WBC DIFF neutrophil count we can be 95% 
confident the venous ADVIA 2120 neutrophil count is ≥1.0 x109/L? 
The AUC of the ROC analysis for the capillary Hemocue WBC DIFF neutrophil count 
indicating a venous ADVIA 2120 neutrophil count of <1.0 x109/L demonstrated a high 
accuracy (AUC  0.956).  This is shown in Figure 26.   The capillary Hemocue WBC DIFF 
neutrophil count of <1.1 x109/L is the lowest threshold with no false negatives, and the 
sensitivity is 100% and specificity is 73.3%.  Table 32 displays the performance analysis of 
Hemocue WBC DIFF neutrophil count thresholds as surrogates for a venous ADVIA 2120 
neutrophil threshold of <1.0 x109/L.  Using the capillary Hemocue WBC DIFF neutrophil 
threshold of <1.0 x109/L as an example,  22 patients were correctly categorised as 
neutropenic (true positive), 6 were incorrectly categorised as neutropenic (false positive), 
2 were incorrectly categorised as not neutropenic (false negative) , and 39 were correctly 
categorised as not neutropenic (true negative).  The statistical terms were calculated as 
described in Table 4, section 1.3.1.1.1.    
Maximising the product of sensitivity and specificity indicated that the WBC DIFF 
neutrophil threshold of <1.0 x109/L performed the best.  However, this did not take into 
consideration clinical acceptability, or otherwise, of the false negative rate using this 
threshold.  Using the threshold of <1.1 x109/L, there were no false negatives, which is 
reflected in the false negative rate of 0%, and sensitivity and negative predictive values of 
100%.  Using this same threshold, only 33.3% of those asked to come to hospital for an 
acute assessment would have been found to have a neutrophil count ≥1.0 x109/L on the 
ADVIA 2120 (
𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒
(𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒+𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒)
 𝑥 100).  These patients would have been 
inconvenienced by a trip to hospital that would not have altered management.  This is 
17.4% of all the patient samples analysed who would have been incorrectly advised to 
come to hospital (
𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 
𝑛
𝑥 100). 
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Figure 26:  Receiver operator characteristic (ROC) curve evaluating the performance of 
capillary Hemocue WBC DIFF neutrophil count as a surrogate of venous ADVIA 2120 
neutrophil count threshold of <1.0 x109/L.   
The red observation represents the plot for capillary Hemocue WBC DIFF neutrophil count 
of <1.1 x109/L.  This is the lowest threshold with no false negatives, the sensitivity is 100% 
and specificity is 73.3%. 
 
 
What is the maximum capillary Hemocue WBC DIFF neutrophil count we can be 95% 
confident the venous ADVIA 2120 neutrophil count is <1.5 x109/L? 
The AUC of the ROC analysis for the capillary Hemocue WBC DIFF neutrophil count 
indicating a venous ADVIA 2120 neutrophil count of <1.5 x109/L also demonstrated a high 
accuracy (AUC  0.981).  This is shown in Figure 27.  Table 33 displays the performance 
analysis of Hemocue WBC DIFF neutrophil count thresholds as surrogates for a venous 
ADVIA 2120 neutrophil threshold of <1.5 x109/L.  Using the capillary Hemocue WBC DIFF 
neutrophil threshold of <1.0 x109/L as an example,  28 patients were correctly categorised 
as neutropenic (true positive), 0 were incorrectly categorised as neutropenic (false 
positive), 15 were incorrectly categorised as not neutropenic (false negative) , and 26 were 
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Capillary 
Hemocue WBC 
DIFF threshold 
(x109/L) 
Raw Data Performance Analysis 
True 
Positive 
False 
Positive 
False 
Negative 
True 
Negative 
Sensitivity 
% 
(95% CI) 
Specificity 
% 
(95% CI) 
NPV 
% 
(95% CI) 
PPV 
% 
(95% CI) 
FNR 
% 
FPR 
% 
Correctly 
classified 
% 
<1.0 22 6 2 39 
91.7 
(73.0-99.0) 
86.7 
(73.2-95.0) 
95.1 
(83.5-99.4) 
78.6 
(59.1-91.7) 
8.3 13.3 88.4 
<1.1 24 12 0 33 
100.0 
(85.8-100.0) 
73.3 
(58.1-85.4) 
100.0 
(89.4-100.0) 
66.7 
(49.0-81.4) 
0 26.7 82.6 
<1.2 24 16 0 29 
100.0 
(85.8-100.0) 
64.4 
(48.8-78.1) 
100.0 
(88.1-100.0) 
60.0 
(43.3-75.1) 
0 35.6 76.8 
<1.3 24 19 0 26 
100.0 
(85.8-100.0) 
57.8 
(42.2-72.3) 
100.0 
(86.8-100.0) 
55.8 
(39.9-70.9) 
0 42.2 72.5 
<1.4 24 20 0 25 
100.0 
(85.8-100.0) 
55.6 
(40.0-70.4) 
100.0 
(86.3-100.0) 
54.6 
(38.9-69.6) 
0 44.4 71.0 
<1.5 24 20 0 25 
100.0 
(85.8-100.0) 
55.6 
(40.0-70.4) 
100.0 
(86.3-100.0) 
54.6 
(38.9-69.6) 
0 44.4 71.0 
Table 32: Performance analysis of capillary Hemocue WBC DIFF neutrophil count thresholds as surrogate indicators of the venous ADVIA 2120 neutrophil 
count threshold of 1.0 x109/L.   
CI, confidence interval.  NPV, negative predictive value.  PPV, positive predictive value.  FNR, false negative rate.  FPR, false positive rate.  Prevalence of 
neutropenia (<1.0 x109/L) measured on the venous sample by the ADVIA 2120 was 34.8%. 
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Figure 27: Receiver operator characteristic (ROC) curve evaluating the performance of 
capillary Hemocue WBC DIFF neutrophil count as a surrogate of venous ADVIA 2120 
neutrophil count threshold of <1.5 x109/L.   
The red observation represents the plot for capillary Hemocue WBC DIFF neutrophil count 
of <1.1 x109/L.  This is the highest threshold with no false positives, the specificity is 100% 
and sensitivity 83.7%. 
 
correctly categorised as not neutropenic (true negative).  The statistical terms were 
calculated as described in Table 4, section 1.3.1.1.1.      
 
Maximising the product of sensitivity and specificity indicated that the WBC DIFF 
neutrophil thresholds of <1.3 and <1.4 x109/L performed the best.  However, taking into 
consideration clinical acceptability of the threshold, <1.1 x109/L was the safest performing 
Hemocue WBC DIFF neutrophil count threshold indicating the venous ADVIA 2120 
neutrophil count is <1.5 x109/L.  Using the Hemocue WBC DIFF neutrophil threshold of <1.1 
x109/L, there were no false positives, which was reflected in both the positive predictive 
value and specificity of 100%.  Sensitivity was 83.7%, indicating the proportion of those 
who were neutropenic and were correctly identified by the test.  However, 21.2% of 
patients who would have been advised their neutrophil count had recovered sufficiently to  
0.00 
0.25 
0.50 
0.75 
1.00 
S
e
n
s
it
iv
it
y
 
0.00 0.25 0.50 0.75 1.00 
1 - Specificity 
Area under ROC curve = 0.981 
 
 
 
 
1
3
3
 
 
 
Capillary 
Hemocue WBC 
DIFF threshold 
(x109/L) 
Raw Data Performance Analysis 
True 
Positive 
False 
Positive 
False 
Negative 
True 
Negative 
Sensitivity 
% 
(95% CI) 
Specificity 
% 
(95% CI) 
NPV 
% 
(95% CI) 
PPV 
% 
(95% CI) 
FNR 
% 
FPR 
% 
Correctly 
classified 
% 
<1.0 28 0 15 26 
65.1 
(49.1-79.0) 
100.0 
(86.8-100.0) 
63.4 
(46.9-77.9) 
100.0 
(87.7-100.0) 
34.9 0 78.3 
<1.1 36 0 7 26 
83.7 
(69.3-93.2) 
100.0 
(86.8-100.0) 
78.8 
(61.1-91.0) 
100.0 
(90.3-100.0) 
16.3 0 89.9 
<1.2 39 1 4 25 
90.7 
(77.9-97.4) 
90.7 
(77.9-97.4) 
86.2 
(68.3-96.1) 
97.5 
(86.8-99.9) 
9.3 3.8 92.8 
<1.3 40 3 3 23 
93.0 
(80.9-98.5) 
93.0 
(80.9-98.5) 
88.5 
(69.9-97.6) 
93.0 
(80.9-98.5) 
7.0 11.5 91.3 
<1.4 40 4 3 22 
93.0 
(80.9-98.5) 
93.0 
(80.9-98.5) 
88.0 
(68.8-97.5) 
90.9 
(78.3-97.5) 
7.0 15.4 89.9 
<1.5 40 4 3 22 
93.0 
(80.9-98.5) 
84.6 
(65.1-95.6) 
88.0 
(68.8-97.5) 
90.9 
(78.3-97.5) 
7.0 15.4 89.9 
<1.6 42 7 1 19 
97.7 
(87.7-99.9) 
73.1 
(52.2-88.4) 
95.0 
(75.1-99.9) 
85.7 
(72.8-94.1) 
2.3 26.9 88.4 
         Table 33: Performance analysis of capillary Hemocue WBC DIFF neutrophil count thresholds as surrogate indicators of the venous ADVIA 2120    
         neutrophil count threshold of 1.5 x109/L.   
         CI, confidence interval.  Prevalence of neutropenia (<1.5 x109/L) measured on the venous sample by the ADVIA 2120 was 62.3%. 
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deliver chemotherapy safely using the capillary Hemocue WBC DIFF sample, would have 
been found to be neutropenic on the ADVIA 2120 blood count, as reflected by 1-negative 
predictive value.    This was 10.1% of all the patient samples analysed where the patient 
would have been incorrectly advised to come to hospital for chemotherapy delivery 
(
𝑓𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒
𝑛
). 
5.4.1.5 Precision 
Both within-device and between-device variation was calculated using neutrophil results 
measured by the Hemocue WBC DIFF from the second EDTA tube sample collected 
immediately after that used for routine care purposes.  Table 34 displays the calculated 
within-device and between-device co-efficient of variations.  The mean within-device co-
efficient of variation was 13.1%, and the mean between-device co-efficient of variation 
was 13.0%.   
Within-device variation 
Device 
Number with all 3 sample neutrophil 
measurements available (n) 
Co-efficient of variation            
(%) 
1 52 12.4 
2 47 14.7 
3 49 21.1 
Between-device variation 
Sample 
Number with all 3 device neutrophil 
measurements available (n) 
Co-efficient of variation    
(%) 
1 48 13.1 
2 52 16.2 
3 52 9.6 
Table 34: Table showing within and between Hemocue WBC DIFF device co-efficient of 
variations (CV).   
All samples within one set of results were obtained from the same venous EDTA tube and 
measured on the Hemocue WBC DIFF device.  The results were limited to sets of data 
where all 3 neutrophil results were available; either 3 blood droplets from the same EDTA 
tube each measured on the same device (within-device variation), or 1 blood droplet 
measured on each of 3 devices (between-device variation). 
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5.4.2 Patient self-test evaluation 
5.4.2.1 Descriptive data 
Sixty-seven patients were approached to enter this study; of these, 51 patients consented 
to participate.   Of the 16 who declined, only 1 gave the reason that they did not want to 
finger-prick themselves.  In total, 50 patients provided at least one capillary blood sample 
for analysis on the Hemocue WBC DIFF; the remaining patient left the clinic before 
providing a sample.  Each patient participated once only.  Thirty-seven of these patients 
were receiving chemotherapy.  Of the 50 sets of samples available; 
 45 had a venous ADVIA 2120 neutrophil count available. 
 50 had a capillary nurse-obtained Hemocue WBC DIFF neutrophil count available. 
 41 had a capillary patient-obtained Hemocue WBC DIFF neutrophil count 
available. 
 38 had neutrophil counts available for all 3 samples; the venous ADVIA 2120 
sample, the capillary nurse and the capillary patient-obtained samples. 
The Consort diagram in  Figure 28 explains the number of paired neutrophil count results 
available for the analysis. 
Nine patients did not have a self-obtained capillary sample neutrophil count available.  Of 
these, 3 declined , each with a different one of the following explanations; 
 Patient not confident enough to do the finger-prick. 
 Happy for the professional test, but not the self-test. 
 The nurse test hurt more than expected and therefore declined self-test. 
One of the 9 patients was unable to fill the microcuvette due to a tremor, despite 3 
attempts.  The error codes displayed on the Hemocue WBC DIFF for 5 of the 9 patients 
without a self-obtained capillary sample neutrophil count were; 
 Error 1(n=1):  The sample was noted to be a small blood droplet and there was a 
visible air bubble in the microcuvette. 
 Error 4(n=2):  One of these had a visible air bubble in the microcuvette and the 
sample was not repeated.  The other had a repeat sample and the same error code 
was displayed for a second time. 
 Error 60 (n=2):  Neither sample was repeated. 
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No error codes occurred when the nurse obtained and measured the capillary sample. 
Room temperature was recorded when 48 of the 50 nurse-obtained capillary samples were 
measured by the Hemocue WBC DIFF; it ranged from 21.1 to 23.4 o Celsius.  Only time of 
collection and not time of measurement was recorded for the routine venous laboratory 
sample.  The time differences between collection and measurement of all the samples is 
summarised in Table 35.  
Table 36 summarises the neutrophil results according to the sample and device used to 
measure the neutrophil count.  There were no Hemocue WBC DIFF measured capillary 
samples where the device did not display the differential counts due to the total white cell 
count being <1.0 x109/L.  This agrees with the venous ADVIA 2120 measured neutrophil 
counts where there were also no total white cell counts less than 1.0 x109/L.   
5.4.2.2 Accuracy 
Accuracy of both the nurse and patient-obtained capillary Hemocue WBC DIFF measured 
neutrophil counts were analysed in comparison to the paired venous ADVIA 2120 
measured neutrophil counts and to each other.  The correlations were all comparable 
(Table 37).  The scatter plot and correlation of capillary nurse versus patient-obtained 
Hemocue WBC DIFF neutrophil counts is shown in Figure 29.  The agreement analysis of 
the same is shown as a Bland-Altman plot in Figure 30. 
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Figure 28: Consort diagram of study participants and sets of blood samples with paired 
neutrophil counts available for analysis.   
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Parameters 
Mean time difference 
in minutes (range) 
Venous ADVIA 2120 sample collection & capillary nurse 
Hemocue WBC DIFF sample collection 
25 (2-78) 
Venous ADVIA 2120 sample collection & capillary patient-
obtained Hemocue WBC DIFF sample collection 
29 (2-78) 
Capillary nurse Hemocue WBC DIFF sample collection & capillary 
patient-obtained Hemocue WBC DIFF sample collection 
8 (0-36) 
Capillary nurse Hemocue WBC DIFF sample collection and 
measurement 
3 (0-11) 
Capillary patient-obtained Hemocue WBC DIFF sample collection 
& measurement 
4 (0-14) 
Table 35: Table summarising the time differences between collection and measurements 
of the 3 different samples. 
 
 
Device & sample 
used to measure 
neutrophils 
Venous ADVIA 2120 
(n=45) 
Capillary nurse 
obtained Hemocue 
WBC DIFF 
(n=50) 
Capillary patient 
obtained Hemocue 
WBC 
(n=41) 
 Neutrophil count (x109/L) 
Range 0.40 - 11.86 0.6 - 15.4 0.4 - 13.1 
Mean 3.79 3.68 3.59 
SD 2.25 2.46 2.37 
Table 36:  Table summarising the neutrophil results according to the sample and device 
used to measure the neutrophil count.   
The neutrophil counts are reported to the number of decimal places reported by the 
measuring device; ADVIA 2120 to 2 decimal places and Hemocue WBC DIFF to 1 decimal 
place. 
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Samples compared R R2 
Root mean 
square error 
Line of         
best fit 
Capillary patient Hemocue WBC DIFF vs 
venous ADVIA 2120 (n=38) 
0.953 0.908 0.756 Y=0.99𝑥 – 0.15 
Capillary nurse Hemocue WBC DIFF vs 
venous ADVIA 2120 (n=45) 
0.961 0.924 0.718 Y=1.10𝑥 – 0.43 
Capillary patient vs nurse Hemocue WBC  
DIFF (n=41) 
0.960 0.921 0.747 Y=1.06𝑥 – 0.12 
Table 37: Table showing correlation between the 3 blood sample neutrophil counts 
(nurse and patient finger-prick Hemocue samples and venous ADVIA 2120 samples). 
 
 
 
 
Figure 29:  Scatter plot showing the relationship of capillary nurse-obtained Hemocue 
WBC DIFF and capillary patient-obtained Hemocue WBC DIFF neutrophil counts.   
Solid black line is x=y, dashed black line is line of best fit.  RMSE, root mean square error.    
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a) 
 
b) 
Neutrophil counts x109/L 
Capillary nurse 
Hemocue WBC DIFF 
Capillary patient 
Hemocue WBC DIFF 
Venous ADVIA 2120 
3.7 5.3 3.62 
5.2 3.5 4.39 
3.9 5.6 4.51 
15.4 13.1 11.86 
 
Figure 30: Agreement analysis between capillary nurse-obtained and capillary patient-
obtained Hemocue WBC DIFF neutrophil counts.  
a) Bland-Altman plot of the mean neutrophil count against the difference between the 
counts from the two samples.  SD, standard deviation and is 0.75.  The solid black line 
represents the mean difference and is   0.11.  The black dashed lines labelled “1.96 x SD” 
represent the upper and lower limits of agreement which are the 95% CIs.  The upper 
dashed line is 1.59 and the lower dashed line is -1.36.  b) Table displaying the neutrophil 
counts of the four results lying out with the limits of agreement. 
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5.5 Discussion 
5.5.1 Main findings 
Capillary Hemocue WBC DIFF neutrophil counts perform to a clinically acceptable standard in 
the neutropenic range, which is essential if these are to be used as intended in oncological 
practice.  The device performs well when measuring capillary neutrophil counts in comparison 
to venous ADVIA 2120 neutrophil counts.  The linear regression in the neutropenic range is 
remarkably close to the line of equality, with the data fitting this line well for counts outside 
of the normal range.  The capillary Hemocue WBC DIFF neutrophil count performs 
satisfactorily to identify patients at risk of febrile neutropenia, with a count of <1.1 x109/L 
being the lowest threshold that indicates the venous ADVIA 2120 neutrophil count is <1.0 
x109/L with no false negatives.  Similarly, capillary Hemocue WBC DIFF neutrophil counts 
perform sufficiently well to be used to identify patients whose count has not recovered 
adequately for subsequent chemotherapy delivery.  A neutrophil count <1.1 x109/L is the 
highest threshold which indicates the venous ADVIA 2120 neutrophil count is <1.5 x109/L with 
no false positives.   
In the scenario where the device is to be used to exclude patients from being treated on the 
febrile neutropenia pathway, the clinical priority should be patient safety, i.e. ensuring the 
capillary Hemocue WBC DIFF does not identify patients as not neutropenic, when the paired 
venous ADVIA 2120 neutrophil count is <1.0 x109/L.  The most desirable statistical 
characteristics are maximal sensitivity and negative predictive value.  When these parameters 
are satisfied, it is preferable to maximise the positive predictive value to reduce wasted 
patient journeys to hospital, and to gain from use of point of care testing compared to current 
practice.  Taking all of the above into consideration, ≥1.1 x109/L is the best performing 
Hemocue WBC DIFF neutrophil count threshold indicating the venous ADVIA 2120 neutrophil 
count is ≥1.0 x109/L.  However, using the 95% confidence intervals, the sensitivity is 100% with 
a minimum of 85.8% certainty, and the negative predictive value is 100% with a minimum of 
89.4% certainty.  More data are required to reduce the confidence intervals.  When such a 
method of neutrophil determination is introduced into clinical practice, it may be necessary to 
use a higher threshold, until the confidence intervals can be narrowed.  This would be at the 
expense of positive predictive value, initially increasing the number of patients who are 
advised they need to be on the febrile neutropenic pathway, who are subsequently taken off 
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this when the venous ADVIA 2120 neutrophil count indicates otherwise after attendance at 
hospital.   
The potential gain in using the device before subsequent chemotherapy delivery is to identify 
patients whose neutrophil count has not recovered sufficiently, to prevent a wasted journey 
to hospital.  In patients deemed by the device to have sufficient neutrophil recovery, a repeat 
venous ADVIA 2120 neutrophil measurement will still be done on attendance to confirm 
platelet recovery.  This should prevent the scenario where the device incorrectly identifies 
sufficient neutrophil recovery leading to inappropriately delivered chemotherapy.  This means 
the worst case scenario when using home blood count monitoring prior to attendance at 
hospital for delivery of chemotherapy would be that the patient is incorrectly identified as 
having insufficient neutrophil recovery, and so does not attend, leading to them potentially 
receiving suboptimal dose density of chemotherapy.  This could adversely affect survival in 
the neo/adjuvant setting, but is unlikely to be relevant in patients in the palliative setting (59, 
216-218).  Any such “risk” could be mitigated by repeating home testing on subsequent days.  
The most desirable statistical characteristic in the scenario of use of home blood counts 
before subsequent chemotherapy is, therefore, maximal positive predictive value.  Once this 
is satisfied, the next most desirable statistical characteristic is maximal sensitivity, which 
corresponds to correctly identifying which patients have not sufficiently recovered their 
neutrophil counts.  Once this is satisfied, the next most desirable statistical characteristic is 
maximal negative predictive value, which corresponds to minimising the number of patients 
who are incorrectly identified as being safe to chemotherapy delivered by the Hemocue WBC 
DIFF who are subsequently proven otherwise by the ADVIA 2120 count.  Taking all of the 
above into consideration, <1.1 x109/L is the highest neutrophil count threshold which is 
clinically acceptable to indicate the venous ADVIA 2120 neutrophil count is <1.5 x109/L.  Again, 
more data would reduce the confidence intervals around this threshold.  
As expected, when measuring a parameter below the reference range, the correlation of the 
neutropenic data appears to be less good than the reported performance of capillary samples 
in the normal range (r=0.867 compared to 0.98 and 0.931 in published data (200, 201)).  This 
is a measure of how well the data points fit the regression line, but the regression line is 
surprisingly comparable to the published full range data (y= 0.95𝑥 + 0.01 compared to  
y= 0.88𝑥 + 0.33 and y= 0.95𝑥 + 0.2).  None of the four data points that fall outside of the 
limits of agreement in the Bland-Altman plot comparing capillary Hemocue WBC DIFF to 
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venous ADVIA 2120 neutrophil counts in Figure 25 would have resulted in inappropriate 
management of the patient.  In comparison to the XBC analyser performance, the Hemocue 
WBC DIFF performed better in the neutropenic range. As there is more data the performance 
around the thresholds can be stated with more certainty and the error margins can be tighter, 
thus maximising the benefit of such a point of care device.  Moreover, the precision analysis 
of intra- and inter-device variability produced co-efficients of variation of 13.1% and 13.0% 
respectively.  Again, this is higher than the co-efficient of variation quoted by the 
manufacturer, but it is clinically acceptable and is considered reasonable for neutropenic 
results by local pathology experts.  
The Hemocue WBC DIFF is capable of measuring venous neutrophil counts, as evidenced by 
the fact much of the published work predating this study has been done on venous samples.  
However, despite using a droplet of blood from the same EDTA tube as was sent to the 
laboratory for measurement by the ADVIA 2120, the slightly improved r value (0.894) 
compared to the r value for capillary samples (0.867) was offset by the less good linear 
regression of y= 0.86𝑥 + 0.2.  In addition, the error code incidence was far greater using the 
venous samples than the capillary, making measurement on the capillary samples a more 
attractive proposition.  The comparison of venous to capillary blood in the chapter appeared 
to show no consistent bias, and all but 2 of the agreement analysis data points fell within the 
95% limits of agreement.  One of these was outside the upper limit of agreement and the 
other was outside the lower limit of agreement (Figure 23).  Use of capillary samples, 
therefore, appears to be a feasible option within oncology practice.    
This work provided the first opportunity to explore the feasibility of patients performing the 
self-test finger-prick procedure and filling the Microcuvette correctly.  There is no published 
data on patient self-test use of the Hemocue WBC DIFF.  Only one  out of the 16 who declined 
to participate did so as they did not want to self-test.  Nine out of the 50 (18%) who did 
consent to self-test did not produce a result.  Only one of these 9 was unable to fill the 
Microcuvette.  The training of patients in this study was limited to observation of a nurse-
obtained finger-prick sample, and verbal teaching.  This could be improved by, for example, 
video training.  With enhanced training and careful patient selection, there is potential for the 
Hemocue WBC DIFF to be converted to a patient self-test device.   
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5.5.2 Strengths and weaknesses 
The major strength of this work is that the main analysis has been carried out on neutropenic 
blood samples from the patient population in whom it is intended to be used.  This has not 
been done before with the Hemocue WBC DIFF on such a large number of samples to such 
level of detail, and informs the feasibility of using it in oncological practice.  It has enabled 
scrutiny of the performance of the device in both direct comparison of neutrophil counts, but 
also performance around thresholds used in oncological practice to change patient 
management.  Involvement of laboratory haematology experts early in the methods planning 
maximised the opportunity to gather detailed performance data such as intra- and inter-
device precision.  Although in haematological practice, the gold standard method of white cell 
count differential measurement is manual counting, it is common practice to use automated 
analysers in laboratories with high demand.   The ADVIA 2120 used in this analysis is an 
internationally recognised laboratory analyser, making the results applicable to both clinical 
practice in Leeds Teaching Hospitals NHS Trust, but also further afield.  
It should be remembered, however, that this analysis was not carried out under laboratory 
conditions as samples were collected from patients who were navigating the health-care 
system as part of their routine cancer care.  As a consequence, aspects of pre-analytic 
variability were different between measurements by each device, and there was more 
potential for variability with the venous ADVIA 2120 measurements; for example, the venous 
samples were transported to the laboratory for measurement via either the internal pod 
system or manual porter transfer, and the time of venous sample collection was recorded, but 
not sample measurement.  
Neither this study nor standard practice as part of routine clinical care take into consideration 
biological variability of neutrophil counts.  Biological variability is described as “fluctuation of 
the concentration of constituents around their homeostatic set-point” (219).  Neutrophil 
count within-subject variation and between-subject variation is reported to be 17.1% and 
32.8% respectively by a database of biological variability data, which is updated every two 
years using literature searches of newly published articles (220-222).  For example, a study of 
7685 men showed a steady increase in mean value of white cell count up to around 4-5pm, 
followed by a reduction in late afternoon (223).  Some white cell count diurnal variation can 
be attributed to neutrophils moving from the marginated to circulating pool of neutrophils, 
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which they do in minutes in scenarios such as sepsis, high dose steroid use and immediately 
after vigorous exercise (9, 223).  
The potential benefits of using a point of care device in oncological practice would be 
harnessed by using a device suitable for patient self-test use with capability to transfer the 
results electronically to the hospital.  This performance analysis incorporated an aspect of 
patient self-testing, but used samples which involved a professional in at least one aspect of 
the measurement.  As such, it demonstrated the ability to use a professionally operated 
Hemocue WBC DIFF in the pathway of patients on chemotherapy, but leaves further work 
required in the field of patient self-testing.  
5.5.3 Implications 
The primary objectives of this chapter were to obtain data on the performance of capillary 
Hemocue WBC DIFF neutrophil counts in comparison to venous ADVIA 2120 neutrophil counts 
in the neutropenic range, including performance around thresholds important in suspected 
febrile neutropenia and that indicate safe delivery of subsequent chemotherapy.  This data 
could not be obtained through published trials, but was achieved in this study.  The Hemocue 
WBC DIFF performed sufficiently well in the hands of professionals when neutrophil counts 
were less than 2.0 x109/L, to justify use of the device and further work investigating the 
potential role of point of care blood count monitoring in oncological practice.  The inability to 
measure platelets on the Hemocue WBC DIFF necessitated consideration of the risk of 
isolated thrombocytopenia in solid tumour patients in whom such a device is intended to be 
used; this was addressed in Chapter 4.    
Further work needs to address how and where in the pathway of patients on chemotherapy 
the benefits of both a professionally-operated and a patient self-test device can be 
maximised.  The limited analysis of patient self-testing to obtain the capillary sample in this 
work suggests there is potential for conversion of the existing device to a patient self-use 
device.  The Philips Minicare H-2000 device was “Conformité Européene” (CE) marked for 
patient self-test use and had connectivity such that the blood count measurements could be 
transferred via the 3G, 4G or GPRS network.  The pieces around patient self-test use and 
connectivity of the Hemocue WBC DIFF need to be solved in order to gain the benefits of 
preventing unnecessary patient journeys to hospital. 
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Regarding how it can be used, there is merit in a stepwise introduction into clinical practice, 
both for clinicians to gain confidence and to collect further performance data in order to 
narrow the confidence intervals around the thresholds, and hence be able to minimise the 
false positives in the case of suspected febrile neutropenia.  Based on this performance 
analysis, there are plans in motion to use capillary Hemocue WBC DIFF neutrophil counts on 
Leeds Teaching Hospitals NHS Trust acute oncology decision unit, as part of a febrile 
neutropenia risk stratification process.  The patient pathway will be changed depending on 
whether the patients are deemed low, medium or high risk of febrile neutropenia according 
to the device neutrophil count.   The intention to start with is to use this device to save the 
time, financial and opportunity cost burden, such as antibiotic resistance, brought about by 
unnecessary insertion of intravenous cannulas and administration of single doses of broad 
spectrum antibiotics in low and medium risk patients, whilst waiting for the venous ADVIA 
2120 neutrophil count, which commonly takes over two hours to obtain the result.   
In order to understand where in the patient pathway such a device could be used, the 
baseline patient pathways were mapped and quantified to define the starting point of the 
burden of neutropenic complications.  The process of doing this was described in Chapter 2, 
and provided the baseline model which can be used for health economic analysis of potential 
gains and true gains after introduction into clinical practice.  Moreover, the data in this 
chapter confirm the adequate performance of capillary Hemocue WBC DIFF samples, 
indicating suitability to be used to determine neutrophil profiles during chemotherapy.  
Chapter 6 describes the trial of this, using the Hemocue WBC DIFF to profile neutrophil counts 
during chemotherapy in order to explore the potential to build a predictive model for 
neutropenic complications based on neutrophil count changes early in a cycle of 
chemotherapy, and to determine the incidence of suboptimal chemotherapy dosing (through 
inadequate grade and duration of bone marrow suppression). 
5.5.4 Conclusion 
This analysis provides data on the performance of the Hemocue WBC DIFF when measuring 
neutrophiI counts that are specifically relevant to oncological practice and are not available 
through published trials.  It indicates that the device performs adequately to be of use in 
oncology when assessing patients for suspected febrile neutropenia and for sufficient 
neutrophil recovery to safely deliver subsequent chemotherapy.  It justifies the continued use 
of the Hemocue WBC DIFF as the point of care device used to profile neutrophil counts during 
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chemotherapy, as described in chapter six.  It remains to be seen if subsequent iterations of 
the Hemocue WBC DIFF have at least equivalent performance in the hands of patients and can 
address the connectivity aspect sufficiently.     
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Chapter 6 Profiling neutrophil counts during chemotherapy. 
6.1 Introduction 
The first uses of combination chemotherapy to achieve disease remission through 
administering maximal tolerable therapy started in the 1960s with vincristine, methotrexate, 
6-mercaptopurine and prednisolone (VAMP) in childhood leukaemias (224).  Chemotherapy 
then was all given as in-patient regimens, with dosage and intervals changing on a weekly 
basis, depending on the outcome of regular meetings of clinicians, biostatisticians and 
pharmacologists based on disease response and tolerance, particularly bone marrow toxicity 
monitored by daily early morning venous blood samples(225).  As the number of patients 
being treated with cytotoxic chemotherapy increased, there was a need to standardise best 
practice, which is usually now based largely on phase III clinical trials.   
There is a paucity of data on the white blood count profiles during chemotherapy regimens 
commonly given today to patients with solid tumours.  This is in part due to the inconvenience 
of obtaining blood samples when the majority of chemotherapy regimens are now outpatient-
based; also daily blood counts are not clinically indicated, with counts at or around day one of 
each cycle being sufficient.  More detailed knowledge on the profile of blood counts during 
chemotherapy regimens comes from early phase clinical trials in which counts are obtained at 
least weekly, but also pharmacological and clinical studies of GCSF (62, 68, 226).  These show 
that patients receiving GCSF preparations have an earlier and lower grade neutrophil nadir, of 
shorter duration with more rapid recovery.  In a placebo-controlled trial of 211 patients 
receiving cyclophosphamide, doxorubicin and etoposide for small cell lung cancer, the 
incidence of grade 4 neutropenia was 98% in the placebo group and 84% in the GCSF group 
(p<0.001), with the mean duration of grade 4 neutropenia being 6 and 3 days respectively 
(p<0.001) (62).   
There are also published physiological, mechanistic and pharmacodynamics model studies 
describing the time-course of neutropenia over several drugs, indicating that the profile of 
neutrophils during chemotherapy can be fitted to mathematical models (227-232).  Only one 
study produced a predictive model of neutrophil counts that incorporated variation due to 
individual patient characteristics, such as gender, previous anti-cancer therapy, performance 
status, and as such provided a potential basis for the rationale for chemotherapy dosing to be 
tailored to individual patients (227).  Friberg et al. described a model of chemotherapy-
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induced neutropenia that performed with individual drugs; but much chemotherapy is given 
in combination in clinical practice, and the time course of neutropenia for combinations of 
drugs have not been reported.  The data informing the Friberg et al. model was low volume 
for some drugs; for example, that for irinotecan used neutrophil counts from only 20 patients.  
Moreover, all this and other models were formulated for a specific dose of drug, and are 
unlikely to accurately reflect myelosuppression for variable drug doses.  In addition, the 
neutrophil counts informing the models were usually sparse in days 1 to 5 compared to days 7 
to 20, and as such will not have incorporated signals in changes in neutrophil counts in these 
days. 
In clinical practice dosing of chemotherapy is most often adjusted for body surface area, 
notwithstanding the paucity of data to support this practice (233).  Therapeutic drug 
monitoring has been advocated to achieve a “target” therapeutic drug exposure, but is only 
widely used in high dose drug regimens administered with stem cell transplantation, and to 
identify those at increased risk of toxicity due to slow elimination of high dose methotrexate.  
Toxicity is usually identified through symptom reporting, but potential under-dosing 
measured, for example by the lack of myelotoxicity, usually does not lead to dose increments, 
especially in patients with metastatic disease where treatment is almost always “palliative”.  
There are some exceptions, such as vinorelbine, but the recommended dose escalation in 
later cycles in the absence of toxicity has not been shown to improve outcome.  In the 
adjuvant setting, under-dosing of chemotherapy based on an inadequate neutrophil nadir 
may lead to as high as a 20% relative reduction in survival in node positive breast cancer 
patients receiving cyclophosphamide, doxorubicin and 5-fluorouracil, and an estimated 
reduced cure rate of greater than 10% in intermediate prognosis testicular cancer (59, 216-
218, 234).  For example, in the testicular cancer trial, patients who did not reach a nadir white 
cell count of <2.0 x109/L or platelet count <90 x109/L had a higher relapse rate (28% versus 
14% p=0.04).   
There is further evidence in the adjuvant breast cancer and palliative non-small cell lung 
cancer setting, indicating prognostic value in attaining a degree of neutropenia during 
chemotherapy (89-93).  This supports the rationale behind a randomised controlled trial in 
high risk breast cancer patients, where the dose of adjuvant fluorouracil, epirubicin and 
cyclophosphamide was tailored according to the haematological toxicity, and improved 
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relapse-free survival (32.3% breast cancer relapse in tailored chemotherapy group versus 
41.2% relapse in standard chemotherapy plus high dose chemotherapy group, p=0.04) (94).   
Tailoring of chemotherapy as discussed so far, refers largely to adjusting the dose based on 
neutrophil nadir to adjust the dose intensity, which is expressed as 
total dose
time
 .  Dose intensity 
can, therefore, be increased by either decreasing the dose interval or increasing the dose.  
There is convincing evidence in the adjuvant breast cancer setting that increasing optimal 
dose intensity by escalating the dose is associated with better disease-free and overall 
survival, as described above.  Achieving an increase dose intensity by reducing the dose 
interval, often referred to as “dose dense” chemotherapy, can also improve outcomes.  Citron 
et al. reported that dose dense combinations of doxorubicin, paclitaxel and cyclophosphamide 
administered with GCSF support (2-weekly compared to 3-weekly) improved disease-free 
survival with a hazard ratio of 0.74, p = 0.01 and overall survival hazard ratio of 0.69, p=0.013 
(120).  It has subsequently been hypothesized that increased frequency of administration of 
cytotoxic chemotherapy may be a more effective way of minimising residual tumour burden 
than dose escalation (235).  There is, therefore, scope in regimens used in routine practice to 
optimise the dose density on an individual basis, based on the neutrophil profile incorporating 
both depth and duration of nadir and timing of recovery to a suitable threshold for further 
chemotherapy.  
As discussed in Chapter 1, there is evidence to support the prophylactic use of either 
antibiotics or granulocyte colony stimulating factor in patients at high risk of neutropenic 
complications.  “High risk” is defined by population-based trial data, but with the caveat that 
international guidelines advocate taking into account known risk factors on an individual 
patient basis.  Studies could not be identified that aimed to define changes in white cell 
counts early during a chemotherapy cycle, which could be used to instigate a prophylactic 
intervention and abrogate neutropenic complications.  In addition, trials assessing efficacy of 
cytotoxic chemotherapy do not usually report patients assessed for suspected febrile 
neutropenia who were subsequently proven not to be neutropenic.  In an unpublished audit 
of all cases of suspected febrile neutropenia in adult patients with solid tumours at Leeds 
Cancer Centre, over a 3 month period from September to November 2017, the mean number 
of patients assessed acutely with suspected febrile neutropenia was 28 per month; the mean 
number of patients with neutrophil count <1.0 x109/L was 9, and the mean number of 
patients with neutrophil count <0.5 x109/L was 5.  Thus on average 19 patients per month 
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suspected of having febrile neutropenia were proven to have a neutrophil count > 1.0 x109/L 
(Young & Turner, 2017).  These data demonstrate the burden of febrile neutropenia for both 
patients and service providers. 
It is hypothesized that there are four time points during a cycle of chemotherapy where there 
is scope to explore the potential role of home neutrophil count monitoring in individualising 
patient care; 
1. After chemotherapy delivery to identify early changes in neutrophil counts that may 
be predictive of neutropenic complications. 
2. Any time during the cycle to exclude neutropenia in patients with suspected febrile 
neutropenia. 
3. At intervals of up to daily during the cycle to quantify neutrophil nadir.  
4. Prior to delivery of the subsequent chemotherapy cycle to identify patients with 
sufficient neutrophil recovery for continuation of chemotherapy.  
These scenarios are illustrated in Figure 31, which is a line graph demonstrating potential 
neutrophil profiles during chemotherapy, and illustrates where testing of home blood counts 
may be useful. 
The aim of the work described in this chapter was to perform an exploratory analysis of 
neutrophil profiles of patients receiving chemotherapy as part of routine clinical practice, to 
determine if there is scope to develop the role of home neutrophil count monitoring during 
chemotherapy.  A trial used daily home blood count monitoring to profile neutrophil counts 
during chemotherapy in adult patients with solid tumours with the intention of enrolling 
approximately 200 patients.  Recruitment was underway, with some patients having finished 
participation, when the partners providing the device (Hemocue) and the funding through the 
Small Business Research Initiative grant (Philips Home Clinical Monitoring) discontinued their 
commercial relationship, so the trial halted recruitment.  This chapter describes and discusses 
the neutrophil profiles obtained up until that point, which coincided with a planned early 
cohort analysis. 
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Figure 31: Line graph showing potential neutrophil count profiles during chemotherapy.   
This graph was drawn to demonstrate possible scenarios during chemotherapy, but was not 
informed by true neutrophil profiles.  The orange profile represents “under-dosing” with the 
nadir being insufficiently low and recovery in advance of the scheduled subsequent cycle on 
day 22.  The green profile represents “optimal” dosing with the nadir being less than 1.0 
x109/L, but not less than 0.5 x109/L and rapid recovery in-time for the subsequent cycle on day 
21 (and potentially the opportunity to treat early on day ≥19).  The red profile represents that 
of a patient who has been “overdosed” putting them at high risk of neutropenic 
complications, with a rapid descent to neutropenia less than 0.5 x109/L with no signs of 
recovery prior to subsequent cycle on day 22.  The numbers 1-4 refer to points in the cycle 
where it is hypothesized there may be a role for home neutrophil count monitoring.  
  
6.2 Objectives  
6.2.1 Primary 
1. Profile neutrophil counts for the duration of first cycles of chemotherapy. 
2. Determine the potential of home neutrophil count monitoring during chemotherapy. 
6.2.2 Secondary 
1. Confirm acceptability to patients of daily finger-prick capillary blood tests. 
2. Record the prevalence of grade ≥3 neutropenia and its complications for first cycles of 
different classes of chemotherapy regimen. 
3. Determine whether early changes in the neutrophil count soon after chemotherapy 
administration have the potential to predict severe neutropenia and its complications.   
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4. Explore the potential to optimise the dose of chemotherapy based on; 
a. the neutrophil nadir. 
b. the timing of neutrophil recovery above the threshold for retreatment. 
5. Explore the potential for re-scheduling the subsequent chemotherapy cycle prior to 
patient attendance at the hospital, based on insufficient neutrophil recovery. 
6.3 Methods 
This was a single-centre, single-arm trial using a professionally operated finger-prick blood 
count device, the Hemocue WBC DIFF, to obtain daily neutrophil counts for the duration of 
the first cycle of chemotherapy in adult patients with solid tumours.  Profiles from the first 
cohort of patients enrolled in this study are reported and discussed in this chapter.   This was 
to be an interim analysis of the larger trial, which aimed to recruit up to 250 patients. 
6.3.1 Patient population 
Patients were eligible if they had a confirmed diagnosis of a solid tumour, were ≥ 18 years old, 
and were commencing the first cycle within the first or subsequent course of single agent or 
combination cytotoxic chemotherapy.  Patients were enrolled between 1st April 2017 and 16th 
October 2017.  Patients receiving primary prophylactic antibiotics or GCSF were eligible.  
Exclusion criteria were; living outside the service provision boundaries of Local Care Direct , 
who provided nurses to perform the finger-prick measurements in patients’ homes, inability 
to give informed consent, concurrent haematological malignancy, known bleeding disorder, 
known sickle cell disease, known β-thalassaemia major, known poorly controlled anti-
coagulation (INR >3.5 within 6 months for those on warfarin).  The pathway modelling 
described in chapter 2, provided real-life prevalence of neutropenic complications at Leeds 
Cancer Centre.  This was used to identify chemotherapy regimens with differing incidences 
and prevalence of neutropenic fever, including those in which it might be possible to explore 
whether early changes in the neutrophil count following administration of chemotherapy 
have the potential to predict severe neutropenia and its complications.   
6.3.2 Approvals and Funding 
This trial was approved by the Yorkshire & the Humber Leeds West Research Ethics 
Committee (reference 16/YH/0457), by the Health Research Authority, by the University of 
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Leeds, by the NHS Research and Innovation department of Leeds Teaching Hospitals NHS 
Trust and Leeds Cancer Centre Clinical Trials Research Approvals Board (CTRAB).  It was 
registered on the public database clinicaltrials.gov and assigned the National Clinical Trial 
number NCT02806557.  The trial was funded through the Small Business Research Initiative 
grant awarded to Philips Healthcare who supported it through an unrestricted educational 
grant to the University of Leeds, provision of the devices and consumables, and supported the 
services of Local Care Direct. 
6.3.3 Procedures followed 
6.3.3.1 Clinical procedures 
All trial procedures were carried out in addition to standard care.  Data generated as part of 
the trial were not made available to the treating clinical team.  Trial activity directly involving 
patients at the hospital was performed during attendances for standard care. 
Eligible patients signed written, informed consent to participate, including for a nurse to visit 
their house daily to perform finger-prick blood tests.  The trial team notified the patient’s 
general practitioner and Local Care Direct (LCD) of the patient’s consent.   A LCD nurse 
attended the participant’s home, with the Hemocue WBC DIFF system device that was left in a 
secure locked bag at their house for the duration of participation.   
On each visit, the LCD nurse obtained and recorded continuing verbal consent, collected the 
sample and measured the count, performed a visual check of the finger-tips, recorded any 
feedback they received regarding the procedure and enquired about acute illness indicators.  
If the participant had any questions regarding symptoms or their treatment, the LCD nurse 
directed them to the routine advice sheets provided by their treating team and the 
chemotherapy alert card they were given as part of standard care.  Where these did not 
answer the concern, the participant was advised to ring the acute oncology advice number 
provided in the chemotherapy folder.     
 
With their consent, participants continued to have their blood count measured daily up to and 
including the day of delivery of the 2nd cycle of chemotherapy where possible.  This final 
measurement was performed using the Hemocue WBC DIFF either at the participant’s home 
or at the hospital, whichever was most convenient for the participant.  At one week and on 
completion of the test schedule, the trials team contacted the participant to record 
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acceptability of regular finger-prick tests, complications and to identify any unplanned 
participant contact with health-care professionals, and particularly initiation of any 
treatments which may have affected neutropenia or its complications such as granulocyte 
colony stimulating factor or antibiotics.  
 
If a participant was admitted to Leeds Teaching Hospitals, they had capillary finger-prick 
samples performed daily where possible by the trial nurse and measured on the Hemocue 
WBC DIFF.  On days where it was not possible to do a capillary finger-prick test, if venous 
blood was taken and analysed by the laboratory as part of routine care, this neutrophil count 
was recorded for trial purposes.   
If the device failed to measure a neutrophil count, due to procedural problems, insufficient 
filling of the microcuvette or technical failure, the participant was asked if they were willing to 
repeat the test once more.  Participants were not asked to repeat the test if it failed on the 2nd 
attempt.   
6.3.3.2 Blinding to neutrophil count results 
The LCD nurse and participant did not have access to the neutrophil result at the time of the 
test as the device stored it internally and on a USB stick, but it was not displayed.  If there was 
a problem measuring the blood count, the device displayed only an error message, indicating 
a repeat test was necessary.   
6.3.3.3 Quality assurance 
Every Hemocue WBC DIFF device was quality assurance checked by laboratory technicians in 
Leeds Teaching Hospitals NHS Trust Point of Care team, within 2 weeks prior to release for use 
on trial participants and within 2 weeks of return after completion of use during one cycle of 
chemotherapy.  All devices used in this trial performed at both quality assurance checks 
within 10% of the laboratory ADVIA 2120 neutrophil counts when this reference neutrophil 
count was ≥1.0 x109/L and within 0.1 x109/L neutrophils when the reference neutrophil count 
was <1.0 x109/L.  
 
In addition, the method of obtaining the finger-prick was standardised as per 
recommendations by the manufacturer and as defined in the performance analysis (chapter 
156 
 
 
 
4); wash participant hands with soap under warm running water, dry hands, clean finger-tip 
with an alcohol wipe and allow to dry freely, finger-prick side of chosen finger, minimise 
milking finger as allowed by blood flow, discard first blood droplet, collect second droplet in 
microcuvette for measurement.     
6.3.3.4 Definitions of neutropenic complications 
Common toxicities of chemotherapy include asymptomatic neutropenia, febrile neutropenia 
and neutropenic sepsis.  For the purposes of this trial, the “complications” of severe 
neutropenia referred to febrile neutropenia and neutropenic sepsis. 
6.3.3.4.1 Neutropenia 
Neutropenia was defined into grades 0 to 4 as per the Common Terminology Criteria for 
Adverse Events version 4.03 (CTCAE v4.03) in Table 24 (17).  For the purposes of this trial, 
severe neutropenia was considered to be grades 3 and 4.  
6.3.3.4.2 Febrile neutropenia 
Febrile neutropenia was defined as a venous laboratory neutrophil count <0.5 x109/L or 
expected by the senior clinician to fall to <0.5 x109/L within 48 hours AND one documented 
fever of >38.0oC (in-keeping with Leeds Teaching Hospitals NHS Trust and National Institute 
for Health and Care Excellence (NICE) guidelines (19)).    
6.3.3.4.3 Neutropenic sepsis 
Neutropenic sepsis was defined as a venous laboratory neutrophil count <0.5 x109/L AND 
documented or suspected infection in the presence of systemic manifestations of infection.  
Table 3 lists the parameters present in systemic infection-related clinical states, as endorsed 
by the International “Surviving Sepsis Campaign” (20, 21).  Some of the parameters listed 
would be present in patients with cancer on chemotherapy in the absence of sepsis, therefore 
this was interpreted with caution and each parameter considered in relation to an individual’s 
baseline.  The diagnosis of sepsis had to be confirmed by the trial physician. 
6.3.4 Data analyses   
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The neutrophil profiles obtained were from the first cohort of patients of the larger trial.  It 
was intended to enrol between 20 – 30 patients for this interim analysis, which was chosen 
pragmatically, as the prevalence of neutropenic complications was expected to be too small to 
apply statistical tests at this stage.  Moreover, the primary objectives were exploratory and, 
therefore, did not lend themselves to statistical tests.  Descriptive analyses were performed 
using Microsoft Excel 2010 and the neutrophil profiles were generated using StataSE 13 (64-
bit) (188, 189).   
6.4 Results 
6.4.1 Descriptive 
Forty-four patients were approached for this trial, of whom 22 entered and 21 completed 
participation.  Of the 22 who were not entered, 21 declined and 1 was ineligible.  The 1 
patient who entered but did not complete, left the trial on day 2 due to non-compliance with 
the daily visits for finger-prick testing, without specifically indicating the reason.  
Of the 21 patients for whom neutrophil profiles were generated, twelve were female and 9 
were male.  The mean age of participants was 48 years, with a range of 20 to 82 years, and a 
median age of 50 years.  Ten patients had a Eastern Co-operative Oncology Group 
performance status of 0 , 9 patients had a performance status of 1 and 2 patients had a 
performance status of 2 (236).  Eleven patients had co-morbidities, noted as present if 
recorded in medical records from patient consultations with the oncologist; 6 had just 1 co-
morbidity, 2 patients had 2 co-morbidities, 2 patients had 3 co-morbidities and 1 patient had 4 
co-morbidities.  Only 1 patient had received chemotherapy prior to the first cycle of this 
regimen and that patient had received 2 different regimens on separate occasions, one 35 
years previously and the other 24 years previously. 
Table 38 shows the chemotherapy regimens received by patients in whom neutrophil profiles 
were obtained.  Bleomycin / etoposide / cisplatin regimen (BEP) was the most commonly 
included regimen (n=7).  
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Table 38: Table of chemotherapy parameters and frequency of regimens for which the 
neutrophil profiles were obtained.   
AUC, area under the curve. D, day. 
 
 
Chemotherapy 
regimen 
Doses                                                
(cycle length in days) 
Frequency 
Neutrophil 
threshold for 
delivery cycle 2 
(x109/L) 
Bleomycin /                   
etoposide /                      
cisplatin                                 
(BEP) 
30,000 units D1, D8, D15 / 
165mg/m2 D1-D3 / 50mg/m2 D1-D3 
(21) 
3 >1.0 
30,000 units D1, D8, D15 / 
100mg/m2 D1-D5 / 20mg/m2 D1-D5 
(21) 
4 >1.0 
Carboplatin AUC 7 D1 (21) 1 >1.5 
Carboplatin /     
etoposide 
AUC 5 D1 / 120mg/m2 D1, 100mg/m2 
D2 & D3 (21) 
2 >1.5 
Paclitaxel / 
carboplatin  
AUC 5 D1 / 175mg/m2 D1 (21) 1 >1.2 
AUC 2 D1, D8, D15 / 70mg/m2 D1, 
D8, D15 (28) 
1 >1.0 
Carboplatin / 
pemetrexed 
AUC 5 D1 / 500mg/m2 D1 (21) 2 >1.5 
Doxorubicin 75mg/m2 D1 (21) 1 >1.5 
Epirubicin / 
cyclophopspha
mide    (EC) 
90 mg/m2 D1 / 600 mg/m2 D1 (21) 3 >1.5 
Gemcitabine / 
carboplatin 
1000mg/m2 D1 & D8/ AUC 4.2 D1 3 >1.5 
Total  21  
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Of the 21 neutrophil profiles obtained; 
 13 patients completed daily neutrophil counts on the Hemocue WBC DIFF for the 
duration of participation 
 5 patients missed one day of the profile only     
 1 patient missed one day of the profile and had 3 days where there was the 
laboratory ADVIA 2120 neutrophil count only due to an inpatient stay 
 2 patients had 3 or more days where there was the laboratory ADVIA 2120 neutrophil 
counts only due to inpatient stays 
None of the patients enrolled in this trial received prophylactic or therapeutic granulocyte 
colony stimulating factor during the cycle of chemotherapy.  Those who received intravenous 
antibiotics did so as part of admissions for febrile neutropenia and are described in section 
6.4.2.1 on febrile neutropenia.  One patient received oral co-amoxiclav antibiotics for a wound 
infection that did not require admission to hospital; their neutrophil profile never fell below 
0.5 x109/L.  The profile is shown later in Figure 36b.  None of the participants experienced 
prolonged bleeding or infections at the site of the finger pricks. 
6.4.2 The profiles 
Across the 21 profiles obtained, the mean neutrophil count nadir was 0.8 x109/L (range 0.0 - 
3.0 x109/L) and mean day of the nadir was day 15 (range 8 - 26). Ten profiles had a nadir <0.5 
x109/L, with a mean duration of neutropenia <0.5 x109/L of 6.8 days.  The profiles are 
displayed across Figure 32 toFigure 38.  The categories are explained by phenotype in sections 
6.4.2.1 to 6.4.2.3.  
6.4.2.1 Febrile neutropenia 
Four of the 10 patients with a neutrophil nadir of <0.5 x109/L were admitted with febrile 
neutropenia; their profiles are shown in Figure 32.  The profiles of the other 6 patients are 
shown in Figure 33.  All 4 profiles were from males who received BEP chemotherapy; 2 
received the 3-day regimen, 2 the 5-day regimen.  Only 1 of these patients had a significant 
co-morbidity, asthma.   
The duration of neutrophils <0.5 x109/L was 4, 9, 7 and 7 days respectively in patients with 
febrile neutropenia, compared to 5, 5, 5, 7, 10 and 10 days in the 6 patients with a nadir <0.5  
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Figure 32: Neutrophil profiles of the patients who were admitted and treated for febrile 
neutropenia.   
These are the 4 profiles where the patient was treated for febrile neutropenia, out of the 10 
profiles where the neutrophil nadir was <0.5 x109/L. All 4 of these profiles belonged to males 
who received BEP chemotherapy regimen.  Profile a) and d) received 3-day BEP regimen, 
profiles b) and c) received 5-day BEP regimen.  Black observations represent capillary samples 
measured by the Hemocue WBC DIFF.  Red observations represent venous samples measured 
by the laboratory ADVIA 2120.  Observations are linked if they were measured by the same 
device and occurred on consecutive days.  The solid horizontal red line represents absolute 
neutrophil count of 0.5 x109/L.  The dashed horizontal red line represents absolute neutrophil 
count of 1.0 x109/L.  The days between the vertical short dashed red lines represent the 
admission to hospital during which the patient was treated for febrile neutropenia. 
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Figure 33: Neutrophil profiles of the patients with a neutrophil nadir <0.5 x109/L who were 
not admitted to hospital for febrile neutropenia.   
These are the 6 profiles where the patient was not treated for febrile neutropenia, out of the 
10 profiles where the neutrophil nadir was <0.5 x109/L. The chemotherapy regimen delivered 
for each profile were; a) & b) epirubicin and cyclophosphamide, c) BEP 3-day, d) doxorubicin, 
e) and f) BEP 5-day.  Black observations represent capillary samples measured by the 
Hemocue WBC DIFF.  Red observations represent venous samples measured by the laboratory 
ADVIA 2120.  Observations are linked if they were measured by the same device and occurred 
on consecutive days.  The solid horizontal red line represents absolute neutrophil count of 0.5 
x109/L.  The dashed horizontal red line represents absolute neutrophil count of 1.0 x109/L.   
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x109/L who did not experience febrile neutropenia (mean 6.8 versus 7.0 days).  The proportion 
of days during a cycle of chemotherapy spent with the neutrophil count <0.5 x109/L was 
higher in those who experienced febrile neutropenia than those who did not (29.6% versus 
11.2%).  Table 39 shows the proportions and number of days spent neutropenic according to 
regimen received. 
Febrile neutropenia was identified on day 1, 2, 6 and 1 after the first occurrence of neutrophil 
count <0.5 x109/L.  Three of the 4 patients were admitted from a scheduled clinic attendance; 
2 were admitted on day 8, 1 on day 11 and 1 on day 15.  All 4 patients had peripheral and PICC 
line blood cultures sent which were negative for growth of organisms.  Two had urine cultures 
sent which were also negative for growth of any organisms.  One patient experienced rigors 
indicating a bacteraemia, but this was not confirmed on blood cultures.    None of the patients 
met the criteria for neutropenic sepsis, but  4 had documented fever >38.0oC and were 
treated for febrile neutropenia.   
6.4.2.2 Neutrophil recovery 
Four of the 21 neutrophil counts had not recovered above the threshold for safe delivery of 
cycle 2 by day 21 (thresholds in Table 38).  The regimens delivered to these 4 patients were 
EC, BEP 5-day (n=2) and gemcitabine/carboplatin.  In addition, the neutrophil count for the 
patient treated with single agent carboplatin subsequently fell below the threshold beyond 
day 21, albeit for a single day.  The neutrophil count continued to be tested beyond day 21 as 
there was only 1 cycle of chemotherapy planned.  One of the BEP 5-day profiles was collected 
until day 20 only and the count had not reached the safe threshold for delivery of cycle 2 by 
that day.  These 6 profiles are shown in Figure 34. 
Of the 15 profiles where the neutrophil count threshold for safe delivery of cycle 2 was met by 
day 21, 6 did not fall below this threshold at any point during cycle 1; profiles shown in Figure 
35.  The profiles of the remaining 9 patients had recovered in advance of day 21 with a range 
of 0 to 8 days, mean of 2.1 days and median of 1 day.  
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Regimen 
Admitted 
with FN 
Total days ANC 
recorded during 
cycle 
Proportion of cycle days 
ANC <0.5 
x109/L in % 
(days) 
ANC <1.0 
x109/L in % 
(days) 
Bleomycin /                   
etoposide /                      
cisplatin                                 
(BEP) 
No 22 13.6 (3) 27.3 (6) 
Yes 29 13.8 (4) 17.2 (5) 
Yes 22 31.8 (7) 36.4 (8) 
Yes 22 40.9 (9) 45.5 (10) 
Yes 22 40.9 (9) 50.0 (11) 
No 22 31.8 (7) 40.9 (9) 
No 20 35.0 (7) 40.0 (8) 
Carboplatin No 29 0 (0) 20.1 (6) 
Carboplatin /     
etoposide 
No 23 0 (0) 0 (0) 
No 23 0 (0) 13.0 (3) 
Carboplatin /      
paclitaxel 
No 22 0 (0) 0 (0) 
No 22 0 (0) 0 (0) 
Carboplatin / 
pemetrexed 
No 21 0 (0) 0 (0) 
No 22 0 (0) 0 (0) 
Doxorubicin No 23 30.4 (7) 34.8 (8) 
Epirubicin / 
cyclophopsphamide    
(EC) 
No 23 21.7 (5) 34.8 (8) 
No 23 17.4 (4) 52.2 (12) 
No 22 0 (0) 31.8 (7) 
Gemcitabine / 
carboplatin 
No 23 0 (0) 0 (0) 
No 22 0 (0) 0 (0) 
No 24 0 (0) 33.3 (8) 
Table 39: Table showing the proportion of each cycle the neutrophil count is <0.5 x109/L and 
<1.0 x109/L by chemotherapy regimen. 
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Figure 34: Profiles of the neutrophil counts where the neutrophils had not recovered 
sufficiently for delivery of the subsequent cycle of chemotherapy.   
The chemotherapy regimens delivered with neutrophil threshold for safe delivery of the 
subsequent cycle at day 21 were; a) epirubcin and cyclophosphamide, >1.5 x109/L,  b) 
carboplatin and gemcitabine, >1.5 x109/L, c) BEP 5-day, >1.0 x109/L, d) BEP 3-day, >1.0 x109/L, 
e) carboplatin AUC 7, f) BEP 3-day, >1.0 x109/L, but the profiles stops at day 20.  Black 
observations represent capillary samples measured by the Hemocue WBC DIFF.  Red 
observations represent venous samples measured by the laboratory ADVIA 2120.  Green 
observations represent the first measurement after the nadir when the count recovered 
above the threshold for safe delivery of the subsequent chemotherapy cycle.  Observations 
are linked if they were measured by the same device and occurred on consecutive days.  The 
solid horizontal red line represents absolute neutrophil count of 0.5 x109/L.  The dashed 
horizontal red line represents absolute neutrophil count of 1.0 x109/L.  The days between the 
vertical short dashed red lines represent the admission to hospital during which the patient 
was treated for febrile neutropenia.  The green arrow indicates the day the subsequent 
chemotherapy was due. 
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Figure 35:  The six neutrophil profiles where the neutrophil count never fell below the 
threshold for delivery of the subsequent cycle of chemotherapy.  
The chemotherapy regimens delivered for each profile were; a) & b) gemcitabine and 
carboplatin, c) & d) carboplatin and pemetrexed, e)  paclitaxel and carboplatin 3-weekly, f) 
paclitaxel and carboplatin weekly.  Black observations represent capillary samples measured 
by the Hemocue WBC DIFF.  Red observations represent venous samples measured by the 
laboratory ADVIA 2120.  Observations are linked if they were measured by the same device 
and occurred on consecutive days.  The solid horizontal red line represents absolute 
neutrophil count of 0.5 x109/L.  The dashed horizontal red line represents absolute neutrophil 
count of 1.0 x109/L.   
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6.4.2.3 By chemotherapy regimen 
In all 3 profiles from patients receiving epirubicin and cyclophosphamide, there appeared to 
be a “falter” in the descent of the neutrophil count to the nadir, with a rise in neutrophil count 
at days 7,7, and 6.  In the second of these patients, the rise continued for 3 consecutive days.  
Then again all 3 appeared to have a second rise at day 8, 11 and 10, but for one day only.  The 
duration of neutropenia at <1.0 x109/L during epirubicin and cyclophosphamide was relatively 
long (8, 12 and 7 days).  The recovery from the nadir was late but rapid; 2 of the 3 recovered 
the neutrophil count sufficiently in time for safe delivery of cycle 2 on day 21.  These 3 profiles 
are shown in Figure 36. 
All 7 of the profiles from patients treated with bleomycin, etoposide and cisplatin (BEP), 
descended to a nadir of <0.5 x109/L, with the mean nadir being 0.12 x109/L (range 0.00 to 
0.28) and mean duration of neutrophil count <0.5 x109/L being 6.6 days (range 3 to 9).  Three 
of the 7 profiles did not recover sufficiently for delivery of cycle 2 on time.  The gradient of the 
neutrophil recovery appeared less steep and less profound than that of other regimens such 
as epirubicin and cyclophosphamide.  These 7 profiles are shown in  
Figure 37.   
None of the 7 profiles for chemotherapy regimens used to treat patients with lung cancer 
(gemcitabine and carboplatin, carboplatin and pemetrexed, and carboplatin and etoposide) 
had a neutrophil nadir <0.5 x109/L.  All 3 of the gemcitabine / carboplatin patients’ neutrophil 
profiles were similar with a rapid descent of neutrophil count over 3-6 days and then a flat 
profile with 2 out of the 3 showing little sign of neutrophil recovery from the nadir by day 21. 
None of the carboplatin / pemetrexed (n=2), doxorubicin (n=1) or weekly  carboplatin / 
paclitaxel (n=1) neutrophil profiles were smooth curves and they had a jagged appearance to 
the neutrophil descent.  All the profiles of patients not included in either Figure 36 or  
Figure 37 are shown in Figure 38.   
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Figure 36:  The neutrophil profiles for epirubicin and cyclophosphamide chemotherapy 
regimen.   
In profile b) the patient received oral antibiotics from day 4 to day 11 for a wound infection.  
Black observations represent capillary samples measured by the Hemocue WBC DIFF.  Red 
observations represent venous samples measured by the laboratory ADVIA 2120.  
Observations are linked if they were measured by the same device and occurred on 
consecutive days.  The solid horizontal red line represents absolute neutrophil count of 0.5 
x109/L.  The dashed horizontal red line represents absolute neutrophil count of 1.0 x109/L.   
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Figure 37:  The neutrophil profiles for bleomycin, etoposide and cisplatin (BEP) 
chemotherapy regimens.   
Profiles a), b), c) and d) were during BEP 5-day regimen.  Profiles e), f) and g) were during BEP 
3-day regimen.  Black observations represent capillary samples measured by the Hemocue 
WBC DIFF.  Red observations represent venous samples measured by the laboratory ADVIA 
2120.  Observations are linked if they were measured by the same device and occurred on 
consecutive days.  The solid horizontal red line represents absolute neutrophil count of 0.5 
x109/L.  The dashed horizontal red line represents absolute neutrophil count of 1.0 x109/L.  
The days between the vertical short dashed red lines represent the admission to hospital 
during which the patient was treated for febrile neutropenia.   
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Figure 38: Continued on following page. 
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Carboplatin and pemetrexed 
  
Carboplatin and etoposide 
  
Paclitaxel and carboplatin 3-weekly Paclitaxel and carboplatin weekly 
  
Figure 38:  The neutrophil profiles from patients by chemotherapy regimen received, 
excluding epirubicin and cyclophosphamide (EC) and bleomycin, etoposide and cisplatin 
(BEP).   
Black observations represent capillary samples measured by the Hemocue WBC DIFF.  Red 
observations represent venous samples measured by the laboratory ADVIA 2120.  
Observations are linked if they were measured by the same device and occurred on 
consecutive days.  The solid horizontal red line represents absolute neutrophil count of 0.5 
x109/L.  The dashed horizontal red line represents absolute neutrophil count of 1.0 x109/L.    
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6.4.2.4 Telephone consultations 
Ten of the 21 patients telephoned the acute assessment unit on a total of 17 separate 
occasions for advice regarding symptoms during their chemotherapy.  From these 17 phone-
calls, 6 patients attended the acute assessment unit once each for review.  Of these 6 
patients, 3 had suspected febrile neutropenia, 1 of which was proven and admitted, the other 
2 were disproven because they were not febrile or neutropenic, but 1 was still admitted for 
nausea and vomiting.  This is shown in a flow diagram in Figure 39.    
 
Figure 39:  Flow diagram of the unplanned patient-initiated telephone consultations during 
chemotherapy with the nurse practitioner manning the acute assessment line. 
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6.5 Discussion 
6.5.1 Main findings 
Comprehensive neutrophil profiles were generated for 21 out of 22 patients on 
chemotherapy.  The main findings from these profiles were; 
(i) They demonstrated it is feasible to measure home neutrophil counts regularly on 
patients during chemotherapy, albeit that the measurements in this trial were 
carried out by health-care professionals. 
(ii) They showed heterogeneity of neutrophil profiles from patients in routine 
practice. 
(iii) They challenged some preconceptions around neutrophil counts and toxicity 
during chemotherapy, for example, that the risk of febrile neutropenia is 
proportional to the extent and duration of neutropenia. 
(iv) They highlighted the potential of using neutrophil counts during a cycle to 
personalise chemotherapy treatment. 
In some instances, the patients’ neutrophil profiles showed insufficient neutrophil recovery 
prior to the subsequent planned chemotherapy cycle, they identified sub-optimal dosing 
indicated by an inadequate neutrophil nadir, and they demonstrated that some patients were 
neutropenic prior to non-elective symptom-led assessment at hospital.  There were not 
sufficient patients with neutropenic complications in this cohort to analyse patterns in early 
changes in neutrophil counts that may be indicative of neutropenic complications. 
Grade 4 neutropenia occurred in ten out of the 21 profiles, with a mean duration of 6.8 days.  
As expected and in keeping with the pathway modelling described in chapter 2, bleomycin / 
etoposide / cisplatin (BEP) and single agent doxorubicin chemotherapy regimens were 
associated with the highest proportion of days spent with grade 4 neutropenia.  The BEP 
chemotherapy regimen was associated with the highest prevalence of febrile neutropenia, 
with no obvious difference in rate between 3- and 5-day regimens, which concurs with 
previous studies (237).  However, in contrast to the literature, the proportion of days during 
the chemotherapy cycle spent neutropenic, were not directly related to the risk of febrile 
neutropenia.  Moreover, the day of onset of febrile neutropenia was not consistently related 
to the day of onset of uncomplicated neutropenia.  The profiles of those patients who were 
treated for febrile neutropenia show a very rapid descent to neutropenia in 1 out of the 4, 
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compared to a more steady descent in the other 3. There were not enough profiles with the 
outcome of neutropenic complications to identify recurring patterns.  For example, in Figure 
32 the rapid descent to neutropenia associated with a fever was preceded by a spike in 
neutrophil count; further similar profiles are needed to see if this was by chance or in fact 
repeats due to an underlying physiological process which is indicative of neutropenic 
complications.  
Interestingly, many of the profiles display a step-wise and in some cases changing orientation 
of the profile whilst ultimately descending to the neutrophil nadir.  This is best demonstrated 
in Figure 32b, Figure 33a, b, d, Figure 34a, c, d, Figure 35a, d and f.  Endogenous granulocyte 
colony stimulating factor and other cytokines, such as interleukin 1, 5, 6 and 11 are produced 
by multiple cell types including fibroblasts, endothelial cells and macrophages that promote 
the proliferation of bone marrow neutrophil precursors and accelerate release of mature 
neutrophils into the circulating blood (1).  Granulocyte colony stimulating factor is elevated in 
patients during chemotherapy (238), but despite the extensive work on colony stimulating 
factors the feedback mechanism and driver for effect is not understood.  Perhaps the 
changing orientation of the profiles in descent to the neutrophil nadir is an effect of 
endogenous granulocyte colony stimulating factor, which is limited by the effect of the 
chemotherapy insult on the committed multipotent haematopoietic stem cells in the bone 
marrow, but driven either by the change in neutrophil count or by another mechanism of 
insult caused by the chemotherapy.   
There is potential to optimise the delivery of chemotherapy by personalising it according to 
recovery of a patient’s neutrophil counts and the neutrophil nadir obtained.  Recovery of the 
neutrophil count was later than expected, with the median number of days that the count 
recovered in advance of delivery of cycle 2 being 1 day.  In addition, in 4 out of the 21 profiles, 
the neutrophil count did not recover sufficiently in time for cycle 2, and hence use of home 
blood count monitoring could have prevented a wasted trip to hospital for these patients.  In 
contrast, 6 out of the 21 profiles showed that the neutrophil nadir failed to even fall to the 
threshold for safe delivery of cycle 2.  Four of the chemotherapy regimens in this group were 
delivered for non-small cell lung cancer, and none of the 7 regimens given for lung cancer 
achieved a neutrophil nadir <0.5 x109/L.  There is strong evidence in the advanced non-small 
cell lung cancer setting that the higher the grade of neutropenia achieved during 
chemotherapy, the better the survival (hazard ratio death 0.65 with grade 3-4 neutropenia, 
0.74 with grade 1-2 neutropenia compared to no neutropenia, and an absolute survival 
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benefit of 12.3 weeks, p=0.0118 of grade 1 or 2 neutropenia compared to no neutropenia) 
(93).  Often patients with lung cancer have underlying chronic lung disease and as such have 
anatomical abnormalities which predispose them to deep-seated infection, hence the caution 
in real-life practice dosing, but all the more important to be able to individually dose patients 
based on their toxicity profile. 
The proportion of patients who telephoned the acute assessment unit for advice was 
unexpectedly high, albeit that this trial was during first cycles of chemotherapy, which may be 
associated with uncertainty of the unknown.  Only one out of the 17 phone-calls resulted in 
admission to hospital for treatment of febrile neutropenia, as the other three patients with 
febrile neutropenia were admitted from clinic, which may have been due to coincidence, but 
also possibly reflects delay in symptom reporting due to scheduled appointments, or lack of 
recognition by patients of concerning symptoms.  The phone-calls made to the hospital by the 
patients on chemotherapy represented a significant volume of work for staff, as well as 
inconvenience for the patients, and should be considered an integral part of assessing the role 
of home blood count monitoring.    
6.5.2 Strengths and weaknesses 
This trial had significant strengths.  We generated comprehensive finger-prick neutrophil 
measurements for the duration of the first cycle of chemotherapy from patients who were 
being treated within routine clinical care protocols.  As all trial activity was carried out in 
addition to standard care, and the patients and professionals measuring the neutrophil counts 
were blinded to the Hemocue WBC DIFF results, the intervention should not have influenced 
the prevalence of febrile neutropenia.  As there were both venous laboratory neutrophil 
counts and capillary Hemocue WBC DIFF neutrophil counts measured on occasions on the 
same day, the results corroborated the performance analysis of the Hemocue WBC DIFF in the 
neutropenic range, where the two results were largely comparable.  In fact, in some of the 
profiles the laboratory venous curves were almost continuous with those of the capillary 
Hemocue WBC DIFF results.  On the occasions where there was discrepancy between the 
venous laboratory neutrophil count and capillary Hemocue WBC DIFF result, the mean 
neutrophil count tended to be well above the grade 3 neutropenia threshold. 
The major limitation of this trial was that recruitment was limited to 22 patients, and that 50% 
of patients declined participation.  This would limit, but not preclude, home blood count 
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monitoring in this format in clinical practice.  Perhaps patients were put off by the “intrusion” 
of a home visit, or the need to arrange their diaries around the visit.  If so, self-test devices 
may prove more attractive.  It would probably be “best” to give patients the choice of self- or 
nurse-delivered testing.  The small numbers enrolled rendered statistical analyses 
inconsequential, as results could not be described without very large CIs.  Moreover, although 
the proportion of those who experienced febrile neutropenia was actually quite high, the 
absolute number was not enough to identify patterns in neutrophil counts related to this.  The 
broader picture limitation was that this data were collected using a professional to operate 
the blood count measuring device.  Although effective to meet the aims of this trial, many of 
the potential gains of using a point of care finger-prick blood count monitor in oncological 
clinical practice are dependent upon a patient self-test device.  This trial cannot prove proof of 
principle of patient self-test home blood count monitoring, but justifies the continued 
collection of neutrophil profiles to identify with more confidence where in the pathway of 
patients on chemotherapy there is potential for use of home blood count monitoring. 
6.5.3 Implications 
Even with the small number of patients in this trial, the ability to collect patient profiles and 
the profiles themselves demonstrated that there is value in pursuing development of home 
blood count monitoring in patients on chemotherapy.  For example, the one patient with 
proven febrile neutropenia, of the three suspected patients, could have been identified prior 
to attendance at hospital, and could have been directed straight to the ward for admission, 
thus empowering the patient to improve their own experience of healthcare by receiving 
prompt, high quality care, without the interim often long wait on an acute assessment unit.  
The other two patients with suspected febrile neutropenia in whom this was not confirmed, 
could have been spared an unnecessary visit to hospital (although in one case there was a 
secondary cause for admission).  This would meet very much the aims of local practice 
strategies, but also of the Five Year Forward View, which recommends changes for delivery of 
healthcare in the NHS on a National level, published in 2014 (239).  One proposed direction of 
change described in this, is for a more patient-centred and involved healthcare service, with 
more confluent movement of patients between primary and secondary care.   
Most notably, there were a number of patients in this trial where there was evidence of 
“under-dosing” of chemotherapy, whether that be due to an inadequate neutrophil nadir, or 
early recovery of neutrophils prior to the subsequent cycle of chemotherapy.  Given that 
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published data demonstrates improved relapse-free survival from high-risk breast cancer 
using the neutrophil nadir to dose chemotherapy (94), it is warranted to investigate the true 
extent of this under-dosing further by collecting more data, which may support analysis of 
improved dosing of standard chemotherapy.  This may be of particular interest in cancer types 
where the newer biological therapies have yet to have a significant impact on the current 
standard cytotoxic chemotherapies, or where the dosing is crucial to maintaining good 
outcomes, such as in germ cell tumour practice.  This “personalised” increase in dose intensity 
is most obviously applicable in the curative setting (adjuvant breast, colorectal, osteosarcoma 
cancers), but potentially relevant in the metastatic setting where benefits in overall survival 
have been shown (non-small cell lung cancer) (93).     
Neutropenic sepsis remains a life-threatening toxicity of cytotoxic chemotherapy (47, 49, 95), 
and there is support in some circumstances for the use of prophylactic measures (65-67, 72, 
75).  This, and the ability to successfully profile neutrophil counts, provides the rationale in 
part to continue to collect more neutrophil profiles during chemotherapy in an attempt to 
define a biomarker in the form of early changes in the neutrophil count that is predictive of 
neutropenic complications.  The small number of patients with neutropenic complications in 
this study precluded identification or disproof of such indicative changes.  Collection of a 
larger number of profiles may facilitate pattern recognition and enable segregation of early 
changes into groups according to risk of neutropenic complications.  If such changes exist, the 
intention is to quantify how closely data fits the recognised patterns and thus define the limits 
of low, medium and high risk groups with CIs.  This would complement the existing modelling 
work on neutrophil time-course during chemotherapy, as the data from early days following 
chemotherapy used to inform these were sparse, so may have missed key signals, and the 
models were mostly developed for single-agent drugs, not the regimen combinations 
commonly used in practice.   
Projecting beyond collection of more profiles to identify potential uses for home blood count 
monitoring during chemotherapy, evidence needs to be generated to support the principles 
identified.  As discussed, home blood count monitoring could be used in at least four different 
time points during chemotherapy (early on in predictive capacity, mid-cycle identifying 
neutropenia, mid-cycle defining the neutrophil nadir, and end-of-cycle identifying sufficient 
neutrophil recovery), and as such is a complex intervention (170).  Generation of evidence to 
support change of routine clinical practice to incorporate home blood count monitoring will 
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involve careful selection of patients for a “test and treat” trial, possibly using home blood 
count monitoring at more than one time-point during chemotherapy.   
6.5.4 Conclusion 
The work in this chapter serves to demonstrate proof of principle, first and foremost, that 
home blood count monitoring is possible.  Even within the confines of small numbers of 
profiles, it demonstrates that home neutrophil count monitoring provides information on the 
neutrophil count that is otherwise unknown.  Collection of further profiles will demonstrate 
the true extent of this across chemotherapy regimens in routing practice and enable the 
application of statistical tests to define CIs.  This will provide baseline information, much like 
the previous chapter on defining clinical pathways, so that the gains of changing future clinical 
practice can be quantified.  Profiling neutrophil counts has the potential to feed into the 
evidence base for the national agenda of personalising medicine, which in this case, is delivery 
of chemotherapy.  The data in this chapter supports on-going development of the technology 
to facilitate patient self-test home blood count monitoring.   
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Chapter 7 Overall discussion 
Chemotherapy delivery continues to play an important role as part of often multi-modality 
treatment for patients with malignant tumours.  Current chemotherapy dosing schedules and 
supportive therapies are usually based on evidence from clinical trials, which report the 
clinical effectiveness as well as toxicities at a trial population level.  Both complicated and 
uncomplicated neutropenia are well recognised toxicities of cytotoxic chemotherapy, with 
prevalence varying depending on the source and methods of evidence.  As the absolute 
number of patients receiving chemotherapy is projected to increase year on year over the 
coming decades, the burden of  neutropenia associated with cytotoxic chemotherapy is also 
expected to increase.  The vast majority of cancer care within the United Kingdom is carried 
out within the National Health Service, which is under ever increasing financial constraints, 
with targets to improve outcomes of cancer care, which include clinical outcomes such as 
survival rates, but also social outcomes such as patient satisfaction.     
The work described in this thesis aimed to explore the feasibility and potential role of home 
blood count monitoring in patients during chemotherapy.  It started the journey towards 
investigating whether home blood count monitoring could be used to personalise 
chemotherapy delivery with the ultimate goal of improving outcomes for patients with 
cancer.  In current standard clinical practice, blood counts  are measured through venous 
blood samples, obtained by a health-care professional and measured in a haematology 
laboratory.  Using finger-prick blood samples has the advantage that it may be possible for 
patients to self-test and therefore obtain results remote from the health-care provider, 
negating the requirement for venepuncture and for the patient to travel for the procedure.  
This provides the possibility of more frequent blood tests, thus diversifying the potential role 
of home blood count monitoring.   
This thesis is formulated of discrete chapters where different aspects of home blood count 
monitoring were addressed within each and include;  
1. pathway modelling to define and quantify baseline patient pathways. 
2. patient and professional attitudes towards home blood count monitoring. 
3. use of parameters available on finger-prick devices as surrogate markers of the 
venous blood count. 
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4. performance of the finger-prick device in the neutrophil range relevant to oncological 
practice. 
5. collecting neutrophil profiles of patients on chemotherapy. 
Overall, this work showed that amongst patients and professionals there is an enthusiasm for 
and a willingness to embrace home blood count monitoring, and to engage in clinical 
research.  It demonstrated that existing data collected as part of routine clinical care are 
detailed and robust enough to be transformed into quantifiable patient pathways of clinical 
relevance.  It showed that the finger-prick blood count measuring technology is appropriately 
advanced to facilitate finger-prick blood count measurements that perform sufficiently in the 
extreme neutropenic range, which is necessary for use in oncological clinical practice.  All this 
built towards using home blood count monitoring to profile the neutrophil counts of patients 
on chemotherapy.  Certainly the profiles obtained confirm the feasibility to use home blood 
count monitoring, with the caveat that these results were obtained by professional tests and 
with manual electronic transfer of the results.  The heterogeneity of the neutrophil profiles 
challenged preconceptions such as, for example,  that the risk of febrile neutropenia is 
proportional to the extent and duration of neutropenia.  As such, the neutrophil profiles of 
patients on chemotherapy confirmed there is a potential role for home blood count 
monitoring to be used to personalise chemotherapy delivery.  Further neutrophil profiles are 
needed to define and quantify the patients in whom it is considered that home blood count 
monitoring has the potential to improve care.   
When assessing the performance of a test, it is important to consider the intended clinical 
use, hence the requirement to assess performance specifically in neutropenic ranges relevant 
to oncological practice.  In the scenario of using home blood count monitoring to exclude 
neutropenia in a patient at home with suspected febrile neutropenia, the benefit of avoiding 
hospital attendance has to be off-set against the risk of mis-management.  If the threshold 
indicating neutropenia is set too high, the benefit of using the test will not be realised.  If the 
threshold is set too low, the risk of using the test may be unacceptable.  Moreover, there will 
always be a range of uncertainty around thresholds, where a small error in the result could 
classify the patient on a different side of the threshold than the comparator laboratory result.  
This is where use of the trend of results may be of benefit, and action such as test repetition 
for results that fall within predefined limits of the threshold can be included in treatment 
algorithms.  An alternative approach is to build error margins into clinical algorithms.  For 
example, national guidelines for initiating intravenous antibiotic therapy for febrile 
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neutropenia use neutrophil counts of <0.5 x109/L as the cut-off.  Using a neutrophil threshold 
of <1.0 x109/L incorporates an error margin which is 100% of the true value, and allows for the 
area of uncertainty around the threshold.  
The pathway modelling described in chapter five was performed to inform patient selection 
for the home blood count monitoring in chapter six, but also to provide a mechanism by 
which any future changes to patient care as a result of introducing home blood count 
monitoring can be measured.  In addition, it stands alone as an exemplar of how data 
collected for routine clinical care can be transformed into a format that can be meaningfully 
shared with stakeholders involved in service improvement.  This approach was acknowledged 
as being a vanguard in this field when it was presented at the 4th UK Diagnostics Forum in 
Oxford in 2015 (155), and has since initiated interest from the Medicines and Healthcare 
products Regulatory Agency (MHRA) as a method of identifying and confirming signals held 
within data across diagnostic, device and medicines boundaries.     
It is disappointing that during the time-frame of this research, that there was not a device 
available for patient self-test use with remote connectivity capability.  The soft- and hardware 
exist to enable automated electronic transfer of the blood results, but there is work to be 
done to make this compatible with the Hemocue WBC DIFF device.  The self-test data in 
chapter four is the first available on patients using the Hemocue WBC DIFF device, but the 
absence of more robust data on both self-test and the automated transfer of results is the 
most significant limitation of this work.  Progression of this is a key part of realising the 
benefits of home blood count monitoring.  In addition, greater numbers of patients with 
comprehensive neutrophil profiles are needed to inform a “test and treat” trial protocol, 
hence only limited conclusions could be drawn about the potential uses and predicted impact 
of home blood count monitoring.  There were multiple potential uses within a cycle of 
chemotherapy proposed.  If further patients’ neutrophil profiles support the continuation to a 
test and treat trial, this will necessarily be a complex intervention, which will require careful 
multi-disciplinary planning in order to collect appropriate data on all the potential outcomes. 
In contrast to the limitations, the work described in this thesis has significant strengths.  It was 
conducted in collaboration with the National Health Service, academia and industry, drawing 
on the expertise of specialists in all fields, such as patients, data analysts and laboratory 
professionals, to name a few.  Some of the collaborative work was beyond the scope of this 
thesis, but was informed by work within it, such as health economic analysis which is on-going 
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and is dependent upon the Markov model built during the patient pathway modelling 
described in chapter five.  Robust methods were used throughout this research as 
demonstrated by the publication of work from two of the chapters to date (115, 191), with 
plans to submit the content completed later in time (chapters three and six).  The neutrophil 
profiles obtained were comprehensive, with few missing results from daily schedules, 
indicating patient acceptance of the procedure.  In addition, the findings are widely applicable 
to oncology practice as a whole, for example, the performance analysis in the neutropenic 
range may open up the opportunity for use of finger-prick blood count monitoring for 
accurate drug dose escalation in early-phase clinical trials.  The patient pathway mapping 
described reproducible methods which can be applied to many clinical scenarios, providing a 
mechanism of quantifying current service provision that can be applied to identify problems in 
service delivery, inform health economic analysis, and measure the effect of intervention on 
the real-life patient pathway.  Moreover, the principles of this project (which are aiming to 
reduce the frequency and severity of neutropenic complications of chemotherapy, reduce 
patient attendance at and admissions to hospital, improve patient experience and make 
financial savings) are very much in keeping with both local and national health-care agendas. 
In October 2014, NHS England published the “Five Year Forward View” that set out 
approaches for sustaining and improving the NHS, to make it fit for the purpose of serving the 
healthcare needs of the nation with a high quality service (239).  It focused on key areas such 
as ; 
• giving patients more control of their care. 
• new models of care. 
• exploiting the information revolution. 
• accelerating useful health innovation. 
 
The vision for giving patients greater control of their care involved recognising patients can be 
“experts by experience”, and acknowledged merit in allowing patients to manage conditions 
and thus avoid complications.  This approach was also considered to facilitate suggested new 
models of care that break down the boundaries between secondary and primary care, 
allowing more health-care delivery in the community.  It recognised that evaluation of new 
models of care should address healthcare outcomes, of which patient experience and value 
for money are of paramount importance.  It looked to providers of “specialised care”, 
necessary where the relationship between number of patients and quality of care is strong, to 
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develop services deliverable over large geographical areas. It uses cancer care as an example, 
where service re-design could enable making “supporting care available much closer to 
people’s homes” and can “allow more chemotherapy to be provided in the community”. 
Oncological practice is an ideal specialty to use as an exemplar of service development in line 
with the principles of the Five Year Forward View.  The National Confidential Enquiry into 
Patient Outcomes and Death (NCEPOD) and the subsequent National Chemotherapy Advisory 
Group recommendations outlined the need for certain “specialised services” (95, 96).  The 
presence of national audit data, as collected in the National Cancer Waiting Times Monitoring 
Dataset, Cancer Outcomes and Services Dataset, Systemic Anticancer Therapy Dataset and 
cancer registries, serve as a baseline of large scale information collection against which 
subsequent service improvement project outcomes can be measured.   At a more local level, 
Leeds Teaching Hospitals NHS Trust uses an advanced integrated electronic health record 
(PPM) that provides a single interface to access healthcare records from secondary/tertiary 
care, general practice and health and social care, and thus can facilitate collection of 
integrated data.  In addition, the National Institute for Health Research (NIHR) selected Leeds 
(partnership between University of Leeds and Leeds Teaching Hospitals NHS Trust) as one of  
four Diagnostic Evaluation Co-operatives (DECs), which recently evolved into a Medtech and 
In Vitro Diagnostics Co-operative (MIC), with the aim of working collaboratively with the NHS 
and industry to generate evidence to support diagnostics adoption.  Home blood count 
monitoring in patients on chemotherapy is a project with principles that complement the aims 
of national and local NHS-wide and cancer-specific agendas.       
The use of home blood count monitoring in patients on chemotherapy may have the potential 
to (i) improve cancer survival through personalising chemotherapy delivery according to 
neutrophil nadir and recovery, (ii) predict neutropenic complications through identifying 
critical early changes in neutrophils, and (iii) improve the patient pathway and experience 
through triaging those with suspected febrile neutropenia on remote contact with the 
hospital, before unplanned assessment.  Home blood count monitoring in patients on 
chemotherapy would complement the aims of both the 5-Year Forward View, and the latest 
cancer strategy published in 2015, “Achieving Word-Class Cancer Outcomes; a strategy for 
England 2015-2020” (240).  The latter aligns with the former with respect to supporting 
patient empowerment, self-management, and better integration of patient care between 
primary and secondary/tertiary care environments.  The strategy also emphasizes delivery of 
outcomes that matter to patients, including patient experience, high quality modern services 
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and financial savings.  In parallel with these strategies, the National Cancer Patient Survey has 
been carried out annually since 2010.  The field-work for the 2016 survey was carried out 
between October 2016 and March 2017 and had a 66.4% response rate (n=72,788 
respondents) (241).  It reported 87% of patients to score ≥8/10 for overall satisfaction with 
their care.   However, the questionnaire described in chapter 2 of this thesis demonstrated a 
willingness amongst patients to use home blood count monitoring during chemotherapy on 
the basis that it would save time, a luxury often not afforded by people with a terminal illness, 
and thus indicating that the use of home blood count monitoring may provide a mechanism to 
further improve patient experience.  
At local levels, non-surgical oncology Clinical Service Units are looking to implement the 
National Cancer Strategy through tangible, step-wise targets to provide high quality patient 
experience.  An example of this is through waste reduction programmes aiming to reduce 
length of in-patient stays, reduction in drug costs and admission avoidance.  There is potential 
for home blood count monitoring to impact all three of the latter targets through earlier 
diagnosis of febrile neutropenia thus reducing complications and length of intravenous 
antibiotics and in-patient stays, through reduction in wasted chemotherapy by identifying 
those patients with insufficient neutrophil recovery before subsequent chemotherapy is made 
up, and through reducing attendance at acute assessment units by excluding neutropenia 
remotely.         
Both the 5-Year Forward View and “Achieving Word-Class Cancer Outcomes; a strategy for 
England 2015-2020” acknowledge and plan for increasing demand on services over the 
coming decades.  There has been a 10% increase in patients being managed by oncology 
services each year between 2000-2015 (approximately 25,000 additional patients per year) 
(242), which is expected to continue to rise primarily due to an aging population and better 
survival outcomes.  There has been no increase in the proportion of NHS budget that is 
allocated to cancer services in the same time period (approximately 6.7%), thus delivery of a 
high quality, efficient, safe and cost-effective clinical service to increasing numbers of patients 
remains challenging.  Moreover, perhaps the greatest challenge in a modern NHS is bringing 
about change in an organisation of such scale.  There is a requirement for a culture shift of 
those working within it to embrace working with patients, making joint decisions, rather than 
the old-fashioned approach of “doctor knows best” (243).  The phrase “no decision about me, 
without me” was coined by the government in 2012 in a paper addressing this (244).  Use of 
home blood count monitoring would be a step in the right direction towards joint decision 
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making and patient empowerment.  However, it is well known that despite the NHS being 
heavily involved in the research and development of innovations, it is notoriously slow to 
adopt them (245).   
The Accelerated Access Review was published in October 2016, providing a Department of 
Health vision for faster adoption of innovation into the NHS, by describing an approach to 
selecting, accessing, funding and adopting the best innovations (246).  It states that there 
should be “a single set of clear national and local routes to get medical technologies, 
diagnostics, pharmaceutical and digital products to patients”, and that “digital infrastructure 
should enable the system to capture information on the use of innovations and associated 
outcomes”.  The patient pathway mapping described in chapter five serves as an example of 
how electronic patient records can be used to capture health service delivery.  It is proposed 
that re-running of the scripts generated to produce these pathways after introduction of 
home blood count monitoring would enable re-quantification of the pathways, and thus be 
used to quantify how the innovation has changed patient pathways.  This pathway modelling 
also informed preliminary health economic modelling of home blood count monitoring in 
patients during epirubicin and cyclophosphamide chemotherapy, where it was estimated that 
early detection of febrile neutropenia using home blood count monitoring would lead to cost 
savings where the cost of home blood cost monitoring was <£45 per patient per cycle (247).  
This health economic modelling was, however, based on clinical assumptions of effectiveness 
and used the estimated costs of the original “Minicare H-2000” device for patient self-test 
use.     
There remains work to be done to define the national and local routes to be followed to get 
innovations into the NHS efficiently.  The work described in this thesis is preparatory work 
which is contributing to the generation of sufficient evidence to support introduction of home 
blood count monitoring in patients on chemotherapy.  This work, in conjunction with that of 
the larger working party funded by the same Small Business Research Initiative grant, went 
some way towards mapping out a potential pathway to innovation introduction by using 
methods including lean patient pathway mapping (identify the problem), large scale pathway 
mapping (quantify the problem), health economic modelling (cost modelling of proposed 
solution).  Future work will involve bringing together the whole project as an exemplar of 
generating sufficient evidence to support innovation adoption, aligning with the principles of 
the Accelerated Access Review and going part-way towards addressing the following six key 
questions within it; 
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1. How will this innovation change clinical pathways and establish a new standard of 
care? 
2. What will be the clinical, social and economic impacts from this new standard of care? 
3. How will we measure the impacts with sufficient precision to provide evidence for 
adoption? 
4. What changes in workflow will be required? 
5. How will the re-engineering of this workflow be resourced? 
6. How can the benefits be spread across and between healthcare delivery systems? 
 
With respect to the future of home blood count monitoring, the profiling trial described in 
chapter six is proof of principle that home blood count monitoring via finger-prick is feasible, 
but it lacks the patient self-test element to the testing, which is crucial to the concept moving 
forwards.  The Minicare H-2000 device had remote connectivity capability and was 
Conformité Européene” (CE) marked for patient self-test use.  The next steps involve enabling 
connectivity and self-test use of the Hemocue WBC DIFF, testing proof of principle of the self-
test process and connectivity.  Meanwhile, there are plans to continue collecting neutrophil 
profiles from patients on chemotherapy as per the trial protocol to more accurately define 
and quantify projections of potential uses of home blood count monitoring.  The Hemocue 
WBC DIFF is being introduced as a professionally-operated device on an acute oncology 
assessment unit to serve as a triage tool to stratify patients according to their risk of febrile 
neutropenia, with the aim of minimising both the time spent at hospital and wasted resource 
use for those deemed at low or intermediate risk.  This is enabling collection of further 
performance data in order to narrow the CIs around clinically significant thresholds, and is 
building clinician confidence in using results from the device.  It is planned for continuation of 
the wider project in collaboration with the National Institute for Health Research (NIHR) Leeds 
Medtech and In Vitro Diagnostic Co-operative (MIC), working towards a “test and treat” trial 
to measure the complex clinical outcomes and pathways of using home blood count 
monitoring.   
Further work is needed to develop the package of care and idealised patient pathways that 
will ultimately be needed to realise the potential benefits of home blood count monitoring.  
This should include novel pathways such as diverting patients at low risk of febrile 
neutropenia from acute assessment units to alternative health-care provision possibly 
including urgent outpatient appointments, telephone consultations, general practice.  It may 
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require creation of new roles or evolution of current roles to manage the service and data, 
including addressing the challenges associated with twenty-four hours a day, seven days a 
week patient real-time measuring and/or reporting results that could indicate life-threatening 
chemotherapy toxicity.  A patient education and support package would need to be 
developed, and how home blood count monitoring can complement the trend towards using 
patient-reported outcome measures should be considered.   
In conclusion, home blood count monitoring is acceptable and in fact desirable to some 
patients during chemotherapy.  The technology exists to measure finger-prick blood counts 
with sufficient performance for use within oncological clinical practice, and to facilitate 
patient self-test use and remote data connection.  The real-life impact of innovations, such as 
home blood count monitoring, can be recorded using electronic health records to quantify 
patient pathways.  This project is working towards goals that complement national health-
care agendas in so many ways.  The research to date goes part-way towards generating the 
necessary evidence to support adoption of home blood count monitoring into routine clinical 
practice.  Hopefully the planned future work in this field will define the true potential.   
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Appendix 1 – Patient questionnaire 
             
188 
 
 
 
 
189 
 
 
 
 
 
 
  
190 
 
 
 
Appendix 2 – Consultant questionnaire 
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Appendix 3 – Tables of free-text comments from questionnaire 
respondents 
Free-text comments 
I wouldn't feel confident carrying out a self-blood test. 
I would need face to face reassurance. I would not trust my own findings and I 
would feel anxious and worried. 
When you are feeling unwell or old and on your own it's nice to talk to a person to 
be reassured. 
Speaking to someone would make me feel more comfortable. 
I think scenario B is more useful for the patient but given the situation I think it is 
worth seeing a doctor face to face. 
My wife worries a lot about me - she would feel stressed about this responsibility. 
I personally prefer to be reassured by a professional. As an improvement on 
scenario B, I would like to phone a professional as well as having the blood sample 
Reassurance 
Appendix 3, Table 1:  Free-text comments from respondents who indicated they would 
prefer scenario A in question 2, which is the current practice of attending hospital for a 
blood test and face-to-face consultation with a health-care professional.  
 
 
194 
 
 
 
Free-text comments 
Staying at home is a safer option especially if your immune system is compromised, if it is only a 
matter of a couple of hours for your temperature to normalise.  
It is very convenient, saves time and advantageous both to patient and medical staff. Get easily 
result and the information give the patient assurance of the situation. One thing I'm afraid of 
finger pricking, it's a bit painful compare to venepuncture. 
I wouldn't want to travel to hospital and hang around for 3 hours if only my temperature was of 
concern. 
My only concern is if you fall through the net and the computer is not given the right info by us or 
just not picked up through the net. 
Such a long way to come - prefer to stay at home. 
Saves me time. 
As long as I know how to use it. 
The waiting time for a blood test though being by nature a panicker I would like the reassurance 
of a health care professional. 
I rely on family to get me to/from hospital so this scenario would put less pressure on them and 
less travelling for me. 
Drive - not able to drive during chemo as felt so weak and partner at work -hard to get to hospital. 
Tired - on chemo felt too fatigued to come to hospital. 1 hour away - too tired to drive an hour. 
No strength to drive. 
I spent a month in hospital anyway - I'd be happy to use the device rather than come here and sit 
for hours. I would still ring if I felt unwell. 
Would rather stay at home unless it’s needed to come into hospital. 
Having to rely on my daughter to bring me to hospital, for something that would only take a few 
minutes at home. 
Travelling over 1 hour to get to hospital when feeling unwell every time (sometimes when it could 
be avoided). Would be so helpful and aid recovery so much better. 
No need to travel as it takes a lot of time and inconvenience. You are not going to be worried 
whether you have infection if the result is ok and it takes a few minutes. 
If I feel as ok as I usually would but just a temperature I don't see the need to instantly rush off to 
be checked over. I would rather wait and see if I got any worse before going to be checked. 
What is needed most in the situation is reassurance, which I think I would trust the device to give 
- saving time, energy, travel etc. The important factor is the further option of telephoning the 
hospital if I became more unwell. 
I would be happy to trial scenario "B" but with the assurance if I am worried I could still follow 
scenario "A". 
Being at home is less stressful than waiting for results in the hospital (3-4 hrs). There is still the 
availability to call the hospital if you worsen. 
No travelling and results are quick. 
Would rather be at home and not have to visit hospital. I know I can always call if I want to. 
Lives hour away. 
Felt unwell recently. Could not get through on bleep number. 
Don't like coming to hospital. Never been ill until now. 
Keeps me in a bit more control. Just so much more user friendly, although I can see why some 
patients may not feel confident enough. 
Appendix 3, Table 2: Continued on next page 
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Previously had to wait 5/6 hours for blood result at the hospital only to be sent home but needed 
admission later in the same week. Less invasive of time and comfort when feeling unwell. 
In the night this would be good - would save a trip in the ambulance. 
"B" would be ideal as its 3hr or more in traveling and appointment time. 
I was in and out like a yoyo when I was on chemo with a high temp. Once I was in A&E for 6 hours 
waiting for a bed when I was on chemo. 
More simple. On transport. 
Travel time when you feel ill better off staying home. To have the reassurance of your blood 
results there and then. 
Travelling to and from hospital, waiting, parking. All time consuming and worrying. Plus 
convenience! 
It's progress is that. 
Better conveniency. Less time off work. 
During my chemotherapy I have had a low white count and having a device at home to test 
quickly would have been reassuring and time saving. 
Seems easier and probably cost effective. I can see that some people would prefer to be re-
assured face to face however. 
Had to come in one Sunday during chemo for suspected infection. Understandably the dept. was 
lightly staffed but it was still frustrating to have to wait 7 hours. Glad I came in the end, but a test 
at home would have eased my mind considerably. 
As well as there is the opportunity to phone the hospital. This is essential. 
Hospital is a very busy place and if you can prevent patients from waiting about for hours they can 
be at home in the comfort of their own surroundings when not feeling very well. 
If it’s easy to use, it's no problem. 
Appendix 3, Table 2:  Free-text comments from respondents who indicate they would prefer 
scenario B in question 2, which is using the home blood count monitoring device. 
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Free-text comments 
This is a hard question to answer as no one wants to be dangerously unwell but would you not 
be considered to be managed by the machine from the beginning. If your condition worsened 
you can contact or come to the hospital at any time. It could just save the trip for the people 
who came just because they are unsure. The machine would help you to be better informed. 
Proper procedure of finger pricking by the patient minimizes the infection. Overall this new 
method is very advantageous to all. 
It's difficult to understand how to fill in this question! It's very hypothetical; if I felt unwell I'd 
do the test again or ring the hospital. 
I know what to do - I have had so many chemo treatments 
I would not take the risk of becoming unwell due to the seriousness of the possible outcome. 
I would not take any risks. I would not like to reproach myself for not acting upon me feeling 
unwell and the thought that I might have made my illness worse by not contacting the 
hospital when I was at the start of feeling unwell. 
I wouldn't want to take a higher risk with regard to having a dangerous infection because once 
the infection has spread you might not recover. The other argument is if the reading of the 
machine is accurate it would mean that if one attended hosp. would the result also have 
shown no infection and you will be sent home and then later become unwell and have a 
serious infection. 
For my own well-being, I wouldn't mind taking an unnecessary trip to the hospital. This may 
be the fact that I only live 10 mins for Leeds Hospital. 
If the blood test at home said I was ok then I would be willing to take the 20% risk to see how I 
went on until the next day. If I had other symptoms then maybe I wouldn't take such a risk. 
I'm not sure that is a good question. What does 5% risk actually mean? Might be better as a 
worded question. Would want device to alert at a level set by hospital not lower/not higher 
If I was feeling very ill I would have no reluctance in ringing hospital no matter what the test 
"B" had resulted in. Just know your own body really. I think common sense is the rule. Thanks! 
I was admitted into hospital twice while having chemo with an infection. In my experience 
your situation changes very fast and I think in these situations you need to get to hospital 
ASAP. This process may slow down your decision. 
Given the risks outlined to me regarding feeling unwell/temperature fluctuations, I would 
wish to have all but certain assurance that my symptoms did not require a visit to the hospital. 
If I was dangerously unwell I would be on my way to hospital straight away. 
My husband is a natterer and will not sleep with anxiety if I am unwell. I would not take any 
extra risk as he would be too anxious. 
Should I ever need more chemo, I hope this system is in place! 
On the one hand saving trips to the hospital is attractive. On the other if the risk of infection is 
higher than I would opt for inconvenience rather than take any risks. It is not difficult to 
decide. 
So many things have gone wrong - once I nearly "missed the window" and was so unwell I 
nearly could not have chemo. My time is limited - I am running out of options - I do not want 
to take any risk. 
I think this is a good idea as the slightest thing makes you worry which can cause back up in 
hospital and there is always reassurance at the end of the phone. 
I have peculiar blood - antibodies. I would like to be safe. 
Appendix 3, Table 3: Continued on next page 
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The risks involved of treatment by chemo are acceptable on any level. The treating of cancer 
is the priority, everything else is secondary. 
There's a risk in anything. 
During my treatment, I was more willing to take the risk to enable me to stay at home for as 
long as possible. However, this was sometimes an unwise decision. Therefore, this should not 
always be indicative of whether a person actually needs to be seen. How will the patient know 
if they are just slightly unwell due to chemo or home with a serious infection that requires 
treatment? 
I think the new way of monitoring your bloods is good as long as full training is given 
Very difficult choice to make. 
Appendix 3, Table 3: Free-text comments from respondents in question 3 regarding risk they 
are willing to take in order to gain the benefit of avoiding unnecessary trips to hospital. 
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Comments 
 I don't give much chemo these days. 
 The whole idea is to accept a "zero tolerance" for misdiagnosis and management of 
sepsis (neutropenia/otherwise) during chemotherapy. Therefore not sure if 2b is 
relevant. 
 Would need a lot more info about error and validation of device. 
 Use of machines would be encouraged by availability of data on its successful use.  
Risk question is arbitrary - patient dying due to incorrect information/interpretation 
might be more useful (i.e. Is question specific enough?).  FBC in concert with some 
clinical information e.g. EWS might be more useful?  Good/interesting idea though. 
 I worry about the sort of black and white questioning. Q2a answer dependent upon 
what chemo they have received, where they are in the cycle and what other 
supportive meds (?GCSF) they have received.  Q1a Yes but only as part of the 
assessment. 
 Q2a. I assumed the WBC will be checked again next day to ensure it is not low.  Do we 
know how frequently is worth checking WBC - we do daily in hospital. Any data on 6 
hourly? 8 hourly? 
 I'd need to know that the test was validated in prospective cohort and reliable and 
consistent. 
 Death as a complication of management of suspected febrile neutropenia should be a 
never event in terms of failure to establish the correct diagnosis. The test does not 
replace clinical assessment in this context.  I am more comfortable with scenarios 2 & 
3 as the patients are well not potentially ill (less consequences) but may have an 
improved experience. We need to assess feasibility/usability of device first. Do not get 
me wrong, I am on-side with this technology. Step-by-step, walk before running etc. 
etc. 
 Only need "clinical assessment" if high risk and low risk only need clinical assessment 
if become "unwell"; however one defines this.  There is lots of evidence to prove that 
low risk patients with neutropenia can be managed at home.  I would say 20% would 
be ok for "incorrect advise to stay at home" as they would have a repeat blood count 
next day, they would be advised to have a clinical assessment if unwell. 
Appendix 3, Table 4:  General comments volunteered at the end of the consultant 
questionnaire.  FBC, full blood count.  EWS, early warning score.  GCSF, granulocyte colony 
stimulating factor. WBC, white blood cell count. 
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Appendix 4 - Summary of the performance analysis of the Philips XBC 
blood count analyser 
Paired Philips XBC capillary granulocyte counts and standard of care Siemens ADVIA 2120 
venous neutrophil counts were measured in patients attending the oncology outpatient 
department from November 2012 to July 2013.   
There were 115 sets of blood samples collected where there was both a finger-prick 
granulocyte count measured on the XBC and a venous ADVIA 2120 neutrophil result.  Of 
these, 29 sets had a standard of care Siemens ADVIA 2120 venous granulocyte count <2.0 
x109/L.  This range was used to encompass neutrophil counts around the threshold of 1.5 
x109/L, which is often used to denote safe delivery of chemotherapy, and also around the 
threshold of 1.0 x109/L, which is used to change management in suspected febrile 
neutropenia.   
Correlation in the neutropenic range was, as expected, lower than across the full range of 
counts (neutrophils 0.1 to 2.0 x109/L; r = 0.564, p<0.001, neutrophils 0.1 to 19.6 x109/L; r = 
0.975, p <0.001).  The scatter plot of the neutropenic data is shown in Appendix 4, Figure 1 
and the Bland-Altman plot is shown in Appendix 4, Figure 2.  However, the performance of the 
device in identifying granulocyte counts either side of a neutrophil threshold of 1.5 x109/L, 
was clinically acceptable using an XBC granulocyte count of 1.8 x109/L.  The statistical analysis 
of accuracy of incremental capillary granulocyte thresholds, measured using the XBC, at 
identifying venous ADVIA neutrophil counts <1.5 x109/L is shown in Appendix 4, Table 1.  This 
showed that a capillary XBC granulocyte count of ≥1.8 x109/L, was the minimum granulocyte 
count with a clinically acceptable performance.  Using this threshold, there were no false 
negatives, sensitivity was 100% (95% CI 75.3-100.0%) and negative predictive value was 100% 
(95% CI 95.6-100.0%).  Appendix 4, Figure 3 shows the receiver operator characteristic curve 
of accuracy of the capillary XBC granulocyte count at identifying venous neutrophil counts.  
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Appendix 4, Figure 1: Scatter plot showing the relationship of venous ADVIA 2120 
neutrophil counts and capillary XBC granulocyte counts in the extreme neutropenia range. 
Solid black line is 𝑥 = y, dashed black line is line of best fit.  RMSE, root mean square error.  
 
Part of this unpublished analysis involved comparison of patient self-tested capillary 
granulocyte counts with nurse-obtained capillary granulocyte counts, both using the XBC 
device.  There were 24 paired results across a reference venous ADVIA 2120 neutrophil count 
of 1.07 to 7.84 x109/L.  Patient and nurse granulocyte results were more similar to each other 
than either were to the venous ADVIA 2120 neutrophil counts, but correlation was still poorer 
than expected, with nurse versus patient capillary XBC granulocyte counts giving an r value of 
0.848, p<0.001.  The bias was not unidirectional, meaning neither nurse nor patient-generated 
granulocyte counts were consistently above or below the standard of care venous ADVIA 2120 
measurements.   
The main limitations of this work were that precision could not be analysed as there were no 
repeat tests on either the same patient or device, and the number of patients approached 
who declined the self-test was not recorded. 
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Appendix 4, Figure 2: Bland-Altman plot of venous ADVIA 2120 neutrophil counts and 
capillary XBC granulocyte counts in the extreme neutropenic range.   
SD, standard deviation and is 0.47.  The solid black line represents the mean difference and is 
0.24.  The black dashed lines labelled “1.96 SD” represent the upper and lower limits of 
agreement, which are the 95% CIs.  The upper dashed line is 1.16 and the lower dashed line is 
-0.68.  The single data point outside of the 95% CIs represented a venous ADVIA 2120 
neutrophil count of 1.9 x109/L and a capillary XBC granulocyte count of 0.0 x109/L. 
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XBC GRN 
cut-off 
(prevalenc
e %) 
Raw Data Accuracy Analysis 
 A B C D 
Sensitivit
y (%) 
95% CI 
NPV 
(%) 
95% CI 
PPV 
(%) 
95% CI FNR FPR 
<2.0 (11.0) 
1
3 
2
3 
0 
7
9 
100.00 
75.3
0 
100.0
0 
100.0
0 
95.4
0 
100.0
0 
36.1
0 
20.8
0 
53.8
0 
0.00 
22.5
0 
<1.9 (11.0) 
1
3 
2
1 
0 
8
1 
100.00 
75.3
0 
100.0
0 
100.0
0 
95.5
0 
100.0
0 
38.2
0 
22.2
0 
56.4
0 
0.00 
20.5
9 
<1.8 (11.0) 
1
3 
2
0 
0 
8
2 
100.00 
75.3
0 
100.0
0 
100.0
0 
95.6
0 
100.0
0 
39.4
0 
22.9
0 
57.9
0 
0.00 
19.6
1 
<1.7 (11.0) 
1
2 
2
0 
1 
8
2 
92.30 
64.0
0 
99.80 98.80 
93.5
0 
100.0
0 
37.5
0 
21.1
0 
56.3
0 
7.69 
19.6
1 
<1.6 (11.0) 
1
1 
1
7 
2 
8
5 
84.60 
54.6
0 
98.10 97.70 
91.9
0 
99.70 
39.3
0 
21.5
0 
59.4
0 
15.3
8 
16.6
7 
<1.5 (11.0) 
1
0 
1
3 
3 
8
9 
76.90 
46.2
0 
95.00 96.70 
90.8
0 
99.30 
43.5
0 
23.2
0 
65.5
0 
23.0
8 
12.7
5 
Appendix 4, Table 1: Statistical analysis of accuracy of using capillary XBC granulocyte 
thresholds to indicate venous ADVIA 2120 neutrophil count of <1.5 x109/L.   
CI, confidence interval.  NPV, negative predictive value.  FNR, false negative rate.  FPR, false 
positive rate.  Please refer to the introduction for description of NPV, FNR, and FPR. 
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Appendix 4, Figure 3:  Receiver operator characteristic (ROC) curve evaluating performance 
of the capillary XBC granulocyte count as a surrogate of venous ADVIA 2120 neutrophil 
count threshold of <1.5 x109/L.   
The data point indicated to represent capillary XBC granulocyte count of 1.8 x109/L is the 
lowest threshold with no false negatives, with sensitivity of 100.0% and specificity is 80.0%. 
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